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Cholesterol is an essential molecule for mammalian cells as a structural component of plasma 
and intra-cellular membranes, that influences membrane organization and, thereby, membrane 
properties ( 1 ). Cholesterol also provides the backbone for synthesis of biologically important 
compounds in the body, like steroid hormones (e.g. testosterone) and bile salts (e.g. cholate) 
(Figure 1 ). Cholesterol or, more correctly, oxidized cholesterol, steroid hormones and bile 
salts act as ligands for specific nuclear receptors and are, thereby, important in regulation of 
gene expression. As cholesterol is such an essential component in mammalian life, cholesterol 





Figure I. Structure of cholesterol, the steroid hormone testosterone and the bile salt cholate. 
Maintenance of cholesterol homeostasis in the whole body requires adequate 
metabolic adaptations of endogenous de novo cholesterol synthesis and/or turnover to 
compensate for (large) fluctuations in dietary cholesterol intake. Dysbalance may, among 
other consequences, lead to elevated plasma cholesterol levels and increased risk for 
cardiovascular diseases (CVD), the main cause of death in the Western countries. A multitude 
of epidemiological studies has shown the direct link between high plasma cholesterol levels, 
particularly of low density lipoprotein (LDL) cholesterol, and risk of CVD. On the other 
hand, high levels of high density lipoprotein (HDL) cholesterol, also known as the "good 
cholesterol", protect against atherosclerosis and CVD. The primary event in the development 
of atherosclerosis is the accumulation of cholesterol-loaded macrophages (foam cells) in the 
arterial vessel wall. Detailed understanding of the mechanism(s) of action of HDL and 
potential disturbances herein, which may eventually lead to the formation of atherosclerotic 
plaques, is therefore of crucial importance. 
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Cholesterol trafficking 
In cell types unable to metabolically convert cholesterol (e.g., macrophages), cellular 
cholesterol content is, by definition, the net result of local de novo synthesis, influx and 
efflux. The rate of these processes depends, at least in part, on the prevailing concentration of 
specific lipoprotein particles that can either deliver or accept cholesterol from these cells and 
on the activities of specific receptors and efflux mediators. Within cells, homeostatic 
mechanisms controlled by "cholesterol sensors", the sterol regulatory element-binding 
proteins (SREBP's), ensure adequate adaptation of synthesis. 
The cholesterol fluxes through the body can roughly be categorized into the "forward" 
cholesterol transport pathway, which is generally considered to be the flux of cholesterol from 
liver or intestine towards peripheral cells, including macrophages, and the reverse cholesterol 
pathway, which comprises the flux of excess cholesterol from the peripheral cells towards 
excretory organs (liver, intestine). 
Forward cholesterol transport pathway 
The liver plays a central role in the forward cholesterol transport pathway as it synthesizes 
very low density lipoprotein (VLDL) particles, which are transformed in the blood 
compartment into atherogenic low density lipoproteins (LDL). In humans, LDL is the major 
cholesterol-carrying lipoprotein in plasma, contributing about 70% to circulating cholesterol. 
VLDL particles consist of a neutral lipid core containing cholesterylesters and 
triacylglycerols and a monolayer surface with phospholipids, free cholesterol, and 
apolipoproteins. The major apolipoprotein of VLDL is ApoB I 00: human VLDL particles 
carry a single molecule of ApoB I 00 and do not contain any ApoB48, unlike murine VLDL. 
VLDL particles are secreted into plasma and, subsequently, phospholipids and triglycerides 
are hydrolyzed by lipases such as lipoprotein lipase (LPL) and free fatty acids are taken up by 
the peripheral tissues. Formation of VLDL is important upon fasting, as it provides energy in 
the form of free fatty acids to peripheral tissues when no dietary fats are available. Upon 
triglyceride hydrolysis, VLDL particle size decreases and the relative cholesterol content and 
density of the particle increase. Depending on the density, the particles are referred to as 
intermediate density lipoprotein (IDL) particles or LDL particles. LDL cholesterol is pro­
atherosclerotic as it promotes foam cell formation. Oxidized LDL particles in the interstitial 
space of arteries are prone to be taken up by macrophages via scavenger receptors. Excessive 
cholesterol uptake by macrophages leads to foam cell formation due to cholesterylester 
accumulation, which is an important step in atherosclerotic plaque formation. The liver is 
crucial in determining plasma LDL concentrations as it clears most of the plasma VLDL and 
LDL cholesterol, amongst others via the LDL receptor (LDLr). However, also part of the 
LDL is cleared by the intestine via LDLr-dependent and LDLr-independent pathways (2; 3). 
Cholesterol present in the circulation is either de novo synthesized or derived from 
diet. After uptake by the intestinal cells, dietary cholesterol is packed into chylomicrons and 
secreted via the lymph to the circulation (4). Chylomicrons differ from liver-derived VLDL 
particles by their size and protein content. Chylomicrons are very large ( - 100-400 A) and 
contain ApoB48, ApoA-I and ApoA-IV but, in contrast to VLDL, no ApoB l OO. In the 
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capillaries of tissues, most of the triglycerides are hydrolyzed by lipoprotein lipase (LPL) and 
free fatty acids are taken up by peripheral tissues. This modifies the particles into chylomicron 
remnants, which still contain essentially almost all absorbed cholesterol. Chylomicron 
remnants are rapidly taken up by the liver upon binding to the LDLr, the LDL receptor-related 
(LRP) protein or hepatic lipase (HL) (5). Involvement of the scavenger receptor-B 1 (SR-B 1 )  
in chylomicron clearance has recently been described (6). Via these pathways, virtually all 
cholesterol that is being absorbed from the intestine ends up in the liver. Hepatic de novo 
synthesis of cholesterol mirrors intestinal cholesterol absorption: When a lot of cholesterol is 
being absorbed, synthesis will be low and vice versa. A schematic overview of the forward 
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Figure 2. Schematic overview of the "forward" cholesterol transport pathway. 
CM, chylomicron; CM-remnant, chylomicron-remnant; FFA, free fatty acids; LDL, low density lipoprotein; 
LDLr, LDL receptor; LPL, lipoprotein lipase; VLDL, very low density lipoprotein; SR, scavenger receptors. 
Reverse cholesterol transport pathway 
The reverse cholesterol transport (RCT) pathway is classically defined as the HDL-mediated 
flux of excess cholesterol from peripheral cells to the liver, followed by its secretion into bile 
and disposal via the feces. Lipid-poor ApoA-I, the major apolipoprotein of HDL, is lipidated 
via interactions with the ATP-binding cassette (ABC) transporter A I  (ABCAl )  protein, 
leading to the formation of nascent pre-� HDL (7). Pre-� HDL in the circulation acquires free 
cholesterol and phospholipids from peripheral cells and, after the actions of lecithin­
cholesterol acyltransferase (LCAT), becomes cholesteryl ester (CE)-enriched mature spherical 
HDL. Mature HDL can acquire more cholesterol from the peripheral cells via ATP-binding 
cassette transporter G 1 (ABCG 1 )-mediated efflux of cholesterol from these cells (8). HDL 
cholesterol is cleared from the circulation via the actions of (hepatic) SR-B 1 ,  which 
selectively takes up cholesterol ester from HDL without internalizing the particle (9). Whole 
particle clearance by the liver can occur via the actions of LDLr/LRP after acquirement of 
ApoE ( 10). In humans, but not in rodents, HDL cholesterol can be transferred to ApoB­
containing lipoproteins as VLDL or LDL via the action of cholesteryl ester transfer protein 
(CETP). CETP transfers cholesterol from HDL to ApoB-containing lipoproteins in exchange 
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for triglycerides. In the liver, cholesterol originating from HDL is preferentially secreted into 
bile, as shown by Robins and Fasulo who used sitostanol as non-exchangeable marker for free 
cholesterol to monitor cholesterol fluxes in isolated perfused rat liver ( I I ;  1 2). Under normal 
conditions in mice, this flux appears to be mediated by SR-B 1 ,  as SR-B !-deficient mice 
showed a decrease in biliary cholesterol secretion ( 1 3; 1 4) while SR-BI overexpression has 
the opposite effect ( 15). Since effects of SR-BI deficiency on cholesterol excretion are 
relatively small, it is evident that redundant systems exist. Finally, biliary cholesterol enters 
the intestine, where part will be taken up again and part will leave the body via the feces. A 
schematic overview of the reverse cholesterol transport pathway is depicted in Figure 3. 
Intestine 
<:=> 
<> -- Pre-!i HDL 
Bile 
mature HDL 
Liver Peripheral tissue 
Figure 3. Schematic overview of the "reverse" cholesterol transport pathway. 
ABCA I ,  A TP-binding cassette (ABC) transporter A I ;  ABCG I ,  ABC transporter G I ;  ABCG5/G8, ABC 
transporter G5/G8;BA, bile acids; BSEP, bile salt export pump; HDL, high density lipoprotein; LCAT, lecithin­
cholesterol acyltransferase; LDLr, low density lipoprotein receptor; SR-BI, scavenger receptor-b I 
Epidemiological studies have shown the importance of HDL in the prevention of 
atherosclerosis development, as there is a strong negative correlation between serum HDL 
cholesterol levels and the risk for CVD, independent of total plasma cholesterol levels (16). 
On the basis of this relationship, plasma ApoA-1 was long thought to be the key player in 
control of RCT ( 17). Recent data, however, indicate that the concept of RCT requires 
extensive re-thinking ( 1 8). Overexpression of cholesteryl ester-transfer protein (CETP) in 
mice, resulting in low HDL levels, showed that neither HDL levels nor the level of CETP 
activity dictated the magnitude of centripetal cholesterol flux (i.e., RCT) to the liver in mice 
( 1 9). Studies in ApoA-r'· mice, which have strongly decreased plasma HDL, revealed that 
neither HDL nor ApoA-1 levels are important determinants of centripetal cholesterol flux: 
cholesterol flux and cholesterol synthesis in peripheral tissues and in the liver and intestine 
appeared unchanged in ApoA-r'· mice (20). More recently, it was shown that the absence of 
plasma HDL, and thus of HDL-mediated RCT, in Abcal-null mice does not at all affect 
hepatobiliary cholesterol transport nor fecal sterol loss (2 1 ;  22). These data indicate that other 
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cholesterol-carrying entities can take over the putative role of HDL and, therefore, the 
concepts concerning the atheroprotective actions of HDL need to be revised 
ABC transporters 
The ABC transporter superfamily plays a major role in maintenance of cholesterol 
homeostasis. In humans, the superfamily consists of 48 proteins classified in 7 subfamilies 
based on structure and homology. They are membrane proteins able to transport a variety of 
compounds at the cost of ATP hydrolysis. The typical ABC transporter contains 2 
transmembrane domains and 2 nucleotide-binding domains (NBDs). The transmembrane 
domains are formed by 6 membrane-spanning -helixes. Each NBD contains two sequence 
motifs, Walker A and Walker B, which are common to the general category of ABC 
transporter proteins. Some ABC transporter contain only one transmembrane domain and a 
single NBD domain, these transporters are called half-transporters and form functional 
proteins after dimerization with other half-transporters. Work presented in this thesis is 
focused on specific ABC transporters involved in cholesterol and phospholipid transport and 
only these will be discussed below. 
ABCAJ 
ABCAI mediates the transport of cellular cholesterol and phospholipids to lipid-poor ApoA-I 
and to pre-� HDL. The role of ABCAl in HDL biogenesis became clear when Tangier 
disease was linked with mutations in ABCAJ (23-25). Tangier disease is an inborn error of 
metabolism characterized by an almost complete absence of plasma HDL, abnormal 
accumulation of cholesteryl esters in reticuloendothelial cells of many tissues and a high 
incidence of atherosclerosis. This finding and the subsequent generation of Abcar1• mice, 
which showed the same lack of plasma HDL (26), provided evidence that ABCAl is indeed 
crucial for HDL formation. 
ABCAl is widely expressed throughout the body (27); however, not all tissues are 
important for the regulation of plasma HDL. Bone marrow transplantations studies using bone 
marrow of wild-type or Abcar1· mice transplanted into wild-type or Abcar'· recipients 
revealed that macrophage expression of Abcal contributed only minimally to plasma HDL 
(28). Macrophage ABCAl is important for the development of atherosclerosis, as deficiency 
of Abcal in bone marrow-derived cells increased the susceptibility for atherosclerosis 
development in ApoF1. and LDLr·'· mice (29; 30) and overexpression of ABCA J  in bone 
marrow-derived cells inhibited the progression of atherosclerotic lesions in LDLr.f· mice (3 1 ) . 
Using liver-specific Abcal -deficient mice, Timmins et al. recently showed that hepatic 
ABCAl is critical for the maintenance of plasma HDL by direct lipidation of the liver-derived 
lipid-poor ApoA- 1 particle. However, additional extra-hepatic sites must exist that contribute 
to HDL biogenesis since HDL levels were reduced by only 80% (7). 
ABCB4 
ABCB4, formerly known as Mdr2 in mice or MDR3 in humans, mediates the ATP-dependent 
translocation of phosphatidylcholine from the inner leaflet to the outer leaflet at the 
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canalicular membrane of hepatocytes. Consequently, Abcb4-deficiency in mice leads to an 
inability to secrete phospholipids into the bile (32; 33). Abcb4·'· mice develop liver disease 
due to damage of the canalicular membrane and small bile ducts induced by toxic bile salts 
unshielded by pho pholipids, resulting in extensive bile duct proliferation and hepatocyte 
damage (33). In humans, mutations in ABCB4 lead to a more severe cholestatic phenotype, 
presumably due to the fact that humans have a more hydrophobic bile salt pool. Mutations in 
ABCB4 thus lead to progressive familial intrahepatic cholestasis (PFIC) type-3 (34; 35). 
PFIC 3 is characterized by an early onset of cholestasis that progresses into cirrhosis and liver 
failure before adulthood. 
ABCB4 is highly expressed in the liver, however, low expression in the heart, skeletal 
muscle, spleen, and in cells from the B-cell compartment has also been described (36). 
Although in earlier studies the protein could not be detected in tissues other than the liver (37) 
it appears to be presented in murine macrophages and deficiency of macrophage Abcb4 was 
very recently shown to be pro-atherogenic in LDLr·' mice (38). 
ABCGJ 
ABCG I is the recently discovered human homologue for the Drosophila gene white!ABCB 
and is a so-called half-transporter (39). ABCG I mediates the transport of cholesterol and 
phospholipids to mature HDL, but not to lipid-poor ApoA-1. In contrast to ABCA I, the 
function and importance of ABCG l in lipid homeostasis in humans is unknown: no disease 
linked to mutations in ABCGJ has been described yet. Expression of ABCG I is relatively 
high in macrophages and is induced by cholesterol loading (8). Recently, Kennedy et al. 
constructed A beg r'· mice and ABCG 1 transgenic mice, which showed no overt phenotype on 
chow diet (40). High fat/high cholesterol feeding, however, revealed a critical role for Abcgl 
in preventing cellular lipid accumulation especially in macrophages, in liver, and in lung 
tissue (40). Interestingly, the potential role of ABCG l in atherosclerosis development has not 
been assessed yet. 
ABCGS and ABCG8 
The half-transporters ABCG5 and ABCG8 are critical for apical sterol secretion in polarized 
cells such as hepatocytes and enterocytes. ABCG5 and ABCG8 act as a functional 
heterodimer (41 )  and are localized at the canalicular membrane in hepatocytes and the brush 
border membrane in enterocytes (42). Mutations in the human genes encoding ABCG5 or 
ABCG8 have been shown to cause the inherited disease sitosterolemia (43-45), which is 
characterized by the accumulation of plant sterols (e.g., sitosterol, campesterol) in blood and 
tissues due to enhanced intestinal plant sterol absorption and a decreased ability of 
hepatobiliary removal. Although deficiencies in Abcg5 and/or Abcg8 in mice clearly enhance 
phytosterol absorption (46-48), cholesterol absorption was not affected (47; 48). 
Overexpression of ABCG5 and ABCG8 in mice, however, did lead to decreased cholesterol 
absorption ( 49), showing the importance of this transporter pair in control of cholesterol 
absorption under specific conditions. 
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Nuclear receptors 
Cellular cholesterol metabolism is tightly regulated by several nuclear receptors. The nuclear 
receptor family consists of 48 identified members in humans. Nuclear receptors act as ligand­
inducible transcription factors by directly interacting with DNA response elements in 
promoter regions of their target genes. Upon their activation by specific ligands nuclear 
receptors can act as momomers, as homodimers, and as heterodimers with the Retinoid X 
Receptor (RXR). The main regulator of cholesterol homeostasis, and therefore of major 
interest for work described in this thesis, is the Liver X Receptor (LXR). An other nuclear 
receptor involved in cholesterol metabolism, and discussed in this thesis, is the peroxisome 
proliferator-activated receptor (PPAR) &. 
LXR 
The Liver X Receptors have emerged as the key regulators in cholesterol and lipid 
metabolism. Two LXRs have been identified in mammals, which show an amino acid 
homology of 78 % in both the DNA-binding domain and in the ligand-binding domain (50). 
The expression of LXRa (NRI H3) is restricted to specific organs, with highest expression in 
the liver and significant lower expression in kidney, intestine, adipose tissue, spleen, adrenals 
and macrophages (5 1 ;  52), whereas the expression of LXR� (NR I H2) is more ubiquitous 
(53). LXRa is thought to be the major sensor of dietary cholesterol in the liver, as LXR(/ 
mice fed cholesterol failed to induce Abcg5/Abcg8 and Cyp7Al expression and developed 
massive accumulation of cholesterylester in the liver (54). LXR,B-deficient mice remained 
resistant to dietary cholesterol overload, indicating no overlapping function of LXRa and 
LXR� in liver and intestine (55). The natural ligands for LXR are believed to be oxidized 
derivatives of cholesterol such as 24 S- and 25-epoxycholesterol and 24 S- and 22-R­
hydroxycholesterol (56-58). After activation, LXR heterodimerizes with RXR to bind to LXR 
response elements in their target genes. LXR target genes include genes involved in 
cholesterol efflux like ABCAJ,  ABCGJ, ABCG5, and ABCG8 (59-61 ), genes involved in bile 
salt synthesis (Cyp7Al) (58) and genes involved in lipogenesis like SREBPlc, fatty acid 
synthese, and Acetyl-CoA carboxylase (62-64). 
LXR activation by synthetic agonists has been shown to be anti-atherogenic in mouse 
models prone to develop atherosclerosis (65; 66). Activation of LXR in mice leads to elevated 
HDL levels, increased biliary cholesterol excretion, reduced intestinal cholesterol absorption 
efficiency and, finally, to increased neutral sterol loss via the feces (22; 59; 64). However, 
general LXR activation also leads to increased lipogenesis, hypertriglyceridemia and hepatic 
steatosis in rodents (67) and is therefore not suitable for use in humans as an atheroprotective 
therapy. Organ- or gene-specific LXR agonists, however, have great theoretical potency in 
this respect and are eagerly awaited for. 
PPARs 
Peroxisome proliferator-activated receptors (PPARs) control the transcription of genes 
involved in lipid metabolism and inflammation. Three mammalian PPARs are known: 
PPARa (NRI C l ), PPAR&/� (NRIC2), and PPARy (NRI C3). PPARs are considered to be 
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fatty acid sensors, as they are activated by (poly)unsaturated fatty acids and eicosanoids 
(reviewed by Willson eta/., (68)). PPARa. is mainly expressed in the liver and is critically 
involved in the metabolic adaptations necessary to maintain energy during fasting (69). 
PPARy is highly expressed in adipose tissue and is the key regulator of adipogenesis and 
insulin sensitivity (reviewed by Rosen et al., (70)). The well-known insulin sensitizers 
thiazolidinediones act through PPARy. PPAROIP is ubiquitously expressed and is considered 
to be involved in lipid metabolism, differentiation and inflammation (for review see (7 1 )). 
Recently, PPARo/P was shown to be involved glucose metabolism and control of insulin 
sensitivity as well (72). Interestingly, synthetic PPAROIP agonists have a major effect on 
cholesterol metabolism as they increase plasma HDL levels in primates (73). 
Outline of this thesis 
Although the liver is considered the major "control center" for maintenance of whole body 
cholesterol homeostasis, recent indications (22) pointed towards the intestine as a potential 
target for novel anti-atherosclerotic treatment strategies. 
As discussed above, LXR is considered to be a key regulator of reverse cholesterol 
transport. LXR activation in rodents leads to increased fecal cholesterol loss which is 
generally ascribed to increased biliary cholesterol secretion and decreased cholesterol 
absorption caused by hepatic and intestinal Abcg5/Abcg8 induction. However, Plosch et al. 
(22) suggested that, besides the liver, the intestine might also contribute to cholesterol loss via 
direct cholesterol secretion into the intestinal lumen. These authors calculated that the 
intestine contributes directly to fecal cholesterol loss in mice and general LXR activation in 
mice tripled this intestinal cholesterol secretion. As this work only provided indirect proof, we 
examined the LXR sensitive intestinal pathway in a murine model lacking biliary cholesterol 
secretion in chapter 2. Abcb4·l· mice and wild-type mice were treated with a synthetic LXR 
agonist in order to further evaluate the contribution of this novel pathway. 
As discussed above, a protein central in control of HDL metabolism is the ABC­
transporter A 1 .  ABCA 1 is highly expressed in the intestine, although its function in this organ 
is unknown. As it is expressed at the basolateral membrane, it is clear that it does not function 
as a general efflux pump towards the intestinal lumen as previously suggested (59). In the 
liver, ABCA I is important for the lipidation of the lipid-poor ApoA-1 particle (7). Besides the 
liver, the intestine also produces and secretes ApoA-1 (74; 75), which suggest that intestinal 
ABCA I might be involved in HDL biogenesis. In chapter 3, we explored this possibility with 
the use of intestine-specific Abcal -deficient mice. The physiological effects of intestine­
specific LXR activation on plasma HDL levels and in reverse cholesterol transport were 
evaluated in a rat model (chapter 4). 
Plasma cholesterol levels are influenced by (dietary) cholesterol absorption. Therefore, 
identification of mechanisms modulating cholesterol absorption are of great interest. Plant 
sterols and stanols have been known for many years to decrease cholesterol absorption and to 
lower plasma LDL cholesterol levels. Functional foods containing plant sterols/stanols for 
lowering plasma cholesterol are on the market. Yet, the mechanism(s) by which plant sterols 
and stanols act is unclear. The recent indication that plant sterol derivatives might act as 
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ligands for LXR (76) suggested that plant sterols and stanols could act by increasing 
ABCG5/ABCG8 expression. In chapter 5 we explored this possibility by feeding mice 
cholesterol-enriched diets with or without plant sterols or stanols and subsequent analyzed 
intestinal gene expression patterns of LXR target genes. Feeding of Abcg5·!- mice the plant 
sterol diet and assessment of the physiological effects hereof was performed to provide final 
physiological proof whether or not Abcg5/g8 heterodimers are involved in plant sterol­
induced decreases of cholesterol absorption. 
In chapter 6 we investigated the effects of PPARo/� activation on cholesterol 
metabolism in mice. As discussed above, PPARo/� activation in primates led to increased 
HDL levels (73), which raised the question whether PPARo/� activation would accelerate 
reverse cholesterol transport and lead to enhanced fecal cholesterol loss. To determine 
whether the increase in HDL was Abcal-dependent, we treated wild-type and Abcar'· mice 
with a synthetic PPARo/� agonist and determined the effects on cholesterol metabolism. 
Finally, the current state of knowledge regarding the emerging roles of the intestine in 
control of cholesterol metabolism is reviewed in chapter 7, which puts the topics addressed 
in this thesis in a physiological and clinical perspective. 
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Abstract 
Background & aims: Reverse cholesterol transport (RCT) is defined as high-density 
lipoprotein (HDL)-mediated flux of excess cholesterol from peripheral cells to liver, followed 
by secretion into bile and disposal via the feces. Various steps of this pathway are controlled 
by the liver X receptor (LXR). We addressed the role of the intestine in LXR-dependent 
stimulation of fecal cholesterol excretion. Methods: To segregate biliary from intestine­
derived cholesterol, wild-type and Mdr2 P-glycoprotein deficient mice (Mdr2"1"), which are 
unable to secrete cholesterol into bile, were treated with the LXR agonist GW3965. Results: 
Treatment with GW3965 increased biliary cholesterol secretion by 74 % in wild-type mice, 
but had no effect in Mdr2·'· mice. LXR activation increased fecal neutral sterol excretion 2. 1 -
fold in wild-type mice. Surprisingly, an identical increase was observed in Mdr2"1- mice. 
Fractional cholesterol absorption was reduced upon LXR activation in both strains, but more 
pronounced in Mdr2·'· mice coinciding with reduced Npcl l1 expression. Intestinal gene 
expression of Abcal,  Abcg 1, Abcg5 and Abcg8 was strongly induced upon LXR activation in 
both strains, while expression of HMGCoA reductase, controlling cholesterol synthesis, 
remained unaffected. Additionally, LXR activation stimulated the excretion of plasma-derived eH]cholesterol into the fecal neutral sterol fraction in Mdr2"1- mice. Conclusions: Increased 
fecal cholesterol loss upon LXR activation is independent of biliary cholesterol secretion in 
mice. An important part of excess cholesterol is excreted directly via the intestine, supporting 
the existence of an alternative, quantitatively important route for cholesterol disposal. 
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Introduction 
Cholesterol accumulation in macrophages (foam cells) in the arterial vessel wall is considered 
a primary event in the development of atherosclerosis. Removal of excess cholesterol from 
these cells, as well as from other peripheral cells, is therefore of crucial importance. This 
pathway, referred to as reverse cholesterol transport (RCT), is usually defined as the HDL­
mediated flux of cholesterol from peripheral cells to the liver, followed by its secretion into 
bile and disposal via the feces. The ATP-binding cassette (ABC) transporter A I  (ABCAI )  
facilitates the obligatory first step of RCT, i.e., the efflux of cholesterol from peripheral cells 
towards HDL. HDL-cholesterol is subsequently taken up by the liver, mainly via scavenger 
receptor-BI (SR-BI), and finally may be excreted into bile, either as free cholesterol or after 
conversion to bile salts. Hepatobiliary elimination of cholesterol was shown to be mediated, at 
least partially, by the half-transporters ABCG5 and ABCG8 ( 1 ). Part of biliary cholesterol 
which mixes with dietary cholesterol in the lumen of the small intestine is taken up by the 
Niemann-Pick C I  Like 1 (NPC I LI )  protein, which has recently been shown to play a role in 
cholesterol absorption (2), and transported back to the liver by the chylomicron-remnant 
pathway. Another part, however, is lost into feces. It has become clear that cholesterol 
absorption is not a passive process, but depends on the combined actions of transporter 
proteins involved in uptake (NPCIL I )  and efflux (ABCG5, ABCG8). 
Fecal excretion of cholesterol in mice can be enhanced via activation of the nuclear 
liver X receptor (LXR), for which oxysterols have been identified as natural ligands. LXR 
regulates expression of a number of genes crucially involved in RCT, including the members 
of the ATP-binding cassette transporter family mentioned above. Activation of LXR in mice 
leads to elevated HDL levels, increased biliary cholesterol excretion, reduced intestinal 
cholesterol absorption efficiency and, finally, to increased neutral sterol loss via the feces (3). 
Recent data, however, indicate that the concept of RCT requires extensive re-thinking 
( 1 ). Overexpression of cholesteryl ester-transfer protein (CETP) in mice, resulting in low 
HDL levels, showed that neither the HDL levels nor the level of CETP activity dictated the 
magnitude of centripetal cholesterol flux (i.e., RCT) to the liver in mice (4). Studies in 
ApoA-r'· mice, which have strongly decreased plasma HDL, revealed that neither HDL nor 
ApoA- 1 levels are important determinants of centripetal cholesterol flux (5). More recently, 
we reported that the absence of plasma HDL, and thus of HDL-mediated RCT, in Abcal-null 
mice does not at all affect hepatobiliary cholesterol transport (3; 6). 
Recent data from our laboratory indicate that, besides the liver, the intestine may play 
a role as excretory organ in RCT (3): upon pharmacological LXR activation, fecal cholesterol 
excretion in various mouse models (C57BU6J, DBA/I ,  Abcal ·'· on a DBA/ I background) 
was increased to a much larger extent than could be explained by stimulation of biliary 
cholesterol secretion alone. To resolve the apparent discrepancies between the "classical" 
biliary route for removal of excess cholesterol and these findings, we now used an animal 
model in which biliary cholesterol secretion is strongly reduced, i.e., Mdr2 P-glycoprotein 
(Pgp)-deficient (MdrT1-) mice. Mdr2 (or Abcb4 according to new nomenclature) mediates the 
ATP-dependent translocation of phospholipids at the canalicular membrane of hepatocytes. 
Consequently, Mdr2 P-glycoprotein deficiency in mice leads to an inability to secrete 
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phospholipids into the bile. Due to the tight coupling of phospholipid and cholesterol 
excretion, these mice also show a strongly impaired biliary cholesterol secretion (7; 8). 
The first question we addressed was whether LXR activation, known to strongly 
increase biliary cholesterol output in wild-type mice (3), would stimulate biliary cholesterol 
secretion in a phospholipid-independent manner. For this purpose, MdrT'· and wild-type mice 
were treated with the synthetic LXR agonist GW3965 (9). Upon GW3965 treatment, biliary 
cholesterol secretion remained nearly undetectable in MdrT'· mice, whereas it increased in 
wild-type mice. This allowed us to assess whether activation of LXR would stimulate fecal 
neutral sterol output independent of its effects on biliary cholesterol secretion. It was found 
that wild-type and Mdr2"1• mice treated with a synthetic LXR agonist showed a similarly 
increased fecal neutral sterol output without induction of genes involved in cholesterol 
synthesis, indicating that this increase must result from intestinal sources. This conclusion 
was supported by the finding that Mdr2"1• mice showed increased secretion of plasma-derived 
radio-labeled cholesterol into the feces upon treatment with the LXR agonist. We therefore 
postulate that, besides the liver, the intestine plays an important and up to now underestimated 
role in cholesterol disposal. 
Experimental procedures 
Animals and diet 
Female Mdr2"1• mice (4-6 months) on an FVB background were obtained from the Central 
Animal Facility, Academic Medical Center, Amsterdam, The Netherlands. Age-matched FVB 
wild-type mice were purchased from Harlan (Horst, The Netherlands). Mice received standard 
mouse chow, containing 0.01 7  w/w % cholesterol (Arie Blok BV, Woerden, The 
Netherlands), or chow supplemented with the synthetic LXR agonist GW3965, 35 mglkg/day 
(based on 26 g body weight and consumption of 3 g chow/day) for I 0 days. GW3965 was 
kindly provided by GlaxoSmithKiine, Stevenage, UK. All experiments were performed with 
the approval of the Ethical Committee for Animal Experiments of the University of 
Groningen. 
Experimental methods 
Animals were housed in groups and feces were collected upon day 8 until day I 0 of treatment. 
After 1 0  days, animals were anaesthetized by intraperitoneal injection of Hypnorm 
(fentanyllfluanisone, I ml/kg) and diazepam ( 10  mglkg). After puncturing the gallbladder and 
disposal of its content, hepatic bile was collected for 30 minutes from the common bile duct 
via the gallbladder. During bile collection, body temperature was stabilized using a 
humidified incubator. Bile flow was determined gravimetrically assuming a density of 1 g/ml 
for bile. After bile collection, animals were killed by cardiac puncture. Blood was collected in 
EDT A-containing tubes. Livers were excised and weighed. The small intestine was rinsed 
with cold phosphate-buffered saline containing 1 00 J.1M phenyl methyl sulforyl fluoride 
(PMSF) and divided into three equal parts. Parts of both the liver and intestine were snap­
frozen in liquid nitrogen and stored at -80°C for mRNA isolation and biochemical analysis. 
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Samples for microscopic evaluation were frozen in isopentane and stored at -80°C, or fixed in 
paraformaldehyde, for hematoxylin/eosin, oil red 0 and Ki-67 staining. 
Fractional cholesterol absorption was measured in a separate experiment using the 
fecal dual-isotope method. Animals were housed individually one week prior to the 
experiment. Wild-type and Mdrz'· mice were fed normal chow or chow supplemented with 
GW3965 (35 mg/kg/day). After 6 days, mice received by gavage 150 111 of medium-chain 
triglyceride oil containing I IJ.Ci of [ 14C]cholesterol (Amersham Bioscience,Buckinghamshire, 
UK) and 2 IJ.Ci of eH]sitostanol (American Radiolabeled Chemicals, St Louis, USA). Feces 
were collected for the next 4 days. After 4 days animals were sacrified and the small intestine 
was removed. The intestinal contens were flushed with saline containing 0.5 mM taurocholate 
and radioactivity was measured upon dissolving the intestine in NCS-TS (Amersham 
Bioscience,Buckinghamshire, UK). 
For determination of cholesterol kinetics, only Mdrz'· mice were used. Mice were 
housed individually one week prior to the experiment. Mice were fed normal chow or chow 
supplemented with GW3965 (35 mg/kg/day). After 8 days, mice received an intravenous 
injection of 1 .7 1J.Ci eH]cholesterol (NEN Life Science, Zaventem, Belgium) dissolved in 
Intralipid (20%, Fresenius Kabi, Den Bosch, The Netherlands) via retro-orbita injection. 
Blood samples (751J.I) were drawn at day I ,  2, 3 and 4 after injection by orbita puncture. Feces 
were collected from individual mice at day 1 ,  2, 3 and 4 after injection. After 4 days, bile was 
collected as described above and animals were sacrificed afterwards. Liver and intestine were 
collected for radioactivity measurement. 
Analytical methods 
Bile salts were measured enzymatically ( 1 0). Commercially available kits were used for the 
determination of free cholesterol (Wako, Neuss, Germany), total cholesterol and triglycerides 
(Roche Molecular Biochemicals, Mannheim, Germany) and phospholipids (Wako) in plasma. 
From each group, plasma samples were pooled and used for lipoprotein separation by fast 
protein liquid chromatography (FPLC) on a Superose 6B 1 0/30 column (Amersham 
Bioscience). Livers were homogenized and hepatic lipids were extracted according to Bligh 
and Dyer ( 1 1 ). Hepatic triglyceride and cholesterol concentrations were determined using 
commercially available kits (Roche, Wako). Phospholipids in bile and liver were determined 
as described by Bottcher et al. ( 1 2). Cholesterol in bile was measured according to Gamble et 
al. ( 1 3). Feces were weighed and homogenized. Neutral sterols and bile salts were analyzed 
according to Acra et a/. ( I  4) and Setchell et a/. ( 1 5). 
Feces collected for cholesterol absorption measurements after oral administration of eH]sitostanol and [ 14C]cholesterol were freeze-dried, saponified, and neutral sterols were 
extracted. The [ 14C] and eH] content of the feces and dosing mixture were counted and the 
ratio was used to calculate the percentage cholesterol absorption: 
% cholesterol absorption = x I  00 
[ 14 C/3H dosing mixture - 14C/3H feces) 
1 4CPH dosing mixture 
To measure kinetics of fecal disposal of plasma-derived eH]cholesterol, the eH] 
content of plasma ( 1 0  IJ.I) was measured by liquid scintillation counting. Before counting the 
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[3H] content of feces, feces were freeze-dried, saponified, and neutral sterols were extracted 
according to Bligh and Dyer ( I I ). 
Histology-
Liver and small intestine were examined after hematoxilin-eosin (HE) staining and oil red-o 
(ORO) staining for neutral lipids. HE staining was performed on paraformaldehyde-fixed, 
paraffin-embedded sections by standard procedures. Oil-red-o staining was performed on 
frozen sections by standard procedures. 
lmmunolzistoclzemical staining of intestine 
Ki-67 staining was performed on paraformaldehyde-fixed, paraffin-embedded intestinal 
sections. Endogenous peroxidase activity was blocked by incubation of sections in 0.3% (v/v) 
H202 in 30 % (v/v) methanol for 4 minutes. Sections were pretreated with 1 0  nM citrate 
buffer (pH 6) for 8 minutes at I 00 °C. Nonspecific binding was blocked by pre-incubation 
with normal goat serum. Sections were incubated with Ki-67 polyclonal antibody (Novo 
Castra, Newcastle, UK) ( l :500) for 60 minutes. Secondary antibody against rabbit (IgG) 
labeled with biotine (Dako, Glostrup, Denmark) ( 1 :  1 00, 30 min.) was used. Antibody binding 
was visualized using streptavidine labeled with peroxidase (Dako), DAB (Sigma, St. Louis, 
USA) and peroxide. Sections were counterstained with hematoxylin. 
lmmunoclzemical staining of Abcal and Abcg5 in tlze small intestine 
For homogenates and brush border membrane isolation, mid sections of the small intestines 
were used. Mucosa was scraped before homogenization in buffer containing 250 mM sucrose, 
1 0  mM Tris-base (pH 7.4), and a mixture of protease inhibitors containing 1 00 J.l.M PMSF and 
Complete (Roche Diagnostics, Almere, The Netherlands). From these homogenates, brush 
border membrane (BBM) fractions were isolated by calcium precipitation as described by 
Schmitz et al. ( 1 6) . Enrichment of BBM fractions was determined by alkaline phosphatase 
activity measurements according to Keeffe et al. ( 17). Protein was determined according to 
Lowry et al. ( 1 8). Homogenates (50 Jlg protein) for detection of Abca l and BBM fractions 
( 1 5  Jlg protein, corrected for enrichment) for detection of Abcg5 were electrophoresed 
through polyacrylamide gels and blotted on nitrocellulose membranes. Membranes were 
blocked in Tris-buffered saline (pH 7.4) containing I %  Tween 20 and 5% skim milk powder. 
Membranes were incubated with anti-Abcal antibody ( 1 9), kindly provided by M. Hayden, 
( I :  1 000 in blocking buffer), or A begS antiserum (20) ( 1 :  1 500 in blocking buffer) for 2 hours 
at room temperature. After washing, immunocomplexes were detected using horseradish 
peroxidase-conjugated sheep anti-mouse IgG (Abcal )  or goat anti-rabbit IgG (Abcg5) and 
ECL detection (All three from Amersham Bioscience, Little Chalfont, UK). 
RNA isolation and PCR procedures 
Total RNA was isolated with Trizol (Invitrogen, Parsley, UK) and quantified using Ribogreen 
(Molecular Probes, Eugene, USA). eDNA synthesis was done according to Bloks et at. (2 1 ) .  
Equal amounts of RNA from the three distinct parts of the small intestine were pooled prior to 
reverse transcription. Real-time quantitative PCR (22) was performed using an Applied 
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Biosystems 7700 Sequence detector according to the manufacturer's instructions. Primers 
were obtained from Invitrogen. Fluorogenic probes, labeled with 6-carboxy-fluorescein 
(FAM) and 6-carboxy-tetramethyl-rhodamine (TAMRA), were made by Eurogentec (Seraing, 
Belgium). Primers and probes used in these studies have been described elsewhere (Abcal, 
Abcg5, Abcg8, Acat2, Hmgcr and Sr-bl (3), except Abcgl (NM_009593; forward 
CAAGACCCITITGAAAGGGATCTC, reverse GCCAGAAT A TTCATGAGTGTGGAC, 
probe CCCATGATGGCCACCAGCTCTCC), Abcg2 (AF1402 1 8; forward 
AATCAGGGCATCGAACTGTCA, reverse CAGGT AGGCAA TTGTGAGGAAGA, probe 
CAAGCCAGGGCCACATGA TTCTTCC) and Npc 1 Ll (A Y 437866; forward 
GAGAGCCAAAGATGCT ACT ATCTTCA, reverse CCCGGGAAGTTGGTCATG, probe 
ACTCCAGCAAACACCGCACTGCC). All expression data were subsequently standardized 
for /3-Actin RNA, which was analyzed in separate runs. 
Statistics 
Statistical analyses were performed using SPSS 1 0.0 for Windows (SPSS Inc., Chicago, 
USA). Differences between the groups were analyzed by Kruskal Wallis test followed by 
Mann-Whitney-U-test. A p-value smaller than 0.05 was considered statistically significant. 
Results 
Plasma alld liver parameters upoll LXR activatioll ill wild-type alld Mdr2·'· mice 
Treatment with the LXR agonist GW3965 led to a significant increase in plasma cholesterol 
levels in wild-type mice (Table I ). Plasma cholesterol levels also increased upon treatment in 
the Mdr2"1. mice, with basal plasma cholesterol levels of 36% of wild-type values (Table I ). 
The increase in plasma cholesterol in both strains was mainly confined to the HDL-sized 
fractions, as shown by FPLC analysis (Figure I). Plasma triglyceride concentrations were not 
significantly affected by GW3965 treatment in wild-type or Mdr2"1" mice (Table 1 ). 
Although it has been reported that treatment of C57BU6J mice with the LXR agonist 
T090 1 3 1 7  has a profound effect on liver weight (23), no significant change in liver weight 
was seen in FVB mice after treatment with GW3965 (Table I ). Mdr2"1" mice had an increased 
liver weight compared to wild-type mice (+ 7 1  %), in agreement with earlier reports (24). Bile 
duct proliferation was observed in all Mdr2"1. mice, but in none of the wild-type mice (data 
not shown). As shown earlier with the LXR agonist T090 1 3 17 by us (23) and others (25), 
GW3965 treatment also Jed to an increased triglyceride content in the liver of wild-type mice 
(+ 106%). Surprisingly, no increase was seen in Mdr2"'· mice upon GW3965 treatment, as 
confirmed by oil red-o staining (data not shown). GW3965 treatment did not lead to changes 
in liver cholesterol levels in wild-type or Mdr2"1" mice. 
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Table 1: Plasma and liver lipid levels of wild-type and Mdr2-l- mice maintained on chow diet in the presence or 
absence of the LXR agonist GW3965. 
Wild-type Mdr2·'· 
Control GW3965 Control GW3965 
Plasma cholesterol (mM) 2.34 ± 0.41 3.22 ± 0.33 . 0.85 ± 0.20" 1.36 ± 0.11 b 
Plasma triglycerides (mM) 2.3 1 ± 0.67 2.76 ± 0.39 1.67 ± 0.28 1.77 ± 0.34 
Body weight (g) 25.8 ± 3.3 25.7 ± 3.6 26.3 ± 1.6 26.9 ± 2.8 
Liver weight (% of body weight) 4.5 1 ± 0.40 4.79 ± 0.23 7.72 ± 0.75" 9.47 ± 1.02b 
Liver cholesterol (nrnlmg liver) 6.00 ± 1 .19 5.33 ± 1. 1 9  6.67 ± 0.98 5.79 ± 0.53 
Liver phospholipids (nmol/mg liver) 31.37 ± 3.16 34.38 ± 4.96 29.92 ± 4.08 25.96 ± 1.04b 
Liver triglycerides (nmol/mg liver) 12.83 ± 4.87 26.43 ± 5.91 " 4.55 ± 1.23" 4.58 ± 1.08 
Female FVB wild-type (n = 7 per group) and Mdr2''· mice (n = 6 per group) were fed a chow diet in the 
presence or absence of GW3965 (35 mglkgld) for 10 days. Blood was collected by cardiac puncture. Livers were 
collected and frozen immediately. Analysis of lipids was performed as described in "Experimental Procedures". 
Values represent means ± S.D. " Indicates significant difference (Kruskal Wallis test followed by Mann-Whitney 
U test. p<O.Ol) compared to control wild-type mice. b Indicates significant difference (Kruskal Wallis test 
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Figure 1. Effect of LXR activation on 
distribution of cholesterol in plasma 
lipoprotein fractions of wild-type and Mdr2-l­
mice. FPLC analysis of plasma cholesterol 
of female FVB wild-type (A) and Mdr2·'· (B) 
mice. Mice were maintained for I 0 days on 
chow diet in the presence (closed circles) or 
absence (open circles) of the LXR agonist 
GW3965 (35 mglkgld). Blood was collected 
via cardiac puncture and pooled before FPLC 
analysis. Analysis was performed as 
described in "Experimental Procedures". 
We have previously shown that LXR stimulation enhances cholesterol secretion without 
increasing phospholipid secretion into bile, resulting in uncoupling of biliary cholesterol and 
phospholipid secretion (3). Treatment with GW3965 increased biliary cholesterol secretion 
1 .7-fold in wild-type mice, whereas bile flow, biliary bile salt and phospholipid secretion 
were not affected (Table 2). As a result, the ratio of cholesterol to phospholipids doubled upon 
GW3965 treatment. Mdr2-t- mice, compared to wild-type mice, showed an increased bile 
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flow, similar to earlier reports (24) and a severely decreased biliary cholesterol secretion. 
Upon GW3965 treatment biliary cholesterol secretion remained unaffected. As expected, 
phospholipids in bile of Mdr2"1" mice were not detectable (Table 2). 
Table 2: Biliary output parameters of wild-type and Mdr2·'· mice maintained on a chow diet in the presence or 
absence of the LXR agonist GW3965. 
Bile flow (J.tl/min/100 g body weight) 
Bile salts (nmol/min/ 100 g body weight) 
Cholesterol (nmol/min/ 100 g body weight) 
Phospholipid (nmol/min/ 100 g body weight) 
Wild-type 
Control 
4.7 ± 1.0 
293 ± 97 
1.9 ± 0.6 
52.1 ± 1 1.6 
GW3965 
4.8 ± 1.0 
3 18 ± 137 
3.3 ± 1. 1' 
44.2 ± 15.6 
Control GW3965 
7.4 ± 1.3' 10.0 ± 3.3 
395 ± 67 549 ± 351 
0.3 ± 0.2' 0.2 ± 0.2 
ND ND 
Cholesterol/phospholipid ratio 0.04 ± 0.02 0.08 ± 0.02' 
Female FVB wild-type (n = 7 per group) and Mdr2·'- mice (n = 6 per group) were fed a chow diet in the 
presence or absence of GW3965 (35 mg/kg/d) for 10 days. Bile was collected for 30 min. Analysis of bile was 
performed as described in "Experimental Procedures". Phospholipids in bile in Mdr2�- mice were not detectable 
(ND). Values represent means ± S.D. • Indicates significant difference (Kruskal Wallis test followed by Mann­
Whitney U test. p<O.Ol) compared to control wild-type mice. 
Fecal sterol balance 
Neutral sterols and bile salts were determined in the feces (Figure 2). Fecal neutral sterol 
output was increased by 2 . 1 -fold in wild-type mice after GW3965 treatment. Surprisingly, 
Mdr2"1- mice showed a similar 2. 1 -fold increase in fecal neutral sterol loss as wild-type mice 
after GW3965 treatment. There was no change in fecal bile salt output upon LXR activation 
in either strain. 
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Figure 2. Fecal loss of bile salts and neutral sterols 
of wild-type and Mdr2�- mice maintained on chow 
diet in the absence or presence of the LXR agonist 
GW3965. Female FVB wild-type and Mdr2"1" mice 
were maintained on chow diet in the absence (white 
bars) or presence (black bar') of the LXR agonist 
GW3965 (35 mg/kg/d) for I 0 days. Animals were 
housed in groups during the experiment and feces 
were collected last 48 hour of experiment. Feces 
were analysed as described in "Experimental 
Procedures". * Indicates significant difference 




GW3965 treatment reduced fractional cholesterol absorption as measured by the oral dual 
isotope test in wild-type mice by about 50% (Figure 3). Surprisingly, fractional cholesterol 
absorption in untreated MdrT'· mice was similar to that in wild-type mice. Upon LXR 
activation, however, fractional cholesterol absorption in Mdr2"1. decreased drastically to 
undetectable levels. The recovery of [ 14C]cholesterol in the small intestinal wall at 4 days 
after its intragastric administration was similar in untreated wild-type and Mdr2"1- mice (3.9 ± 
1 .2% of dose in wild-type and 3.3 ± 0.2% in MdrT1- mice). LXR activation did not reduce this 
percentage in wild-type mice (3. 1  ± 0.7% of dose), however, Mdr2"1- mice showed a strongly 
reduced recovery of [ 1 4C]cholesterol in the intestinal wall (0.8 ± 0.4% of dose). 
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Figure 3. Fractional cholesterol absorption of wild-type and Mdr2�- mice maintained on chow diet in the 
absence or presence of the LXR agonist GW3965. Female FVB wild-type and Mdr2·'· mice were maintained on 
chow diet in the absence (white bars) or presence (black bars) of the LXR agonist GW3965 (35 mglkg/d) for 10 
days. Animals were housed individually. Fractional cholesterol absorption was measured using the fecal dual­
isotope method as described in "Experimental Procedures". ¥ Indicates significant difference (Mann-Whitney U 
test. p<0.05). 
mRNA and protein expression in the small intestine-
As the results described above suggest involvement of the intestine in cholesterol excretion 
into the feces, we determined expression levels of several genes involved in cholesterol 
metabolism in the small intestine of wild-type and Mdr2"1- mice upon LXR activation. LXR 
activation by GW3965 treatment resulted in a more than 2-fold induction of Abcg5 and Abcg8 
mRNA levels in the small intestine in both strains (Table 3), in agreement with increased 
protein expression of Abcg5 (Figure 4A). In addition, LXR activation led to a more than 9-
fold increase in Abca ! mRNA levels (Table 3) and concomitant increase of Abcal protein 
(Figure 4B) in the small intestine in both strains. Abcgl mRNA expression in the small 
intestine was more than 1 2-fold induced after LXR stimulation in both strains (Table 3) .  
Expression of Sr-bl increased over 2-fold in both strains after LXR activation (Table 3). In 
contrast, intestinal expression of Npclll, recently identified as intestinal cholesterol 
absorption protein (2), tended to decrease upon LXR activation in wild-type mice and was 
significantly decreased under these conditions in MdrT'- mice. Expression of Hmgcr and 
Acat2, indicative of intestinal cholesterol synthesis and esterification, remained unaffected 
upon GW3965 treatment in wild-type and Mdr2-l- mice (Table 3). 
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1 .00 ± 0.41 
1 .00 ± 0.22 
1 .00 ± 0.30 
1 .00 ± 0.24 
1 .00 ± 0.30 
1 .00 ± 0.42 
1 .00 ± 0.38 
1 .00 ± 0. 1 9  
1 .00 ± 0.30 
GW3965 
9.5 1 ± 2.8 1 '  
1 3.3 1 ± 4.48" 
1 .42 ± 0.57 
3. 1 2 ± 1 .2 1 '  
2.88 ± 0.8 1 '  
0.7 1 ± 0.20 
2. 1 9  ± 0.80' 
1 . 1 9  ± 0.45 
1 .07 ± 0.26 
Mdr2"'· 
Control GW3965 
0.44 ± 0. 1 5" 4.40 ± 0.96b 
0.83 ± 0.24 1 0.03 ± 3.96b 
0.93 ± 0.40 1 .2 1  ± 0.23 
0.69 ± 0. 1 7" 1 .94 ± 0.74b 
0.82 ± 0.36 1 .79 ± 0.58b 
1 .06 ± 0.2 1 0.47 ± 0. 1 4h 
0.55 ± 0. 1 8" 1 .7 1  ± 0.7 1 h 
0.92 ± 0.43 1 .04 ± 0.4 1 
0.89 ± 0.27 1 .07 ± 0.44 
Female wild-type FVB and Mdr2·l- mice were maintained on chow diet in the absence or presence of the LXR 
agonist GW3965 (35 mglkg/d) for 1 0  days. RNA was isolated from 3 parts of the small intestine; equal amounts 
of RNA were pooled before synthesis of eDNA. Synthesis of eDNA and quantitative real-time PCR was 
performed as described under "Experimental Procedures". All data were standardised for -actin RNA. 
Expression in wild-type mice on control diet was set to 1 .00. Values represent means ± S.D. " Indicates 
significant difference (Kruskal Wallis test followed by Mann-Whitney U test. p<O.O I )  compared to control wild­
type mice. b Indicates significant difference (Kruskal Wallis test followed by Mann-Whitney U test. p<O.O I )  
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Figure 4. Abcal protein and Abcg5 protein expression in small intestines of wild-type and Mdr2.J mice 
maintained on chow diet in absence or presence of the LXR agonist GW3965. Female wild-type FVB (A) and 
Mdr2"1' (B) mice were maintained on chow diet in absence or present of the LXR agonist GW3965 (35 mg/kg/d) 
for 1 0  days. Homogenized small intestine samples (50 )lg of total protein) were subjected to SDS/PAGE and 
immunoblotting for Abca l .  Brush border membranes were isolated and subjected to SDS/PAGE and 
immunoblotting for Abcg5. 
To test whether increased intestinal cell proliferation might contribute to enhanced 
fecal cholesterol loss, Ki-67 staining was performed to visualize dividing cells. Visual 
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inspection of Ki-67 stained intestinal sections, however, did not reveal indications for 
increased cell proliferation upon LXR activation (data not shown). 
Plasma-derived cholesterol excretion in feces of Mdr2·'· mice 
In order to determine whether cholesterol excreted into the feces upon LXR activation could 
originate from the plasma compartment, untreated and GW3965-treated Mdr2"'· mice received 
an intravenous injection of eH]cholesterol dissolved in Intralipid. Although no difference 
could be detected in the specific activities of plasma cholesterol between both groups (Figure 
SA), LXR activation did markedly increase (by 66%) the recovery of plasma-derived 
eH]cholesterol in the neutral sterol fraction of the feces after 4 days by 66% (6.87±0.55 vs. 
4. 1 3±0.68 %/dose) (Figure 5B). As expected, no [3H] was detectable in the sterol fraction of 
bile after Bligh and Dyer extraction (data not shown). 
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Figure 5. Specific activity of 3H-cholesterol in 
plasma and cumulative excretion of radioactivity 
in the neutral sterol fraction of feces in MdrT'· 
mice treated with or without the synthetic LXR 
agonist GW3965. Female individually housed 
MdrT1' mice were maintained on chow diet in the 
absence (n = 4) or presence (n = 5) of LXR 
agonist GW3965 (35 mg/kg/d) for 1 2  days. After 
8 days of diet mice received 3H-cholesterol 
intravenously and blood samples were taken and 
feces were collected every 24 hours until the end 
of the experiment. Radioactivity was measured in 
samples as described in "Experimental 
Procedures". * indicate significant difference 
(Mann-Whitney U test. p<0.05). 
Reverse cholesterol transport (RCT) is usually defined as the pathway responsible for removal 
of excess cholesterol from peripheral cells by HDL, its transport to the liver and, finally, 
disposal from the body. LXR activation has been proposed to enhance RCT by induction of 
Abcal (and other transporters) in peripheral cells to allow cholesterol efflux towards HDL, 
increasing biliary cholesterol secretion and, ultimately, stimulating fecal cholesterol output. 
Recently, we calculated that part of the increased fecal cholesterol output upon LXR 
activation in mouse models must be of intestinal origin (3). These calculations were, however, 
based on estimates of 24h biliary cholesterol secretion. In the present study, we therefore 
chose to dissect hepatobiliary cholesterol secretion from intestinal cholesterol secretion by 
using Mdr2-1- mice, a model in which hepatobiliary cholesterol secretion is almost absent. 
As previously shown, LXR activation in wild-type mice led to increased HDL levels, 
increased biliary cholesterol secretion, decreased fractional cholesterol absorption and to 
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stimulation of fecal neutral sterol loss. In wild-type mice, but not in Mdr2"1- mice, LXR 
activation also induced hepatic steatosis (23; 26). Grefhorst et al. proposed that the 
development of hepatic steatosis upon LXR activation is related to increased de novo 
lipogenesis in combination with an increased free fatty acid flux toward the liver (23). The 
lack of steatosis upon LXR activation in Mdr2"1- mice is under investigation. 
As reported before (27), Mdr2"1- mice had reduced plasma HDL levels compared to 
wild-type mice. Expression of Abcal appears to be a major determinant of plasma HDL (28; 
29). Our data show that, in Mdr2-t- mice, Abcal mRNA expression was significantly reduced 
in the intestine as well as in the liver (data not shown). The reason herefore remains to be 
elucidated, but reduced Abcal expression is a plausible explanation for low HDL levels in 
Mdr2"1. mice. 
As expected, biliary cholesterol secretion in Mdr2 "1- mice was severely impaired, i.e., 
by 87% compared to wild-type mice, whereas biliary phospholipid secretion was 
undetectable. Fecal neutral sterol and bile salt outputs were, however, similar to that observed 
in wild-type mice. These findings in female Mdr2·'· mice differ from previous observations in 
our laboratory, i.e., an increased fecal neutral sterol loss in male Mdr2"1" mice compared to 
sex- and age- matched controls (27). As this difference was rather striking, we additionally 
measured fecal neutral sterol loss in male wild-type and Mdr2"1- mice kept on the same diet as 
the female mice studied. From these analyses it appeared that fecal neutral sterol output, 
although two-fold higher compared to females, was similar in male wild-type and Mdr2"1-
mice (data not shown). To date, we cannot explain this discrepancy in outcome of studies that 
were conducted 6 years apart from each other. We suggest that differences in age of the mice, 
housing conditions and, particularly, changes in chow composition may contribute to these 
divergent results. 
Fractional cholesterol absorption in untreated female MdrT'· mice was found to be 
similar to that of wild-type mice. This was surprising, as Mdr2"1- mice lack biliary 
phospholipids which is expected to limit incorporation of cholesterol into micelles. 
Cholesterol absorption measurements using the plasma dual-isotope method employing i .v. 
administration of eH]cholesterol and oral administration of [ 14C]cholesterol in male by 
Voshol et al. (27) indicated a decreased cholesterol absorption in Mdr2"1" mice. However, as 
already stated in the original paper (27), these results should be judged with caution as the 
liver and intestine did not reach in isotopical equilibrium with plasma within 48 hours. 
Clearly, intrinsic differences between both techniques to measure cholesterol absorption have 
to be taken in account. Data from the currently used test indicate that Mdr2"1- mice take up 
cholesterol normally from the lumen, as supported by unaffected Npcl Ll expression and the 
similar [ 14C]cholesterol content of the intestinal wall after termination of the experiment. 
However, it is plausible to assume that the delayed chylomicron production in Mdr2-l- mice 
(30) influences further processing of the enterocytic cholesterol pools. 
Biliary cholesterol secretion in Mdr2_,_ mice remained impaired upon LXR activation, 
demonstrating that phospholipid secretion is a prerequisite for hepatobiliary cholesterol 
excretion also during LXR-induced hypersecretion. Surprisingly, however, fecal neutral sterol 
output increased to a similar extent in wild-type and Mdr2"1-mice. As dietary intake was 
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similar in all groups and biliary cholesterol was almost absent in Mdr2"1- mice, a considerable 
part of this cholesterol has to originate directly from the intestine. 
To gain insight in the relative magnitude of LXR-induced "direct" intestinal secretion, 
it was of importance to assess the effects of LXR activation on fractional cholesterol 
absorption in both strains. As demonstrated by us (3 1 )  and others (32; 33), fractional 
cholesterol absorption was reduced by about 50% in wild-type mice upon LXR activation. 
Surprisingly, a much greater reduction was observed in the MdrT'· mice, indicating a virtually 
complete suppression of fractional cholesterol absorption upon treatment. The combination of 
a pronounced reduction of intestinal Npcl 11 expression, increased Abcg5/Abcg8 expression 
and relatively small amount of intraluminal cholesterol due to absence of biliary cholesterol 
are probably responsible for this surprising finding. Knowing the daily input of dietary 
cholesterol, as estimated from measurement of food intake, and biliary cholesterol, as 
calculated on the basis of 30 min output rates, and the fractional absorption rates, it is 
possible to estimate the apparent contribution of direct intestinal excretion to total fecal 
neutral sterol output. This calculated contribution was 20% in untreated wild-type mice, 
which increased to 38% upon LXR activation. Corresponding values for untreated and treated 
Mdr2"1- mice were 4 1 %  and 57%, indicating that this pathway contributes significantly to total 
fecal neutral sterol loss. 
Part of this cholesterol could, in principle, originate from enhanced sloughing of 
intestinal cells or be due to increased de novo cholesterol synthesis. Based on unchanged 
HMGCoA reductase gene expression, we consider it unlikely that cholesterol synthesis was 
increased upon LXR activation. Staining for the proliferation marker Ki-67 revealed no signs 
of increased intestinal cell proliferation upon LXR activation, making the possibility of 
enhanced cell shedding less likely. We also showed that the specific activity of cholesterol in 
plasma remained unchanged upon LXR activation in Mdr2"1- mice, whereas the excretion of 
plasma-derived labeled cholesterol into feces was increased (Figure 5). The amount of radio­
labeled fecal neutral secretion at 24 h after injection was about 0.7 % /dose in untreated 
Mdr2"1 mice. Assuming equilibration of the labeled cholesterol within 24 h (34) and a total 
cholesterol pool of 143 Jlmol (35) it can be calculated that about 1 .0 Jlmol cholesterol leaves 
the body via this route per day. This value approximates 64% of the amount of neutral sterol 
actually measured in the stool of these mice, which is of the same order of magnitude as 
calculated from the fractional absorption rate. Since part of the labeled cholesterol may be 
reabsorbed this value may underestimate the true plasma-to-intestine flux. These three 
observations together strongly indicate that the intestine, independently of biliary cholesterol, 
plays an important role in the disposal of plasma-derived cholesterol from the body upon 
LXR activation. Therefore, we consider intestinal excretion a second route for cholesterol 
transport from the periphery to the feces and, by definition, an intrinsic part of the RCT 
system. 
The efflux of cholesterol towards the intestinal lumen is presumably mediated by 
Abcg5 and Abcg8, as increased fecal neutral sterol output upon LXR activation requires the 
presence of Abcg5 and Abcg8 (33). The question remains, however, which pathway mediates 
the uptake of plasma-derived cholesterol by the enterocyte. In addition to that of Abcg5 and 
Abcg8, intestinal gene expression of Abcal and Abcgl was increased upon LXR activation. 
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Abcal is known to be localized at the basolateral membranes of CaCo-2 cells (36) and of 
chicken enterocytes (37) and may facilitate uni-directional cholesterol transport from these 
cells towards HDL (38). Thus it is highly unlikely that Abcal contributes to uptake of 
cholesterol into the enterocyte. Moreover, Abcar'· mice increase their fecal cholesterol 
secretion - in the absence of HDL - upon LXR activation to the same extent as wild-type mice 
do (3). Abcgl is known to regulate cholesterol and phospholipid transport in macrophages 
(39). Localization and function of Abcg l in the intestine is currently unknown, but based on 
the macrophage study (39) it is very likely that Abcg I plays a role in intracellular lipid 
transport processes. 
SRBI, at least in macrophages, has been implicated in bi-directional flux of cholesterol 
and phospholipids (40; 4 1 ). The direction of cholesterol transport is probably determined by 
the free energy difference between cholesterol pools. In the small intestine, Sr-b I is localized 
both at the apical membrane of the brush border and at the basolateral membrane, with 
different expression levels along the length of the small intestine (42). This suggests that Sr­
b I has several functions in the intestine. Mice deficient in Sr-b I ,  however, show only a small 
increase in cholesterol absorption efficiency and small decrease in fecal neutral sterol output 
(43). This suggests a relatively small contribution of intestinal Sr-b l to control of fecal 
cholesterol excretion. However, basolaterally located Sr-b I could theoretically play a role in 
cholesterol uptake into the enterocyte particularly when, due to activation of Abcg5 and 
Abcg8, free cholesterol in the enterocytes decreases and uptake of the sterol from the plasma 
compartment may become energetically favorable. 
In conclusion, our results demonstrate that increased fecal neutral sterol excretion 
upon LXR activation is independent of biliary cholesterol excretion in mice. We propose the 
intestine as an additional excretory organ in RCT, which would imply that e "classical" 
definition of RCT may need to be modified. 
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Abstract 
Plasma high density lipoprotein (HDL) cholesterol levels are inversely related to risk for 
atherosclerosis. The ATP-binding cassette transporter A l  (ABCAl )  mediates the rate­
controlling step in HDL particle formation, the assembly of free cholesterol and 
phospholipids with apolipoprotein A-1. ABCAl is expressed in many tissues; however, the 
physiological functions of ABCAl in specific tissues and organs are still elusive. The liver is 
known to be the major source of plasma HDL, but it is l ikely that there are other important 
sites of HDL biogenesis. To assess the contribution of intestinal ABCA I to plasma HDL 
levels in vivo we generated mice that specifically lack ABCAl in the intestine. Our results 
indicate that approximately 30% of the steady-state plasma HDL pool is contributed by 
intestinal ABCAI in mice. In addition, our data suggest that HDL derived from intestinal 
ABCA I is secreted directly into the circulation and that HDL in lymph is predominantly 
derived from the plasma compartment. These data establish a critical role for intestinal 
ABCAl in plasma HDL biogenesis in vivo. 
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Introduction 
High density lipoprotein (HDL) particles mediate the transport of cholesterol from peripheral 
tissues to the liver in a process termed reverse cholesterol transport ( I  ;2), which is postulated 
to explain, at least in part, their ability to protect against foam cell formation and 
atherosclerosis. Despite the widespread interest in HDL as a potential therapeutic target (3), 
the origins of plasma HDL are still elusive. The ATP-binding cassette transporter A I 
(ABCA I )  mediates the rate-controlling step in HDL particle formation by promoting the 
efflux of cholesterol and phospholipids to apolipoprotein A-I (apoA-1) (4;5). Mutations in 
ABCA I cause Tangier Disease (6-8), characterized by near absence of HDL cholesterol and 
increased risk for atherosclerosis (9- 1 1 ). ABCA I is widely expressed throughout the body 
( 1 2; 1 3) ;  however, the contributions of ABCA 1 in specific tissues to HDL levels and reverse 
cholesterol transport are still being unraveled, and only recently the role of hepatic ABCA 1 in 
homeostasis of HDL levels was elucidated. 
Overexpression of hepatic ABCAI raises HDL cholesterol levels ( 14; 1 5) and liver­
specific deletion of ABCA I results in a substantial ( -80%) decrease in plasma HDL 
cholesterol in chow-fed mice ( 1 6). Similarly, a 50% knockdown of hepatic ABCA1 
expression by adenovirus-mediated RNA interference in mice is associated with a 40% 
decrease in HDL cholesterol ( 1 7). These results indicate that the liver is the single most 
important source of plasma HDL in vivo, but also suggest the existence of additional, 
extrahepatic sites of HDL biogenesis. 
The intestine, along with the liver, is an important site for the synthesis and secretion 
of apolipoprotein A-I (apoA-I), the principal apoprotein of HDL, and contributes 
approximately 50% of total plasma apoA-I ( 1 8). In humans, approximately 1 .5 grams of 
dietary and biliary cholesterol enters the intestinal lumen each day ( 19). Cholesterol that is 
absorbed or synthesized locally in the enterocytes (20) is thought to be either expelled into the 
intestinal lumen through the actions of the ABCG5/ ABCG8 heterodimeric transporter for 
eventual excretion via the feces (21 ), or esterified by the action of ACAT and packaged into 
chylomicrons and very low density lipoprotein particles for transport into the body (22). 
Cholesterol transport from the intestine is thought to occur almost exclusively by the 
lymphatic system (23). 
A potential role for the intestine in HDL particle assembly was initially inferred from 
studies in hepatectomized dogs (24) and studies describing the presence of HDL of distinct 
composition and morphology in mesenteric lymph of rats (25-28). More recent studies in 
cultured cells have identified an apoB-independent pathway of cholesterol secretion from 
intestinal epithelial cells (29-3 1 ). However, the physiological contribution of the intestine to 
HDL levels is unknown, and the molecular mechanisms involved in intestinal HDL assembly 
are obscure. In addition, the origin of mesenteric lymph HDL has been a subject of 
considerable controversy (32-36), raising the question of whether HDL in mesenteric lymph is 
in fact derived from the intestine. 
To specifically assess the role of intestinal ABCA1 in HDL metabolism in vivo, we 
have generated mice that lack ABCA l exclusively in the intestine (Abcaril·i mice). Our 
results show that intestinal ABCAI is importantly involved in HDL biogenesis and 
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contributes approximately 30% to steady-state plasma HDL cholesterol levels in mice. 
Furthermore, our data suggest that intestinal ABCAI participates in HDL assembly via a 
direct mechanism into the circulation. 
Methods 
Animals 
Abcal floxed mice were generated by inserting loxP sites into introns 44 and 46 of the murine 
Abcal gene in a l 29Sv/Ev embryonic stem cell that was injected into a C57BU6 blastocyst, 
as previously described ( 1 6). Mice with intestinal-specific deletion of ABCAI were 
generated by crossing Abcal floxed mice to Villin-Cre transgenic mice, generously provided 
by Dr. Deborah Gumucio (University of Michigan) (37}, to generate Abcal+l-i heterozygotes. 
Intercrossing led to the Abcal+1+, Abcal+f.i and AbcaT11.1 mice used in this study. Control 
mice, collectively designated Abca1+1+, consisted of littermates carrying floxed Abcal alleles 
in the absence of Cre, or wildtype Abcal alleles in the presence or absence of Cre, and plasma 
HDL cholesterol levels between these two groups were not different (Figure l ). ABCA l 
liver-specific knock-out mice (Abcaru-L) have been previously described ( 1 6). Mice lacking 
hepatic and intestinal ABCAl were generated by breeding Abcaru-L and Abcaril-i mice, and 
genotypes with regards to Villin-cre or Albumin-ere transgenes determined by promoter­
specific PCR. ABCAl global knock-out mice (Abcar'·) were generously provided by Dr. 
Omar Francone (Pfizer Global Research and Development) (4 1 ) . Animals were housed under 
1 2  hour light/dark cycles and received a standard lab chow diet. These studies were approved 
by the University of British Columbia Animal Care Committee . 
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Figure I. Plasma HDL cholesterol levels in mice with wild-type (+/+) or floxed (fllfl) Abcal alleles. 
Southern Analysis 
Southern blotting was performed as previously described ( 16). Briefly, genomic DNA was 
isolated from indicated tissues, digested with proteinase K and incubated with EcoRV 
restriction enzyme (Promega). Digested DNA was separated on a 0.8% agarose gel and 
transferred to Nytran Super Charge Nylon membrane (Schleicher and Schuell Bioscience). 
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Southern blots were hybridized with a probe spanning intron 44 to yield the 6 Kb, 7.3 Kb, and 
4.2 Kb fragments corresponding to the wild type, floxed, and knockout alleles, respectively. 
Western Analysis and Realtime PCR 
Western blotting was performed as previously described ( 1 2). Briefly, tissues were 
homogenized and sonicated in 20 mM Hepes, 5 mM KCI, 5 mM MgCh, 0.5% (v/v) Triton X-
1 00, and complete protease inhibitor (Roche), and protein concentration was determined by 
the Lowry assay. Equivalent amounts of total protein were separated by SDS-PAGE, 
transferred to PVDF membranes and probed with anti-ABCA I ( 12) or anti-GAPDH 
(Chemicon) antibodies. For lymph samples, equal volumes of FPLC fractions were separated 
by SDS-PAGE and probed with an anti-apoA-1 antibody (Chemicon). 
RNA was isolated using TRizol® reagent according to manufacturer's instructions 
(Invitrogen). Three jlg of RNA were reverse transcribed with Superscript II (Life 
Technolgies) to generate eDNA for real time PCR using SYBR® Green PCR Master Mix 
(Applied Biosystems) in an ABI Prism 7700 Sequence Detection system. The following 
primer sequences were used: mAbcAI F  CGTTTCCGGGAAGTGTCCTA, mAbcA I R  
CT AGAGATGACAAGGAGGA TOGA, mGapdhF TGCACCACCAACTGCTT AG 
mGapdhR GATGCAGGGATGA TGTTC, mNpc l l lF TGGACTGGAAGGACCA TTTCC, 
mNpc I l l  R GCGCCCCGTAGTCAGCTAT, mAbcg5F TGGCCCTGCTCAGCATCT, 
mAbcg5R A TTTTT AAAGGAATGGGCATCTCTT, mAbcg8F 
CGTCGTCAGA TTTCCAATGA, mAbcg8R GGCTTCCGACCCATGAATG, mHmgcsF 
GCCGTGAACTGGGTCGAA, HmgcsR GCA TAT AT AGCAATGTCTCCTGCAA. 
lmmunofluoresence 
Mouse intestines were fixed in 3% paraformaldehyde for three hours, and unfrozen ten 
micron sections were cut and mounted on slides. Samples were blocked in I 0% normal goat 
serum for 30 minutes in 0. 1 %  bovine serum albumin/0. 1 %  Tween-20/PBS, incubated with a 
polyclonal antibody directed to ABCA l ( 12) at a concentration of lO!Jg/ml, followed by a 
goat anti-rabbit IgG secondary antibody, then washed and counterstained with DAPI or 
phalloidin prior to coverslipping. Images were captured with a Zeiss Axioplan 2 camera and 
analyzed using Metamorph software. 
Plasma and tissue lipid analysis 
Plasma lipid concentrations were determined in 4 hour fasted mice as previously described 
(5 1 ). Briefly, cholesterol and triglyceride concentrations were determined by enzymatic 
assays using commercially available reagents (BioMerieux). Plasma HDL cholesterol levels 
were determined after precipitation of apoB-containing lipoproteins with phosphotungstic acid 
(Roche Diagnostics GmbH). Plasma levels of apoA-1, apoA-11, apoB, and apoC-III were 
measured by an immunonephelemetric assay using specific mouse polyclonal antibodies as 
described previously (65). Fast Protein Liquid Chromatography was preformed as previously 
described (65). This system allows separation of the three major lipoprotein classes, VLDL + 
IDL, LDL, and HDL in individual animals. Cholesterol concentrations were determined in the 
eluted fractions. Accumulated data were analyzed by the Millenium 20/0 program (Waters). 
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Intestinal and hepatic free and total cholesterol was determined by gas-liquid 
chromatography, as previously described (66). 
Enterocyte studies 
Mouse primary enterocyte studies were performed according to published protocols (29;30) . 
Briefly, freshly isolated enterocytes were incubated with I jlCi/mL of [3H] cholesterol in 
DMEM at 37 ac with constant shaking, and cell suspensions were gassed with 95% 02, 5% 
C02. After I hour, enterocytes were centrifuged at 3,000 rpm for 5 min and the cell pellets 
were washed twice with DMEM (Gibco), and incubated at 37 °C with micelles containing 
0. 14 mM sodium cholate, 0. 1 5  mM sodium deoxycholate, 0. I 7 mM phosphatidylcholine, 1 .2 
mM oleic acid, and 0. I 9 mM monopalmitoylglycerol. At the end of the incubation, 
enterocytes were centrifuged (3,000 rpm, 5 min) and radioactivity in media was counted 
directly or in fractions following density gradient ultracentrifugation, performed as previously 
described (29). Total lipids were extracted from cells with isopropanol and counted by liquid 
scintillation, and proteins were dissolved in O. I N  NaOH and measured by the Bradford 
method (67). Data represent n = 6 mice per genotype. 
Cholesterol absorption 
Acute cholesterol absorption was determined as previously described (30). Briefly, overnight 
fasted mice were gavaged with 0.2 j.!Ci eH] cholesterol (NEN Life Sciences) and 0.2 mg 
unlabeled cholesterol in 15 jll olive oil. After 2 hours, plasma, liver and small intestine (first 
20 em from pylorus) were harvested and eH] content was determined by liquid scintillation 
counting. Data for liver represent dpm per tissue mass multiplied by total liver mass, and for 
plasma represent dpm per ml plasma multiplied by total mouse plasma volume (estimated by 
mass of animal). Data represent n = 3-6 mice per genotype. 
For dual fecal isotope studies to quantify fractional cholesterol absorption, mice were 
gavaged with 0. 1 jlCi [ 14C] cholesterol and 0.2 jlCi eH] sitosterol (American Radiolabeled 
Chemicals) in 0.2 ml soybean oil (Sigma) and feces were collected for 72 hours. Lipids were 
extracted from feces and counted by liquid scintillation spectroscopy. Fractional cholesterol 
absorption was calculated by the formula: (dose [ 14C] : [3H] - fecal [ 14C] :eH]) I dose 
[ 14CJ:eH]. 
Mesenteric lymph collection 
Mesenteric lymph cannulation was performed as previously described (68) with minor 
adjustments. Non-fasted mice were anesthetized by intraperitoneal injection of 
fentanyllfluanisone (1 ml/kg) and diazepam ( 10  mg/kg), and remained anesthetized over the 
course the experiment. After extra-abdominal displacement of the intestine, the main 
mesenteric lymph duct was punctured and cannulated with a 0.305 x 0.635 mm (id x od) 
silicone tubing which was primed with a heparin sodium solution ( 1000 U/ml). A second 
cannula was inserted into the duodenum. Both cannulas were secured with tissue adhesive 
and externalized through the abdominal wall. After repositioning the intestine, the abdominal 
incision was closed with 8-1 0  sutures. The animals received an infusion of 4% Intralipid® 
(0.3 mllh) through the duodenal cannula during lymph collection. After I hour of lymph 
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collection, animals received a lipid bolus via the duodenal cannula containing 1 )!Ci of [ 14C] 
cholesterol and 0. 1 1J.Ci of eH] oleate in 0. 1 ml of 4% Intralipid®. Lymph was collected by 
gravity for 4 hours in total. Body temperature was stabilized using a humidified incubator. 
Cholesterol and triglyceride concentrations in lymph were determined as described for 
plasma. Pooled lymph samples of each group were used for lipoprotein separation by fast 
protein liquid chromatography (FPLC) on a Superose 6B 10/30 column (Amersham 
Bioscience). The eH] and [ 14C] content of lymph was measured by liquid scintillation 
counting. Data represent n = 6-8 mice per genotype. 
Statistical analysis 
Differences between groups were compared using Student's t-test or one-way ANOVA using 
Graphpad Prism software. Data are presented as means ± standard error of the mean. 
Results 
To evaluate the role of intestinal ABCAl in HDL biogenesis in vivo, we generated mice that 
specifically lack ABCAl in enterocytes by crossing Abcal floxed mice ( 1 6) to mice 
expressing Cre recombinase under the control of the intestinal epithelium-specific Vi/lin 
promoter (37). The Vi/lin promoter drives robust expression of Cre through the length of the 
small and large intestine from 12.5 days post coitum (37). Abcaril·i mice were born at the 
expected Mendelian frequencies, were fertile, and did not differ significantly in weight from 
littermate controls. Figure lA shows Southern blot analysis of EcoRV-digested genomic 
DNA from livers and intestines of Abca/+l+ and Abcaril-• littermates probed with a DNA 
fragment corresponding to intron 44. Cre-mediated deletion of Abca/ is evident in the 
intestine of Abcaril-i mice, but not in the liver of these mice, or in the intestine or liver of 
Abca/+l+ controls (Figure 2A). 
Recombination of the floxed Abcal allele resulted in a significant decrease in 
intestinal ABCAl mRNA (Figure 2B) and protein levels (Figure 2C). ABCAl protein 
expression in other tissues was unaltered (Figure 2C), indicating that AbcaFil-i mice 
specifically lack ABCAI in the intestine. 
Hepatic ABCA1 levels are a critical determinant of plasma HDL cholesterol 
concentration ( 1 6). Figure 2D shows hepatic Abcal mRNA levels as determined by 
quantitative real-time PCR, revealing no alteration in expression of hepatic ABCA 1 in AbcaF 
if-• mice compared to controls. Figure I E  shows a representative immunoblot of liver Iysates 
from Abcaril-i mice and controls, indicating that hepatic ABCA I protein expression is 
normal. Therefore, hepatic ABCA 1 levels are unaltered by deletion of intestinal ABCA l ,  and 
do not exhibit compensatory changes. 
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Figure 2. Generation of ABCA l intestinal specific knockout mice (Abcar"-'). (A) Southern blot of genomic 
liver (L) and intestine (I) DNA from mice with wildtype (+/+) or floxed (-i/-i) alleles in the presence of Cre 
recombinase. DNA was digested with EcoRV and hybridized with a probe to the genomic region between exon 
44 and 45 in the Abcal gene to produce the 6 kb wildtype, 7.3 kb floxed or 4.2 kb knock-out bands. (B) 
Quantitative real-time PCR of RNA isolated from mouse intestine. Reverse-transcribed RNA was amplified 
with oligos specific for Abcal and Gapdh. (C) Western blot of tissue lysates from control (+/+) and Abcal" ' (­
i/-i) mice with antibodies to ABCA l ,  and GAPDH as loading controL (D) Quantitative real-time PCR of RNA 
isolated from l ivers of Abcal•t• andAbcal "·• mice. Reverse-transcribed RNA was amplified with oligos specific 
for Abcal and Actin. (E) Representative western blot of liver lysates from Abcar'• and A bear"·• mice. 
Figure 3 shows ABCA I expression in mouse small intestine as detected by 
immunofluorescence. Ten micron sections of fixed mouse intestine were stained with a 
polyclonal antibody to ABCAl ( 12) (green), and counterstained with DAPI for cell nuclei 
(blue). ABCAl protein was found to be highly expressed in enterocytes of the ileum (Figure 
3A, B, and C) and jejunum (Figure 3D). ABCA 1 expression was primarily observed in the 
intestinal villi, with less expression in crypts, consistent with a role in the absorptive regions 
of the intestine. ABCAI expression was not detectable in the duodenum, cecum or colon of 
wildtype mice (data not shown). ABCAI appeared to be present both intra-cellularly and at 
the plasma membrane, including the basolateral membrane (Figure 3D), consistent with 
previous reports of ABCAI localization (38;39). Abcar;,.; mice had undetectable ABCAI 
protein expression in all sections analyzed (Figure 3E, F and G), indicating complete ablation 
of ABCAl protein expression in these mice. Figure 3H shows a section of wildtype jejunum 
stained with a random lgG to control for non-specific staining. 
Fasting plasma lipid and apolipoprotein concentrations in Abcal•'•, Abcar' ' and 
Abcarit-i mice are shown in Table I .  Total plasma cholesterol was significantly reduced by 
approximately 30% in Abcarit-i compared to Abcal+l+ mice, due primarily to a significant 
reduction in plasma HDL cholesterol (-30%, P<O.OO l ) . Plasma levels of apoA-1 and apoA-11 
were significantly decreased by -25% and 35%, respectively (P 0.05, Table 1 ). Plasma apoB 
was also significantly reduced in Abcar'l-i mice compared to controls by approximately 30% 
(P<O.Ol ,  Table 1 ) .  Notably, a gene-dosage effect was evident, with Abcal+l-i heterozygotes 
showing total plasma cholesterol and HDL cholesterol levels intermediate between wildtype 
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and knockout mice and significantly reduced compared to wildtype (P<O.OS, Table 1 ). 
Plasma apoA-1 concentrations in Abcal+l-i heterozygotes tended to be reduced compared to 
controls, but this difference was not statistically significant. 
Figure 3. Expression of ABCA I in mouse 
intestine. Ten micron sections of mouse 
intestine were stained with an antibody to 
ABCA I (green), or with DAPI (blue) or 
phalloidin (red). (A) Ileum, 20x 
magnification, (8 and C) ileum, 40x 
magnification from Abca /+I+ mice. (E, F 
and G) are corresponding sections from 
Abca r"·• mice. (D) Jejunum, 60x 
magnification from Abcal•'• mouse. (H) 
Jejunum. 60x magnification from Abcar'• 
mouse stained with random mouse JgG as 
negative control. For full color figure see 
JCI. 2006;2 16: 1 052- 1 062. 
Table 1. Plasma lipid and apolipoprotein values for ABCAI intestinal specific knock-out mice consuming a 
standard lab chow diet 
Abcal TPC HDL-C TG ApoA-1 ApoA-11 ApoCIII ApoB 
Genot;rl!e (m�dl) (m�dl) (m�dl) (m�dl� (m�dl) (m�dl) (m�dl) 
+I+ 1 1 6 ± 5 (2 1 )  75 ± 2 (3 1 )  1 05 ± 1 2  (9) 8 1  ± 4 (9) 1 52 ± 9 (9) 58 ± 7 (9) 2 1  ± I  (9) 
+1-i 96 ± 6 ( 1 3)" 63 ± 5 ( 1 2)" 91 ± 9 (8) 76 ± 6  (8) 1 28 ± 1 5 (8) 5 1  ± 7  (8) 1 8  ± 2  (8) 
-ii-i 8 1 ± 7 ( 14)b 49 ± 6  ( IO)b 1 05 ± 1 0 (6) 6 1  ± 1 0 (6)" 1 0 1  ± 1 7  (6)" 43 ± 4  (6) 15 ± I  (6)" 
Blood was obtained from mice after a 4 hour fast. Values are mean ± SEM. Number of mice is indicated in 
parentheses. TPC, total plasma cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; 
ApoA-1, apolipoprotein A-1. "P 0.05, bP<O.OO I compared to +1+. 
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Figure 4. Analysis of plasma lipoproteins by fast 
protein liquid chromatography (FPLC) . 
(A) Equal volumes of plasma from 4-hour fasted 
Abcar1+, Abcar'·' and Abcar"-• mice were pooled 
and fractionated by FPLC. Total cholesterol in each 
fraction was determined by enzymatic assay. (B) 
Plasma from individual 4-hour fasted mice was 
fractionated and cholesterol concentration determined 
on-line by FPLC. n=6-9 mice per group. * P<0.05. 
FPLC analysis confirmed the significant decrease in HDL cholesterol concentration in 
Abcaril-i mice (Figure 4A). No shift in particle size was evident, indicating that the reduction 
in HDL cholesterol primarily reflected a reduction in the number of similarly sized particles. 
Quantification of the cholesterol concentration in the FPLC-separated lipoprotein classes 
confirmed that HDL cholesterol was reduced by approximately 30% in Abcaril·i homozygotes 
(Figure 3B, P<0.05) and also revealed a significant decrease in LDL cholesterol concentration 
(Figure 3B, P<0.05), similar to that observed in Tangier Disease patients and in ABCA1 total 
knockout mice (40;41 ) .  
To determine the cumulative contribution of intestinal and hepatic ABCA 1 to plasma 
HDL cholesterol levels, we bred mice that carry both the Villin-Cre and Albumin-Cre 
transgenes, such that ABCA1 is deleted from both liver and intestine (Abcar•V-iL) .  Figure 5A 
shows plasma HDL cholesterol levels in control mice, and mice lacking intestinal ABCA1 ,  
hepatic ABCA1 ,  or both. Compared to mice lacking hepatic ABCA1 ,  mice lacking both 
intestinal and hepatic ABCA1 display a further significant decrease in plasma HDL 
cholesterol levels, indicating that the contribution of intestinal ABCA 1 to HDL cholesterol 
levels is independent of hepatic ABCAl .  Figure 5B shows HDL cholesterol levels as a 
percentage of respective age- and strain-matched controls. The combined deletion of both 
hepatic and intestinal ABCAl results in -90% decrease in plasma HDL cholesterol levels, 
similar to that seen in ABCAl total knockout mice. Therefore, the intestine and liver are the 
two major sites of initial HDL particle assembly, and ABCA1 in other tissues cannot 
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Figure 5. Tissue-specific contributions of ABCAI to 
plasma HDL cholesterol levels. (A) Plasma HDL 
cholesterol levels in control mice, and mice lacking 
intestinal ABCAI (-i/-i}, hepatic ABCA I (-U-L), or 
both (-iU-iL). Mice lacking both hepatic and 
intestinal ABCA I have a further significant decrease 
in plasma HDL cholesterol compared to mice lacking 
hepatic ABCA I .  (B) Plasma HDL cholesterol levels 
as a percentage of strain-matched controls. The 
percentage decrease compared to strain-matched 
control is indicated over each bar. Deletion of hepatic 
and intestinal ABCA I results in a -90% decrease in 
plasma HDL cholesterol, similar to that in mice 
lacking ABCAI globally (-/·). n 4 mice per group . 
*P<O.Ol .  
+I+ -i/-i -U-L -1U-il -1-
To study the metabolic consequences of loss of intestinal ABCA I on intestinal 
cholesterol transport, we fed Abcal+l+ and Abcaril-l mice eH] cholesterol and measured the 
appearance of the cholesterol tracer in plasma, liver and intestine after 2 hours. Figure 6A 
shows the appearance of eH] cholesterol in plasma, HDL and non-HDL 2 hours after oral 
gavage. Mice lacking intestinal ABCA l had a significant -35% reduction in the level of eH] 
cholesterol in plasma and HDL after 2 hours (P<0.05). eH] cholesterol appearance in non­
HDL was not significantly different between genotypes. Figures 6B and 6C show the amount 
of eH] cholesterol recovered in the liver and in the intestine after a luminal rinse, at 2 hours 
after the oral gavage. Abcaril-i mice displayed significantly less eH] cholesterol in liver 
(P<0.05, Figure 6B), as well as significant retention of eH] cholesterol in the small intestine 
compared to controls (P<0.05, Figure 6C). These data indicate that cholesterol uptake from 
the intestinal lumen is not impaired in mice lacking intestinal ABCA I ,  but that the transport 
of absorbed cholesterol into plasma is significantly reduced. The reduced appearance of 
radiolabeled cholesterol in plasma is unlikely to be secondary to the reduced plasma HDL 
cholesterol pool in these mice, because it has previously been shown that raising plasma HDL 
levels does not prevent decreased appearance of a gavaged cholesterol tracer in plasma in a 
chicken model of total ABCA 1 deficiency ( 42). 
To further assess the role of enterocyte ABCA 1 in the uptake of luminal cholesterol, 
we measured fractional cholesterol absorption by the dual-fecal isotope method. Figure 6D 
shows fractional cholesterol absorption in Abcal+l+ and Abcaril·i mice. We found no effect 
on this parameter in the absence of intestinal ABCA 1 ,  indicating that enterocyte ABCA I does 
not influence luminal cholesterol absorption. 
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Figure 6. Intestinal cholesterol transport in mice lacking intestinal ABCA I .  (A) Appearance of eHJ 
cholesterol in whole plasma, HDL and non-HDL l ipoprotein fraction after 2 hours. Mice were gavaged with 0.2 
JJCi of [3H] cholesterol and the appearance of the tracer was assessed after 2 hours. (B) eHJ cholesterol in liver 
2 hours after oral gavage. (C) eHJ cholesterol in small intestine 2 hours after oral gavage. The small intestine 
was rinsed with PBS to remove luminal contents. (D) Fractional cholesterol absorption determined by fecal 
dual-isotope method. n=6 mice per group. *P<0.05 
Figure 7 shows intestinal and hepatic cholesterol content in control mice and mice 
lacking intestinal ABCAI .  Mice lacking intestinal ABCAI displayed a trend towards 
increased total and free cholesterol in the small intestine, and a significant 1 0-fold increase in 
intestinal cholesterol ester content (P<0.05, Figure 7 A). There was no difference in hepatic 
cholesterol content (Figure 7B). Figure 7C shows the relative amounts of mRNAs involved 
in sterol metabolism in intestines of control and Abcaril·• mice. Mice lacking intestinal 
ABCA I had significantly increased levels of Abcg5 and AbcgB (P<0.05) as well as a trend 
towards reduced levels of HMG-CoA synthase (Hmgcs) mRNA (P=0.06). These gene 
expression changes are consistent with increased sterol content in enterocytes, leading to 
activation of LXR target genes such as ABCG5 and ABCG8 (43), and suppression of 
cholesterol synthesis genes. No change was observed in the levels of Npclll mRNA, the 
putative cholesterol absorption protein (44;45), consistent with our finding of normal 
cholesterol absorption in Abcaril·i mice (Figure 60). 
To further characterize the mechanism by which intestinal ABCA I influences plasma 
HDL cholesterol levels and intestinal lipid transport, we investigated cholesterol secretion by 
primary enterocytes isolated from Abcal+l+ and Abcal4' mice. This system has previously 
been shown to accurately model the secretion of cholesterol into both apoB-containing 
chylomicron and VLDL-sized particles, as well as non-apoB-containing particles in the size 
range of HDL (29;30). Primary enterocytes were isolated and incubated with eH] cholesterol 
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and then chased for 2 hours in the presence of micelles. Figures 8A and 8B show eH] 
cholesterol levels in cells and media, respectively, after 2 hours. Enterocytes from Abcal.,;.; 
mice contained significantly more eH] cholesterol (Figure 8A) and secreted less eH] 
cholesterol into the media over 2 hours (Figure 8B). 
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Figure 7. Tissue cholesterol levels and gene 
expression. (A) Intestinal cholesterol levels in 
control mice and mice lacking intestinal ABCA I .  
. n=3 mice per group. (B) Hepatic cholesterol levels 
in control mice and mice lacking intestinal ABCA I .  
n=3 mice per group. (C) Relative amounts of 
various mRNAs in intestines from control mice and 
mice lacking intestinal ABCA I .  Values are relative 
to the mRNA amount in control mice which is 
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Figure 8. Cholesterol secretion from primary enterocytes. Primary enterocytes from Abcal+t+ and Abca / "11 ' 
mice were isolated and radiolabeled with eHJ cholesterol, then chased in the presence of micelles. (A) eHJ 
cholesterol remaining in cells after 2 hour chase. (B) eHJ cholesterol in media after 2 hour chase. (C) Media 
was fractionated by ultracentrifugation and eHJ cholesterol measured in each fraction. n=6 per group. *P<0.05. 
**P<O.OO I .  
The media were subsequently subjected to density gradient ultracentrifugation and 
eH] cholesterol was determined in the isolated fractions. Figure 8C shows eH] cholesterol 
levels in the isolated fractions. Enterocytes lacking ABCA I secreted 40% less eH] 
cholesterol specifically into the highest density fractions in the density range of HDL and 
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containing most of the secreted apoA-1 (29;30) (Figure 8C, p<O.OOI ). In contrast, there was 
no difference in cholesterol secretion into the lower density fractions representing 
chlyomicrons and VLDL (fractions 1 -3), and which contain most of the apoB (29;30). These 
in vitro results therefore recapitulate the findings in vivo that absence of enterocyte ABCAl 
results in accumulation of cellular cholesterol, and reduced secretion of cholesterol. These 
data further indicate that ABCA l is directly involved in the secretion of cellular cholesterol 
into HDL from enterocytes. 
Cholesterol secretion by the intestine is thought to occur almost exclusively via the 
lymphatics (23). As Abcal4; mice had impaired transport of dietary cholesterol into plasma, 
we examined whether this was due to decreased transport of cholesterol via lymph. The 
mesenteric lymph ducts of Abcal+l+ and Abcar;;.; mice were cannulated and lymph was 
collected during an intra-duodenal infusion of 4% Intralipid containing [ 14C] cholesterol and 
[3H] oleate. Lymph production rates were similar in both groups of mice (approximately 
0. 1 0-0. 1 5  ml/h). Figure 9A and 98 show the rate of transport of cholesterol and triglyceride 
into mesenteric lymph in Abcal+l+ and Abcarit-i mice. There were no significant differences 
in lipid transport rate between genotypes indicating that total lymphatic lipid transport is not 
altered by the absence of intestinal ABCA I .  Monitoring the appearance of [ 14C] cholesterol 
and eH] oleate in lymph (Figure 9C) revealed that the rate of appearance of [ 14C] cholesterol 
in lymph as a fraction of eH] oleate was not significantly different in Abcal+t+ compared to 
Abcarif.i mice (0.53±0.2 vs. 0.65±0.2 after 4 hours, P=0.7), indicating that intestinal ABCAl 
does not participate in the transport of dietary cholesterol into lymph. 
Lymph collected from mice of each genotype was pooled and subjected to FPLC 
separation. Lymph from Abcal+t+ mice showed a major cholesterol peak corresponding to 
chylomicron/VLDL-sized particles and a minor peak in the size range of HDL, confirming 
that HDL cholesterol is present in the mesenteric lymph of wildtype mice (Figure 9D). 
Surprisingly, lymph from Abcar
if.i mice showed a similar cholesterol profile to that of 
wildype mice. A slight reduction was evident in the amounts of cholesterol in 
chylomicron/VLDL sized fractions. However, measurement of cholesterol in chylomicrons 
isolated by density gradient ultracentrifugation revealed that this difference was not 
statistically significant (0.70±0.07 vs. 0.59±0.06 mM, P=0.3). Notably, Abcar'f.i and 
Abcal+l+ mice had equivalent amounts of cholesterol in HDL-sized fractions (Figure 9D). 
This finding indicates that lymph HDL arises independently of intestinal ABCA I .  Assessing 
the distribution of [ 14C] cholesterol across the FPLC-separated lipoprotein fractions showed 
that virtually all of the radiolabeled cholesterol secreted into lymph was associated with the 
chylomicron/VLDL sized fractions in both and Abca/+1+ and Abcarit-i mice with essentially 
no [ 14C] cholesterol detectable in HDL-sized fractions (Figure 9E). 
We reasoned that HDL cholesterol present in mesenteric lymph could either arise from 
the intestine in an ABCA ! -independent manner, or could be derived from the plasma, as some 
reports have suggested (32-36). To determine if lymph HDL originates from plasma, we 
collected mesenteric lymph from mice in which ABCAI is deleted in the liver but is present 
in extrahepatic tissues, including the intestine (Abcaru-L mice) ( 1 6). AbcarV·L mice have an 
-80% reduction in plasma HDL cholesterol levels, and any alteration in lymph lipoprotein 
concentration detected in Abcaru-L mice should be directly attributable to the action of 
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hepatic ABCAl .  Lymph from Abcaru-L mice had no detectable HDL cholesterol (Figure 
9F), whereas the distribution of [ 14C] cholesterol among FPLC fractions was unchanged 
(Figure 90). In addition, the HDL-sized fractions from Abcaru-L lymph contained only trace 
amounts of apoA-1 in comparison to the equivalent fractions in lymph from wildtype and 
Abcaril·i mice (Figure 9H). These data indicate that HDL present in mesenteric lymph of 
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Figure 9. Analysis of lymph lipoproteins in Abca / •1• and Abcar"·' mice. (A) Lymph cholesterol transport rate 
in Abca/ +1+ and AbcaF" ' mice. (B) Lymph triglyceride transport rate in Abca/ •1• and Abcar"·• mice. (C) 
Appearance of [ 14C] cholesterol in lymph during intra-duodenal infusion as a fraction of eHJ oleate. (D) FPLC 
analysis of lymph from Abcar1• and Abcar"·• mice. (E) Distribution of [ 14C] cholesterol in FPLC fractions of 
Abcal+l+ and Abcar"·• mice. (F) FPLC analysis of lymph from Abcar'• and Abcal UL mice. (G) Distribution 
of [ 14C] cholesterol in FPLC fractions of Abcar1• and AbcarU·L mice. (H) Western blot of apoA-1 in HDL­
sized fractions from lymph of Abca / •1•, Abcar"� and AbcarU·L mice. n 6 mice per group. 
Discussion 
Using a novel mouse model in which ABCAl is specifically inactivated in the intestine, we 
have shown that intestinal ABCAl is critically involved in HDL biogenesis, contributing 
approximately 30% to the steady-state plasma HDL cholesterol pool. Intestinal ABCAl acts 
by directly mediating cholesterol transfer towards plasma HDL, and absence of intestinal 
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ABCAI is associated with decreased transport of intraluminally administered cholesterol into 
plasma. The absence of intestinal ABCAI was shown to have no effect on the transfer of 
luminal cholesterol into lymph and on lymphatic HDL particle content, suggesting that 
secretion of HDL by the intestine occurs into plasma. Finally, analysis of lymph from liver­
specific ABCAI -deficient mice with very low plasma HDL levels provides evidence that 
HDL present in mouse lymph originates from plasma. 
Since the discovery of the highly significant inverse relationship between HDL 
cholesterol concentration and risk for coronary heart disease (46), the origin of plasma HDL 
has been a subject of intense study. Successful development of therapeutic strategies to raise 
HDL levels relies crucially on knowledge of the molecular nature of HDL particle formation 
as well as the cellular origin of these particles. However, it has not been until recently that we 
have had the tools necessary to address these questions. 
The original conceptualization of the reverse cholesterol transport theory, as described 
by Glomset ( 1 ;2), postulated that HDL cholesterol would be mainly of peripheral origin and 
be transported to the liver for removal from the body by excretion into bile. The discovery of 
ABCA I as the cause of Tangier Disease ( 6-8), and the finding that the ABCA I gene product 
is indispensable for the maintenance of plasma HDL cholesterol levels in mice (39;4 1 ;47), has 
shed new light on the molecular mechanisms of HDL biogenesis. ABCA I is expressed 
widely throughout the body ( 12; 13), but only the liver and the intestine are known to 
synthesize apoA-I ( 1 8;48). However, co-expression in the same tissue does not constitute 
evidence for a functional relationship. Overexpression of ABCA I in the liver of mice via 
adenoviral delivery ( 14; 1 5) or by transgenesis under the control of either its endogenous (49) 
or an Apoe (50) promoter raises HDL levels and protects against atherosclerosis in mice with 
the Apoe·l· background (5 1 ) . We have recently described mice with liver-specific deletion of 
hepatic ABCA 1 ( 1 6), demonstrating the essential role of hepatic ABCA I in both the 
biogenesis and maintenance of plasma HDL. Here we report that deletion of intestinal 
ABCA I results in a significant reduction in plasma HDL cholesterol in mice, establishing the 
intestine as a second crucial player in HDL biogenesis. 
Absence of intestinal ABCAI was shown to result in decreased transport of dietary 
cholesterol into HDL in vivo and in vitro, along with accumulation of cellular cholesterol. 
However, our data indicate that in chow-fed mice absence of intestinal ABCAI does not 
affect fractional cholesterol absorption as determined by the dual-fecal isotope method. 
Previous studies assessing intestinal cholesterol absorption in mice lacking ABCAI globally 
have yielded conflicting results (41 ;52;53), suggesting the overall effect of ABCAl  on 
absorption is at most minor (54). Our findings indicate that the primary function of 
enterocyte ABCAl is to mediate the basolateral efflux of cholesterol and, presumably 
phospholipids, into plasma, a model which is supported by studies in CaCo-2 cells (29;55;56) 
and chickens lacking ABCAl globally (42). Structural and functional polarity is a 
fundamental feature of enterocytes, and indeed of a variety of epithelial cell types involved in 
vectorial transport (57). It is therefore perhaps not surprising that while absence of intestinal 
ABCAl impairs the basolateral transport of cellular cholesterol into plasma (Figure 6A), 
fractional cholesterol absorption as measured by dual-fecal isotope, which assesses only 
luminal uptake, is not affected (Figure 6D). These results also indicate that the reduction in 
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HDL cholesterol in plasma of Abca/"'1.; mice is the direct consequence of a secretory defect in 
enterocytes. 
Results obtained in ABCA I deficient enterocytes were similar to those observed in 
primary enterocytes lacking apoA-I (30), indicating that ABCA l and apoA-I are obligate 
partners for the secretion of HDL cholesterol from the intestine. While these data suggest that 
the intestine, along with the liver ( 1 6), is essential for the biogenesis of HDL particles, likely 
by initial lipidation of newly secreted apoA-I, it remains to be determined if the bulk of 
cholesterol carried by these lipoproteins originates from the intestine and the liver, or, as 
implicated by the reverse cholesterol transport hypothesis, from peripheral tissues. 
Cholesterol that is absorbed or synthesized locally in the intestine is thought to be 
secreted almost exclusively via the lymphatics, mostly in the form of cholesterol ester in 
chylomicrons and VLDL (23). Studies of the HDL of mesenteric lymph of rats also 
suggested that a portion of cellular cholesterol is secreted as HDL into lymph (25-27). Rat 
mesenteric lymph contains both discoidal and spherical HDL particles which are enriched in 
phospholipids and protein compared to plasma HDL (25;26), suggesting a distinct origin of 
these particles. We therefore hypothesized that Abcaril-i mice would have reduced HDL 
cholesterol in lymph, underlying the reduction in HDL cholesterol in plasma. 
Surprisingly, our lymph cannulation experiments showed that lymph HDL cholesterol 
and apoA-I contents were essentially unaffected in AbcaFil-i mice, and furthermore that 
transport of luminal cholesterol into lymph is independent of enterocyte ABCAI .  The fact 
that lymph HDL did not appear to decrease in Abca/";1.' mice in proportion to their reduction 
in plasma HDL cholesterol may simply reflect an inability to detect small differences in the 
very small amounts of HDL present in mouse lymph. In addition, plasma lipid values were 
determined in fasted mice, whereas lymphatic analysis was performed on non-fasted, 
anesthetized mice, and it cannot be excluded that transudation of HDL from plasma into 
lymph, or lipolysis of lymph chlymomicrons and VLDL, may be altered under these 
conditions. Importantly, the finding that absence of intestinal ABCAl impairs the transport 
of luminal cholesterol into plasma (Figure 6A), but not into lymph (Figure 9C), suggests the 
existence of an alternative lipid transport system in enterocytes, by which ABCA ! -mediated 
cholesterol efflux to form HDL occurs selectively into capillaries, while chylomicrons are 
secreted predominantly into lymphatics. The intestinal epithelium is in close contact with 
both capillaries and lymphatic vessels of the lamina propria, and indeed other nutrients, such 
as medium-chain fatty acids, are transported directly into the portal circulation (23). To our 
knowledge, intestinal transport of cholesterol into the circulation in mammals has not been 
previously demonstrated. 
In contrast to Abcar;J., mice, lymph HDL cholesterol and apoA-I were virtually absent 
in Abcaru-L mice, suggesting that the HDL present in the lymph of wildtype mice is 
dependent on the activity of hepatic ABCAI and enters the lymph via the plasma. Consistent 
with this, orally administered [ 14C]-labeled cholesterol was recovered only in 
chylomicron!VLDL-sized fractions in Abcar1+, Abca/ ";1.' and Abcal U-L mice, indicating that 
in the time-course of our experiments the intestine did not secrete cholesterol into lymph 
HDL. The origin of HDL particles in mesenteric lymph has been a subject of considerable 
controversy. Beamot et a!. demonstrated that following intravenous injection of [ 125I] apoA-I 
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labeled HDL, the specific activity of lymph HDL-associated apoA-1 did not exceed 
approximately 30% of that of plasma HDL-associated apoA-I, suggesting intestinal secretion 
of HDL apoA-I into lymph (28). In addition, Forester et al. reported that after duodenal 
infusion of eH] cholesterol the specific activity of lymph HDL was much higher than that of 
plasma HDL, although the same study also reported significant transfer of free cholesterol 
between different lipoprotein classes (26). Other studies have suggested that transudation 
from plasma represents the major origin of lymph HDL (32-36). Because of the rapid 
exchange of apoprotein and lipid constituents among lipoprotein classes (58;59) 
radiolabeling experiments may not be able to correctly determine the origin of the 
radiolabeled particles. The reasons for the discrepancies between our results and those 
suggesting secretion of intestinal HDL into lymph (25;26;28;60) remain unclear. In most of 
the studies performed in rats lymph was collected in the presence of an inhibitor of 
lecithin:cholesterol acyltransferase, which we did not use, and some of these discrepancies 
may also be due to species differences between mice and rats. In addition, the small amounts 
of apoA-I in lymph HDL fractions of AbcarU·L mice may represent intestinally-derived HDL 
that arises independently of ABCAl .  Our data showing near absence of lymph HDL 
cholesterol and apoA-I in AbcarU·L mice are most consistent with a model in which lymph 
HDL is predominantly derived from the plasma. 
Patients with Tangier Disease have long been recognized to have reduced LDL 
cholesterol and altered LDL composition, in addition to near absent HDL cholesterol (61 ). 
The mechanisms by which ABCA I impacts the metabolism of apoB-containing lipoproteins 
is unclear (62). One mechanism involves an inability of HDL to supply cholesterol esters to 
LDL via cholesterol ester transfer protein (CETP) (63). However, this is unlikely to be the 
sole mechanism, since patients with apoA-1 deficiency also lack plasma HDL cholesterol but 
do not exhibit the reduction in LDL cholesterol observed in Tangier Disease (64), and mice 
that lack ABCAl globally or in the liver have reduced LDL cholesterol but do not have CETP 
(16;4 1 ) .  Abcar
;;.; mice have significantly reduced LDL cholesterol and apoB despite their 
more modest decrease in HDL cholesterol, suggesting that the reduced HDL cholesterol may 
not entirely underlie the reduction in plasma LDL cholesterol. In addition, lymph 
chylomicronNLDL cholesterol was slightly decreased in AbcaT
;;.; mice, though this 
difference was not significantly different when lymph chylomicron levels were compared 
after isolation by density gradient ultracentrifugation. Our studies in primary enterocytes 
from Abcaril·i mice suggest that secretion of cholesterol into apoB containing particles is not 
impaired (Figure 8C), similar to enterocytes isolated from mice lacking apoA-I (30), and in 
contrast to enterocytes in which microsomal transfer protein is inhibited (29). These results 
suggest that intestinal and hepatic ABCAI may have direct effects on plasma LDL cholesterol 
that are not entirely dependent on their effects on HDL cholesterol concentration. 
In summary, our results establish that the intestine is crucially involved in the 
maintenance of plasma HDL levels through the actions of ABCA l and in addition suggest 
that intestinally-derived HDL may enter the circulation directly rather than via the lymph. 
Additional studies are necessary to determine if deletion of intestinal ABCA I confers 
increased risk of atherosclerosis and thus whether the intestine plays an atheroprotective role 
as a component of its normal physiological function. 
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Rationale Liver X Receptor (LXR) agonists have potentially anti-atherosclerotic actions, 
however, general LXR activation also leads to hypertriglyceridemia and hepatic steatosis in 
rodents. We have recently reported an increased fecal neutral sterol loss independent from 
biliary sterol secretion in mice upon LXR activation. Thus, the intestine can act as an 
excretory organ in the reverse cholesterol transport pathway. In this study, we have examined 
the physiological effects of intestine-specific LXR activation on reverse cholesterol transport. 
Material and Methods Wistar rats were treated with the synthetic LXR agonist GW3965 ( 10  
mglkg/day) for 6 days prior to measurements of cholesterol fluxes and expression of LXR 
target genes in liver and intestine. Results Treatment of rats with GW3965 led to an intestine­
specific LXR response: no changes in expression of LXR target genes in the liver were 
observed. Accordingly, biliary bile acids, cholesterol and phospholipid output as well as 
hepatic triglyceride content remained unaffected upon GW3965 treatment. LXR activation, 
however, did lead to I I - , 7-, and 3-fold increases in intestinal expression of the ABC 
transporters Abcal, Abcg5 and Abcg8, all involved in cholesterol transport, and of additional 
LXR target genes. Fecal neutral sterol output increased by 63% upon LXR activation . 
Turnover studies, using i.v. injected radiolabeled cholesterol, showed a 1 .7-fold induction of 
the flux of plasma-derived cholesterol towards the feces. This increase is due to decreased 
(biliary) cholesterol absorption, as fractional cholesterol absorption was reduced by 45% upon 
treatment, and to increased intestinal excretion. The accelerated efflux of cholesterol from the 
intestinal epithelium into the lumen was increased by 59% upon LXR activation. FPLC 
analysis showed that intestine-specific LXR activation led to an increase in HDL cholesterol 
(-20%) and ApoA-1. Conclusion Intestine-specific LXR activation leads to decreased 
cholesterol absorption, increased direct intestinal cholesterol excretion and increased HDL 
cholesterol levels without adverse effects on triglyceride metabolism in rats. 
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Introduction 
Low plasma levels of high density lipoprotein (HDL) cholesterol provide an important risk 
factor for cardiovascular diseases (CVD) ( 1 ). A multitude of epidemiological studies has 
shown that increasing plasma HDL cholesterol levels substantially lowers the risk for CVD, 
independently of total plasma cholesterol levels (2). Therefore, strategies aiming to raise 
plasma HDL cholesterol levels are currently being developed. Part of the athero-protective 
features of HDL is attributed to its role in the reverse cholesterol transport (RCT) pathway. 
This pathway is generally described as the HDL-mediated flux of (excess) cholesterol from 
peripheral cells towards the liver, followed by its secretion into bile and disposal via the feces. 
The obligatory first step is facilitated by the ATP-binding cassette (ABC) transporter A I 
(ABCAI ), that mediates the efflux of excess cellular cholesterol towards HDL. HDL­
cholesterol is subsequently taken up by the liver, mainly via the scavenger receptor-Bl (SR­
Bl), to be secreted into bile, either as free cholesterol via the action of ABCG5 and ABCG8 or 
after conversion into bile salts. The RCT pathway is particularly important for removal of 
excess cholesterol from macrophages, as accumulation of esterified cholesterol in these cells 
is considered a primary step in the development of atherosclerosis. 
Activation of the nuclear Liver X Receptor (LXR) by synthetic agonists induces the 
RCT pathway, as LXR transcriptionally induces several of the key proteins involved in RCT 
(3). Cholesterol, or more accurately oxysterols, are the natural ligands for LXR. Two LXR 
isotypes have been identified in mammals: LXRa. (NR I H3), which is mainly expressed in the 
liver, kidney, intestine, spleen, and adrenals, and LXR� (NR I H2), which is expressed 
ubiquitously (4; 5). LXR is a major regulator of cholesterol metabolism and LXR agonists are 
considered promising candidates for novel anti-atherosclerotic treatment strategies, as LXR 
agonists inhibit the development of atherosclerosis in sensitive mouse models (6; 7). 
Activation of LXR in mice leads to elevated HDL levels, increased biliary cholesterol 
excretion, reduced intestinal cholesterol absorption efficiency and, finally, to increased neutral 
sterol loss via the feces (8). Unfortunately, general LXR activation also leads to increased 
lipogenesis, hypertriglyceridemia and hepatic steatosis in rodents (9) which precludes its use 
in treatment of subjects at risk for CVD. 
During the past couple of years, it has become apparent that the intestine plays a direct 
regulatory role in RCT. We have recently shown that the intestine itself contributes to fecal 
neutral sterol loss as a cholesterol-secreting organ. Using Mdr2"1. mice, which virtually lack 
biliary cholesterol secretion, we showed that plasma-derived cholesterol can be secreted 
directly by the intestine into the feces and this pathway could be enhanced by LXR activation 
( 1 0). In addition, Brunham and colleagues ( I I )  recently demonstrated, by using intestine­
specific Abca/-deficient mice, that the intestine significantly contributes to the steady-state 
plasma HDL pool. In the current study, we examined the physiological effects of intestine­
specific LXR activation on reverse cholesterol transport, as specific LXR activation in the 
intestine theoretically would lead to decreased cholesterol absorption, increased intestinal 




Animals and diet 
Male Wistar rats (- 275 g) were purchased from Harlan (Horst, The Netherlands). All 
animals were housed in an environmentally controlled facility with a 1211 2-hour day/night 
cycle, were fed ad libitum and had free access to water. Animals were housed individually 1 
week before experiments. During the experimental feeding, rats received standard chow, 
containing 0.0 1 7  w/w % cholesterol (Arie Blok BV, Woerden, The Netherlands), or chow 
supplemented with the synthetic LXR agonist GW3965, 10 mg/kg/day (based on 300 g body 
weight and consumption of 20 g chow/day) for 6 days. GW3965 was kindly provided by 
GlaxoSmithKline, Stevenage, UK. All experiments were performed with the approval of the 
Ethical Committee for Animal Experiments of the University of Groningen. 
Experimental methods 
During the experimental feeding, feces were collected from day 4 until day 6. At day 6, 
animals were anaesthetized by intraperitoneal injection of pentobarbital (0. 1 ml/ 1 00 g b.w.). 
After cannulating the common bile duct, hepatic bile was collected for 30 minutes. During 
bile collection, body temperature was stabilized using a humidified incubator. Bile flow was 
determined gravimetrically assuming a density of 1 g/ml for bile ( 12). After bile collection, a 
large blood sample was taken from the vena cava inferior. Blood was collected in EDTA­
containing tubes. Livers were excised and weighed. The small intestine was rinsed with cold 
phosphate-buffered saline containing I OO JlM phenyl methyl sulforyl fluoride (PMSF) and 
divided into nine equal parts. The tibias were collected for isolation of bone marrow cells. 
Parts of both the liver and intestine were snap-frozen in liquid nitrogen and stored at -80°C for 
mRNA isolation and biochemical analysis. Samples for microscopic evaluation were frozen in 
isopentane and stored at -80°C, or fixed in paraformaldehyde, for hematoxylin/eosin and oil 
red 0 staining. 
Fractional cholesterol absorption was measured in a separate experiment using the 
fecal dual-isotope method. Wistar rats were fed normal chow or chow supplemented with 
GW3965 ( 10  mg/kg/day). After 5 days, rats received by gavage 500 Jll of medium-chain 
triglyceride oil containing I J!Ci of [ 14C]cholesterol (Amersham Bioscience,Buckinghamshire, 
UK) and 2 J!Ci of [3H]sitostanol (American Radiolabeled Chemicals, St Louis, USA). Feces 
were collected for the next 24 hours. 
For determination of cholesterol kinetics, rats were equipped with permanent catheters 
in the bile duct, duodenum, and heart 6 days before the experimental feeding ( 12). Rats were 
fed normal chow or chow supplemented with GW3965 ( 1  0 mg/kg/day). After 4 days, rats 
received an intravenous injection of 5 J.LCi eH]cholesterol (NEN Life Science, Zaventem, 
Belgium) dissolved in 400 Jll Intralipid (20%, Fresenius Kabi, Den Bosch, The Netherlands) 
via the heart catheter. Blood samples and bile samples were taken I ,  6, 24, 48, and 72 hours 
after injection in unstrained, conscious animals via catheters. Feces were collected from 
individual rats at day 1 ,  2, and 3 after injection. After 3 days, animals were sacrificed and the 
intestine was collected for radioactivity measurement. 
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Analytical methods 
Bile salts were measured enzymatically ( 1 3). Commercially available kits were used for the 
determination of free cholesterol (Wako, Neuss, Germany), total cholesterol and triglycerides 
(Roche Molecular Biochemicals, Mannheim, Germany) and phospholipids (Wako) in plasma. 
Individual plasma samples were used for lipoprotein separation by fast protein liquid 
chromatography (FPLC) on a Superose 6B 1 0/30 column (Amersham Bioscience). 
Phospholipids in bile and liver were determined as described by Bottcher et al. ( 14). 
Cholesterol in bile was measured according to Gamble et al. (15). Feces were weighed and 
homogenized. Neutral sterols and bile salts were analyzed according to Acra et al. ( 1 6) and 
Setchell et al. ( 1 7). 
Feces collected for cholesterol absorption measurements after oral administration of 
eHJsitostanol and [14C]cholesterol were freeze-dried, saponified, and neutral sterols were 
extracted. The [ 14C] and eH] content of the feces and dosing mixture were counted and the 
ratio was used to calculate the percentage cholesterol absorption: ( 14C/3H dosing mixture - 14C/3H feces) 
% cholesterol absorption == x I  00 
14CPH dosing mixture 
To measure kinetics of fecal disposal of plasma-derived eH]cholesterol, the CHJ 
content of plasma ( 10  J.ll) was measured by liquid scintiilation counting. Before counting the 
eHJ content of feces, feces were freeze-dried, saponified, and neutral sterols were extracted 
according to Bligh and Dyer (1 8). 
Histology 
Liver and small intestine were examined after hematoxilin-eosin (HE) staining and oil red-o 
(ORO) staining for neutral lipids. HE staining was performed on paraformaldehyde-fixed, 
paraffin-embedded sections by standard procedures. Oil-red-o staining was performed on 
frozen sections by standard procedures 
RNA isolation and PCR procedures 
Total RNA was isolated with Trizol (Invitrogen, Parsley, UK) and quantified using Ribogreen 
(Molecular Probes, Eugene, USA). To collect bone marrow cells, tibias were flushed with 
PBS, cells were washed and Trizol was added. eDNA synthesis was done according to Bloks 
et al. ( 19). Real-time quantitative PCR (20) was performed using an Applied Biosystems 
7700 Sequence detector according to the manufacturer's instructions. Primers were obtained 
from Invitrogen. Fluorogenic probes, labeled with 6-carboxy-fluorescein (FAM) and 6-
carboxy-tetramethyl·rhodamine (TAMRA), were made by Eurogentec (Seraing, Belgium). 
Primers and probes used in these studies have been described elsewhere (Abca/ ,  Abcg5, 
Acat2, Hmgcr, LDLr and Sr-bl (8), Abcgl ( 10), Fas (9), 3584 (21 )  except Abcg8 
(NM_I 30414; forward CCTGGCCAAAGGCAACAG, reverse 
GCCTGAAGATGTCAGAGCGA, probe CTGGTGCTCATCTCCCTCCACCAG), Acat2 
(NM_I 53728; forward AGGTGGAATTATGTGGCCAAGA, reverse 
CCAGGATGAAGCAGGCAT AGA, probe CAAACAGCCCAGAGCCTGGGCAA) and 
Npc/LI (NM_00 1002025; forward GGGCTAAAGATGCTACTGTCTTCA, reverse 
GCCTGGGAAGTTGGTCATG, probe ACTCCAGCAAACACCGCACTGCC). Expression 
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data for liver and intestine were subsequently standardized for fJ-Actin RNA, expression data 
for bone marrow cells were standardized for 36B4 RNA, which was analyzed in separate runs. 
Statistics 
Statistical analyses were performed using SPSS 10.0 for Windows (SPSS Inc., Chicago, 
USA). Differences between the groups were analyzed by the Mann-Whitney-U-test. A 
p-value smaller than 0.05 was considered statistically significant. 
Results 
Oral administration of GW3965 does not result in LXR activation in liver or bone marrow 
in rats 
Oral administration of the synthetic LXR agonist GW3965 had no effect on liver weight 
(Table I )  or liver morphology upon HE or Oil-Red-O staining (data not shown). GW3965 
treatment in rats failed to induce expression of genes involved in cholesterol transport in the 
liver, such as Abcal,  A beg 1, Abcg5, or in genes involved in de novo lipogenesis, such as, Fas 
or Srebplc (Figure 1) .  Expression of Hmg-CoA reductase (Hmgcr), indicative for cholesterol 
synthesis remained unchanged upon GW3965 treatment, while expression of the LDLr did 
increase (Figure 1 ) .  In agreement of the unchanged expression of Abcg5, biliary secretion of 
cholesterol, phospholipids and bile salts remained unchanged upon treatment with GW3965 
(Table 1 ). 
As bone marrow cells are often used for rapid in vivo screening of potentially new 
LXR agonists, we analyzed expression of Abcal and Abcgl in bone marrow of control and 
GW3965-treated rats. GW3965 treatment in rats did not induce expression of Abcal (relative 
expression 1 .0 ± 0.2 vs. 1 . 1  ± 0.4 in control vs. treated rats) or Abcgl (relative expression 1 .0 
± 0.2 vs. 0.9 ± 0.2 in control vs. treated rats), both known to be LXR target genes. 
Table 1. Bile parameters of Wistar rats maintained on chow diet with or without the LXR agonist GW3965. 
Control GW3965 
Body weight (g) 340.5 ± 6.8 336.0 ± 1 1 .9 
Liver weight (% of body weight) 4.2 ± 0.2 4.4 ± 0.3 
Bile flow ( 1/min/1 00 g body weight) 6.09 ± 1 .39 6.3 1 ± 0.32 
Bile salts (nmol/min/1 00 g body weight) 225 ± 68 206 ± 49 
Cholesterol (nmol/min/ 1 00 g body weight) 4.38 ± 0.69 4.26 ± 1 .0 1  
Phospholipids (nmollmin/1 00 g body weight) 24.6 ± 4.2 30.4 ± 7.4 
Male Wistar rats (n = 6 per group) were fed a chow diet with or without GW3965 ( 1 0  mg/kg/d) for 6 days. Bile 
was collected for 30 min. Analysis of bile was performed as described in "Experimental Procedures". Values 
represent means ± S.D. 
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GW3965 administration leads to increased fecal neutral sterol loss in rats 
As oral GW3965 administration is known to increase fecal neutral sterol loss and to decrease 
cholesterol absorption in mice ( 1 0) and the increased hepatic expression of the LDLr suggests 
this is also the case in rats, we measured these parameters. Indeed, GW3965 treatment 
increased fecal neutral sterol output by 63% whereas fecal bile salt Joss remained unaffected 
(Figure 2). Fractional cholesterol absorption decreased by 45% upon GW3965 administration, 
as measured by the oral dual isotope test (Figure 3). 
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Figure 1. Hepatic expression of genes involved in cholesterol and fatty acid metabolism in Wistar rats 
maintained on chow diet with or without the LXR agonist GW3965. Male Wistar rats were maintained on chow 
diet with or without the LXR agonist GW3965 ( 1 0  mg/kg/d) for 6 days. RNA was isolated from the liver. 
Synthesis of eDNA and quantitative real-time PCR was performed as described under "Experimental 
Procedures". All data were standardised for -actin RNA. Expression in rats on control diet was set at 1 .00. 
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Figure 2. Fecal loss of neutral sterols and bile salts of 
Wistar rats maintained on chow diet with or without 
the LXR agonist GW3965. Wistar rats were 
maintained on chow diet with or without the LXR 
agonist GW3965 (I 0 mglkg/d) for 6 days. Animals 
were individual during the experiment and feces were 
collected last 24 hour of experiment. Feces were 
analysed as described in "Experimental Procedures". * 
Indicates significant difference (Mann-Whitney U test. 
p<0.05). 
Oral administration of GW3965 leads to intestinal LXR activation in rats 
Several genes, such as Abcg5, Abcg8, and Npcl ll are known to be involved in cholesterol 
absorption (22-24) and to be regulated by LXR under certain conditions in mice (25; 26). To 
determine whether the decreased cholesterol absorption was associated with altered 
expression of these genes, these were measured in the proximal small intestine where 
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cholesterol absorption takes place. Results are depicted in Table 2. GW3965 administration 
increased intestinal Abcg5 and Abcg8 expression by 6.5-fold and 3 . 1 -fold, respectively, 
showing that GW3965 administration activated LXR in the intestine in rats. Intestinal LXR 
activation, however, had no effect on intestinal Npclll expression. Genes involved in 
cholesterol esterification, i.e., Acat2, or in cholesterol synthesis, i.e., HmgCoA reductase, 
were not affected upon LXR activation. In addition, LXR activation led to a 1 1 -fold increase 
in Abcal expression and to a 1 3-fold increase in Abcgl expression. 
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Figure 3. Fractional cholesterol absorption of Wistar rats maintained on chow diet in absence or presence of the 
LXR agonist GW3965. Wistar rats were maintained on chow diet in the absence or presence of the LXR agonist 
GW3965 ( 1 0  mg/kg/d) for 6 days. Fractional cholesterol absorption was measured using the fecal dual-isotope 
method as described in "Experimental Procedures". * Indicates significant difference (Mann-Whitney U test. 
p<0.05). 
Table 2. Relative RNA levels in small intestine of Wistar rats treated with the LXR agonist GW3965. 
mRNA Control GW3965 
Abcal 1 .00 ± 0.5 1 I I .39 ± 4.36" 
Abcgl 1 .00 ± 0.44 1 2.83 ± 7.04" 
Abcg5 1 .00 ± 0.59 6.52 ± 3 .76 " 
Abcg8 1 .00 ± 0.49 3 . 1 5  ± 0.66 ' 
Acat 2 1 .00 ± 0.33 0.96 ± 0.22 
Hmgcr 1 .00 ± 0.33 0.73 ± 0.1 I 
Npc l l l  1 .00 ± 0.28 0.96 ± 0. 1 5  
Male Wistar rats were maintained on chow diet with or without the LXR agonist GW3965 ( 1 0  mglkg/d) for 6 
days. RNA was isolated from the proximal intestine. Synthesis of eDNA and quantitative real-time PCR was 
performed as described under "Experimental Procedures"'. All data were standardised for -actin RNA. 
Expression in rats on control diet was set to I .00. Values represent means ± S.D. ' Indicates significant difference 
(Mann-Whitney U test. p<0.05) compared to control rats. 
Plasma sterol levels 
As intestinal Abcal is known to be critically involved in HDL biogenesis ( 1 1 ), we measured 
the plasma lipid levels. Although total cholesterol, phospholipid and triglyceride levels were 
unaffected (Table 3), FPLC analysis showed that intestinal LXR activation did result in 
decreased LDL cholesterol levels and increased HDL cholesterol levels (Figure 4). Western 
blot analysis of the HDL-containing fractions showed increased Apo-AI contents upon LXR 
activation (Figure 4). 
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Table 3. Plasma lipids of Wistar rats maintained on chow diet with or without the LXR agonist GW3965. 
Control GW3965 
Total cholesterol (mM) 1 .66 ± 0.08 1 .7 1  ± 0.2 1 
Phospholipids (mM) 1 .57 ± 0. 1 3  1 .57 ± 0. 1 7  
Triglycerides (mM) 1 . 1 6  ± 0.42 1 . 1 3  ± 0.48 
Male Wistar rats (n = 6 per group) were fed a chow diet with or without GW3965 ( 1 0  mg/kg/d) for 6 days. 
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Figure 4. Effect of LXR activation on distribution of cholesterol in plasma lipoprotein fractions of Wistar rats. 
Rats were maintained for 6 days on chow diet with or without the LXR agonist GW3965 ( 1 0  mglkg/d). Blood 
was collected via puncture of the vena cava inferior and lipoprotein separation was done by FPLC. Analysis was 
performed as described in "Experimental Procedures". * Indicates significant difference (Mann-Whitney U test. 
p<0.05). 
Assessment of the intestinal cholesterol excretion pathway 
We have recently shown that increased fecal cholesterol loss upon whole-body LXR 
activation is independent of biliary cholesterol excretion in mice and established the intestine 
as cholesterol-secreting organ that is part of the reverse cholesterol transport pathway ( I  0). 
To determine whether intestine-specific LXR activation could enhance the secretion of 
plasma cholesterol, untreated and GW3965-treated Wistar rats received an intravenous 
injection of eH]cholesterol dissolved in Intralipid®. The eH] label was quantified in plasma, 
bile and the feces for 3 days after administration. No difference could be detected in specific 
activities of plasma cholesterol or biliary cholesterol between both groups at any time point. 
Yet, intestine-specific LXR activation did markedly increase the recovery of plasma-derived 
eH]cholesterol in the neutral sterol fraction of the feces after 3 days (3.2 % ± 1 .0 % vs. 5.4 % 
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± 0.6 %/dose, respectively) (Figure 5). More of the eH]-label was recovered in the fecal 
acidic (bile salt) fraction compared to the neutral sterol fraction. However, the amount of 
eHJ-labeled fecal bile salts did not change upon GW3965 treatment ( 1 2.3 ± 2.7 %/dose in 
control group vs. 1 3.3 ± 3.7 %/dose in GW3965 treated rats). 
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Figure 5. Cumulative excretion of radioactivity in the neutral sterol fraction of feces in Wistar rats treated with 
or without the synthetic LXR agonist GW3965. Wistar rats were maintained on chow without (n = 5) or with (n 
= 4) the LXR agonist GW3965 ( 10 mg/kg/d) for 4 days. After 4 days of diet mice received 3H-cholesterol 
intravenously and feces were collected every 24 hours until the end of the experiment. Radioactivity was 
measured in samples as described in "Experimental Procedures". * indicate significant difference (Mann­
Whitney U test. p<0.05). 
Discussion 
During the last couple of years, novel roles of the intestine in the control of cholesterol 
metabolism have emerged. First, molecular mechanisms involved in cholesterol absorption 
and modes to interfere with this process have been identified and were shown to strongly 
impact on plasma cholesterol levels (24; 27-3 1 ). Secondly, it is now evident that the intestine 
itself contributes to fecal neutral sterol loss as a cholesterol-secreting organ ( 1 0). Finally, very 
recent work has unequivocally demonstrated that the intestine contributes significantly to 
plasma HDL levels ( I I ). In the current study, we demonstrated for the first time the 
physiological effect of intestine- pecific LXR activation on cholesterol transport pathways in 
Wistar rats. 
Treatment of rats with the synthetic LXR agonist GW3965 ( 1 0  mg/kg/day) for 6 days 
led to an intestine-specific LXR response, as gene expression of LXR-target genes in the liver 
or in bone marrow cells, remained unaffected upon GW3965 treatment (Table 2). As a 
consequence of unaltered Abcg5/Abcg8 expression, biliary cholesterol secretion, which is 
clearly enhanced in mice upon LXR activation by other synthetic LXR agonists (8; 10), was 
not affected upon GW3965 treatment (Table I ). Likewise, GW3965 treatment was not 
associated with hepatic steatosis in rats, in accordance with unaffected Srebplc and Fas 
expression. GW3965 treatment did, however, lead to a strongly increased expression of LXR 
target genes like Abcal,  A beg 1 ,  A begS and Abcg8 in the intestine. 
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Intestine specific LXR activation led to decreased fractional cholesterol absorption, to 
an extent similar as observed upon general LXR activation in mice ( 1 0). Fecal neutral sterol 
output increased by 60% upon intestinal LXR activation in part reflecting increased loss of 
plasma-derived cholesterol, as secretion of i.v. injected labeled cholesterol into the feces was 
1 .7-fold higher. The route of the increased fecal cholesterol loss is probably dual. Part will be 
due to decreased biliary/dietary cholesterol absorption upon intestinal LXR activation. 
However, as biliary cholesterol secretion did not change upon intestinal LXR activation and 
its specific activity upon i.v. eH]cholesterol injection did not change, a decreased cholesterol 
absorption alone could not explain the 1 .6-fold increase in fecal neutral sterol loss. Dietary 
cholesterol intake was - 9 mol/day and biliary cholesterol secretion equelled - 2 1  mol/day, 
as calculated on the basis of 30 minutes output rates. Based on fractional cholesterol 
absorption rates of 62 % in control and 34 % in GW3965-treated rats, respectively, the fecal 
neutral sterol outputs of 24.4 mol/day in control and 39.9 mol/day in GW3965-treated rats 
can only be accounted for by intestinal cholesterol secretion of at least 1 2.8 mol/day and 
20.4 mol/day in untreated and treated rat, respectively. Thus, intestinal secretion is clearly 
increased upon intestine-specific LXR activation. 
Assessment of the appearance of intravenously injected eH] labeled cholesterol in the 
feces showed a markedly increased label excretion in the fecal neutral sterol fraction upon 
GW3965 treatment, suggesting that at least part of the cholesterol directly originates from the 
plasma compartment. Expression of the gene encoding HMGCoA reductase, a key enzyme in 
cholesterol synthesis, in liver and intestine remained unchanged upon GW3965 treatment, 
suggesting that cholesterol synthesis was not induced. The reduction of plasma LDL 
cholesterol and increased expression of LDLr in the liver upon GW3965 treatment (Figure 4) 
indicates increased uptake of LDL cholesterol by the liver. The increased influx of cholesterol 
via uptake of LDL cholesterol could theoretically explain the unchanged expression of Hmgcr 
upon GW3965 treatment, although it is appreciated that Hmgcr and LDLr expression usually 
change in parallel as a consequence of similar modes of regulation (32). 
Besides the effect of intestine-specific LXR activation on fecal cholesterol loss, 
GW3965-treated rats showed a relatively small, but clear increase in HDL cholesterol (Figure 
4). ApoA-1 content of HDL-sized fractions was also increased. Recently, Brunham and 
colleagues showed that intestine-specific deficiency of Abcal in mice resulted in a 30% 
decrease in plasma HDL cholesterol, indicating that intestinal ABCA1 ,  in addition to hepatic 
ABCA I ,  is crucial for the maintenance of plasma HDL cholesterol levels ( 1 1 ). LXR 
activation in our study increased intestinal Abcal expression 1 1 -fold. This led to a small, but 
relevant rise of about 20% in plasma HDL levels, showing proof of principle that 
pharmalogical targeting of the intestine can lead to an increase in HDL levels. Compared with 
hepatic overexpression of ABCA1 via adenoviral delivery systems (33; 34), the increase in 
plasma HDL cholesterol is relatively small, especially considering the 1 1 -fold increase in 
intestinal Abcal expression. However, might reflect a metabolic consequence of the increased 
basolateral-to-apical flux of plasma cholesterol through the enterocytes due to LXR 
activation. Overexpression of intestinal Abcal may, theoretically, lead to a larger increase in 
HDL cholesterol levels when intestinal secretion into the lumen and cholesterol uptake from 
the lumen are less affected, e.g., by use of an Abca1 -specific ligand. 
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Most intriguing is the intestine-specific effect of the GW3965 compound in Wistar 
rats. This is unlikely due to a poor bioavailability in this species, as bioavailability of 
GW3965 after oral administration was -74% in rats (M.C. Jaye, GlaxoSmithKline, personal 
communication). This suggests differences in co-factor recruitment by rat LXR in the liver 
versus the intestine. Differential effects of LXR activation by the LXR agonists T0901 3 1 7  
and GW3965 i n  liver vs. intestine have been reported previously. Hepatic expression of 
Srebp-Jc and FAS, both involved in lipogenesis, and of Abcal was induced upon GW3965 
treatment in mice, however, to a lesser extent as with T090 1 3 17.  Induction of Abcal in the 
intestine did not differ between GW3965- and T090 1 3 17-treated mice (35). Slightly different 
results were obtained by Quinet et at., who showed that hepatic expression of genes involved 
in lipogenesis (Srebplc, FAS, ACC) were more pronouncedly increased upon T090 1 3 1 7  
treatment compared to GW3965 treatment, while no differences i n  induction of hepatic 
expression of Abcal were seen (36). Interesting work recently revealed that GW3965 acts as a 
partial agonist for LXRa, inducing a state in which LXRa not only interacts with co­
activators but also with co-repressors. This would indicate that the relative abundance of co­
activators and co-repressors in a certain tissue could influence the consequences of LXR 
activation (37). In contrast, the synthetic LXR agonist T090 1 3 1 7  was shown to be a full LXR 
agonist causing only interaction with co-activators and even repressing of binding of co­
repressors at higher concentrations compared to the no-ligand situation (37). 
In conclusion, these data show that the intestine should be considered as a potential 
target for development of anti-atherosclerotic drugs that, in addition to interference with 
cholesterol absorption, modulate direct cholesterol excretion and plasma HDL cholesterol 
levels. Partial agonists for LXR may be particularly interesting in this respect, as this may 
provide a basis for tissue-specificity. 
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Abstract 
Dietary supplementation with plant sterols, stanols and their esters reduce intestinal 
cholesterol absorption and thereby lower plasma LDL cholesterol concentration in humans. It 
has been suggested that these beneficial effects are partly attributable to induction of genes 
involved in intestinal cholesterol transport, e.g., Abcg5 and Abcg8, via the Liver X Receptor 
(LXR), but direct proof is lacking. Male C57BU6J mice were fed a semi-synthetic diet 
(control) or diets containing cholesterol (0. 1 2  g/IOOg) only or combined with either plant 
sterols or stanols (0.5% g/lOOg) for 4 wk. Plant sterols and stanols dramatically increased 
neutral fecal sterol excretion (2.2 and 1 .4- fold, respectively, when compared to cholesterol­
fed mice; P<0.05). Cholesterol and cholesterol ester concentrations were significantly higher 
in livers of mice fed cholesterol compared to controls ( + 1 35% and + 925%; P<0.05). Plant 
sterols and stanols completely prevented cholesterol accumulation as well as induction of 
LXR target genes in liver. Feeding plant sterols and stanols did not alter intestinal expression 
of Abcg5, Abcg8 or other LXR target genes nor of Npclll.  Fractional cholesterol absorption 
in Abcg5·l· mice was reduced to the same extent as in wild-type littermates by dietary plant 
sterols (49% vs. 44%; n.s.). Plant sterol and stanol-induced reduction of cholesterol 
absorption in mice is not associated with upregulation of intestinal LXR target genes nor 
influenced by Abcg5-deficiency. Our data indicate that dietary plant sterols and stanols inhibit 
cholesterol absorption within the intestinal lumen independent of LXR. 
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Introduction 
Dietary plant sterols and plant stanols have been known to be efficient modulators of plasma 
LDL cholesterol concentrations in humans for decades ( I ;  2). In contrast to cholesterol, these 
compounds are only poorly absorbed from the intestine. Based on their structural similarity to 
cholesterol, it has been postulated that plant sterols and plant stanols physically interfere with 
intestinal cholesterol absorption, for instance by interference with cholesterol micellization in 
the intestinal lumen (3-5). 
Recently, proteins involved in cholesterol absorption as well as in intestinal sterol 
excretion have been identified. Niemann-Pick C l  like protein 1 (NPC 1 L l )  is considered the 
target of the cholesterol absorption inhibitor ezetimibe and has been demonstrated to be 
responsible for the majority of cholesterol uptake into enterocytes (6; 7). Recent findings 
indicate that plant sterols are also taken up by enterocytes via NPC 1 L l  (7).  In the enterocyte, 
cholesterol is readily esterified by the action of acyl-coenzyme A:cholesterol acyltransferase 2 
(ACAT2) and released into lymph in association with chylomicrons. In contrast, plant sterols 
and stanols are effectively excreted back to the intestinal lumen by heterodimers of the ATP­
binding cassette transporters ABCG5 and ABCG8 present at the apical membrane of the 
enterocyte.(8; 9) ABCA 1 is also highly expressed in the intestine, mainly at the basolateral 
domain of the cell membrane, but its role in sterol absorption is unclear ( 10- 1 2).  Expression 
of ABCA 1 ,  ABCG5 and ABCG8, but not of NPC 1 L l ,  is under control of a nuclear receptor, 
the Liver-X-receptor (LXR), activated by oxysterols ( 1 3; 14). Activation of LXR by synthetic 
ligands in mice has been demonstrated to increase fecal neutral sterol loss and to reduce 
fractional cholesterol absorption, as a consequence of increased Abcg5/Abcg8 expression 
leading to enhanced cholesterol excretion back into the intestinal lumen ( 1 4; 1 5).  
The discovery that cholesterol absorption can be actively regulated at the level of the 
enterocyte opens the possibility that plant sterols and plant stanols, in addition to their 
postulated physico-chemical effects (3-5), also influence cholesterol absorption by regulating 
expression of transport proteins. Specifically, plant sterols and stanols may act as LXR 
agonists either directly or after their conversion into oxyphytosterols or oxyphytostanols, 
respectively. Plant sterols and stanols have been demonstrated to act as LXR activators in in 
vitro experiments ( 1 6; 17)  and, for very specific sterols, also in vivo in mice ( 1 8).  Cell lines 
frequently lack ABCG5/ABCG8 expression and therefore may accumulate higher plant sterol 
and stanol levels than enterocytes in vivo. 
To test whether plant sterols and stanols present in functional food items are able to 
induce LXR-activated gene expression in vivo, we fed C57BU6 mice a semi-synthetic diet 
virtually free of cholesterol and the same diet enriched with cholesterol (0. 1 2  g/ lOOg), 
cholesterol and plant sterol fatty acid esters (0. 1 2  and 0.83 g/1 OOg) or cholesterol and plant 
stanol fatty acid esters (0. 1 2  and 0.83 g/lOOg) for 4 wk. The plant sterol and stanol fatty acid 
ester doses equal 0.5 g/ I OOg sterol or stanol, respectively. A semi-synthetic diet with the 
established LXR agonist T090 1 3 17 (0.015 g/IOOg) was used as a positive control for gene 
expression studies ( 19). We furthermore measured intestinal gene expression profiles and 
fractional cholesterol absorption in Abcg5 knock-out mice and their wild-type littermates on 
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both the cholesterol diet and the cholesterol diet enriched with plant sterols. Enterocytes in 
Abcg5 knockout mice are not protected against plant sterol accumulation and should, 
consequently, be more susceptible to LXR-mediated activation of gene expression by plant 
sterols. 
The aim of this study was to determine whether the well-characterized inhibitory 
action of plant sterols and plant stanols on intestinal cholesterol absorption is dependent on 
the activation of LXR in different mouse models. 
Materials and Methods 
Animal experiments 
Male, three months old C57BU6J mice were purchased from Harlan (Horst, The 
Netherlands). Mice were housed in temperature-controlled rooms (2 1 oq with 12 h light 
cycling and received a semi-synthetic diet and water ad libitum. Composition of the semi­
synthetic diet (prepared by Unilever, Vlaardingen, The Netherlands) is listed in Table l .  All 
mice were fed the semi-synthetic control diet for 2 wk (run-in period). Afterwards, mice were 
assigned to five treatment groups (6 mice per group) based on their body weights and were 
fed the specific diets (control, cholesterol diet, plant sterol diet, plant stanol diet, T090 1 3 1 7  
diet) for 4 weeks. T090 1 3 1 7  was purchased from Cayman Chemicals (Ann Arbor, Ml, USA). 
At the end of the experiment, feces were collected for 24 h. Mice were anaesthetized 
by intraperitoneal injection with Hypnorm ® (fentanyllfluanisone, I mUkg) and diazepam 
( 1 0  mglkg). Bile and tissues were collected as described (20). All experimental procedures 
were approved by the local Ethical Committee for Animal Experiments of the University of 
Groningen. 
Analytical procedures 
Biliary bile salt concentrations were measured enzymatically (2 1) .  Phospholipids and 
cholesterol in bile were determined as described by Bottcher et al. (22) and Gamble et al. (23), 
respectively, after extraction according to Bligh and Dyer (24). The same extraction method 
was applied for hepatic lipids, after which commercially available kits were used for the 
determination of unesterified cholesterol (Free cholesterol C, 279-47 1 06, Wako, Neuss, 
Germany), and for total cholesterol and triglycerides (Cholesterol CHOD-PAP, I 1489232-
2 1 6, and Tri/GB, 1 2 1 46029-2 1 6, respectively; Roche, Mannheim, Germany). Plasma lipids 
were measured using the same kits. Cholesterol ester concentrations were calculated from 
total and unesterified cholesterol concentrations. 
Feces were weighted and homogenized to a powder. Aliquots of fecal powder were 
used for analysis of total neutral sterol and bile salt content according to Area et al. (25) and 
Setchell et al. (26), respectively. 
Fractional cholesterol absorption in Abcgs'- mice 
Fractional cholesterol absorption in Abcgs·l· mice and wild-type littermates was measured 
using the plasma dual-isotope ratio method as previously described (27). Male Abcg5"1 mice 
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and littermate controls were housed as described above. All mice were fed semi-synthetic diet 
for 2 weeks (run-in period). Afterwards, mice received semi-synthetic diet enriched in 
cholesterol or in cholesterol and plant sterols (Table l )  for one week. Subsequently, mice 
received an intravenous injection of 2.4 j..l.Ci of 3H-cholesterol (NEN Life Science, Zaventem, 
Belgium) dissolved in Intralipid ® (20%; Fresenius Kabi, Den Bosch, The Netherlands) and 
an oral dose of 1 .2 j..l.Ci of 14C-cholesterol (Amersham Bioscience, Buckinghamshire, 
England) dissolved in medium-chain triglyceride oil . 14C and 3H activity was measured by 
liquid scintillation counting. Blood samples obtained by retro-orbital puncture 48 h after 
administration were used for the calculation of cholesterol absorption. 
T bl 1 C a e : ompos1t10n o h . d. sem1-synt et1c 1ets 
control cholesterol plant sterol plant stanol T090 1 3 1 7  diet 
diet diet diet diet 
KlkR 
Calcium caseinate 1 6 1 .40 
Vitamin mix2 1 1 .30 
Mineral mix3 39.70 
Arbocel BC-200 56.70 
Fat (soybean oil) 1 26. 10  
Carbohydrates (com) 599.90 
L-cysteine HCI 2.00 
Choline bitartrate 2.80 
Cholesterol - 1 .20 1 .20 1 .20 -
Plant sterol esters - - 8.33 - -
Plant stanol esters - - - 8.33 -
T090 1 3 1 7  - - - - 0. 1 50 
1 Semi-synthetic diets were provided by Unilever (VIaardingen, The Netherlands). Analysis of sterol 
composition revealed that the control diet contained 0.03% (w/w) sterols, mainly �-sitosterol (53.8 w/w% of all 
sterols). Plant sterol fatty acid esters were mainly �-sitosterol, campesterol and stigmasterol (36.5%, 20.4% and 
14.9% w/w, respectively). Plant stanol esters were mainly B-sitostanol and campestanol (50.3 and 24.6% w/w). 
The plant sterol or stanol ester dose equals to 5 g of sterol or stanol per kg diet. 2 vitamin mix (g/kg mix): 
nicotinic acid 3, Ca pantothenate 1 .6, pyridoxine-HCI 0.7, thiamine HCI 0.6, riboflavin 0.6, folic acid 0.2, biotin 
0.02, vitamin B - 1 2  (cyanocobalamin) 5, vitamin E (all-rac-a-tocopheryl acetate) (50%) 15 ,  vitamin A (all­
trans-retinyl palmitate) 500000 IE 0.8, vitamin 03 (cholecalciferol) I ,  vitamin K l  (phylloquinone) 0. 1 ,  maize 
starch 97 1 .38.3 AIN-930 mineral mix (glkg mix): calcium carbonate 236.9 1 ,  potassium hydrogenphosphate 196, 
sodium chloride 74, magnesium oxide 24, potassium citrate 70.78, potassium sulphate 46.6, AIN mineral mix 
9 1 .7 1 ,  maize starch 260 (38). 
RNA isolation and PCR procedures 
Total RNA was extracted from frozen tissues with TriReagent ® (Sigma, St. Louis, MO, 
USA) and quantified photometrically. eDNA synthesis was performed using recombinant 
M-MLV reverse transcriptase ( 1 0  U/j..lL), the appropriate buffer, dNTPs (500 j..lmoi/L), 
random nonamers ( 1  j..lmol/L), RNAse inhibitor (2 U/j..lL; all from Sigma) and total RNA (50 
ng/j..lL). The reaction mix was incubated for 1 0  minutes at 25°C for primer annealing, 60 
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minutes at 37"C for synthesis and 5 minutes at 94°C to denature the RT enzyme. Real-time 
quantitative PCR was performed as previously described (20). Primers (Invitrogen, Carlsbad, 
USA) and fluorogenic probes (Eurogentec, Seraing, Belgium) used in these studies have been 
described elsewhere (Srebpia, Srebpic, Srebp2, Srbi, Acat2, Hmgcr, Cyp7a, Abcal, Abcg5, 
AbcgS, ISS rRNA (20); Ldlr (28); Npclll (29). All data were subsequently normalized to ISS 
rRNA which was analysed in separate runs. 
Statistics 
Statistical analyses were performed using SPSS I 0. 1 for Windows (SPSS Inc., Chicago, 
USA). Differences among the dietary groups (control, cholesterol, plant sterol, plant stanols) 
were evaluated using Kruskal-Wallis analysis followed by the Mann-Whitney-U-test. The 
positive control (T090 1 3 1 7  diet) was not included in the statistical analysis. Data presented 
are means ± SD. Differences with P<0.05 were considered significant. 
Results 
Fecal neutral sterol excretion 
Growths rates of male C57BU6J mice fed the semi-synthetic diet with or without cholesterol, 
cholesterol and plant sterols, or cholesterol and plant stanols for 4 wk did not differ (data not 
shown), indicative for similar food intake in all groups. As anticipated, fecal neutral sterol 
excretion in mice fed cholesterol diet was increased by 56% and that of bile salts by 1 3 1 %, 
the latter indicative for increased bile salt synthesis. Addition of plant sterols and stanols 
induced a massive further increase in fecal neutral sterol output compared to mice receiving 
cholesterol diet only (2.2- and 1 .4- fold for plant sterols and plant stanols, respectively; Figure 
I ) .  Bile salt excretion was reduced by 3 1 %  by plant sterols. For comparison, treatment of 
control diet-fed mice with the LXR agonist T090 1 3 1 7  stimulated fecal neutral sterol and bile 








a b  
control cholesterol sterols 
Plasma and hepatic lipid composition 
stanols 
Figure 1: Fecal sterol output of C57BU6 mice 
fed semi-synthetic diet supplemented with 
cholesterol, plant sterols or plant stanols for 4 wk. 
White bars; fecal neutral sterol output (plant 
sterols and stanols not included). Filled bars: fecal 
bile salt output. Values are means ± SD, n=6. 
• different from control; b different from 
cholesterol. P<0.05. 
Plasma cholesterol, triglyceride and phospholipid concentrations did not differ among the four 
groups (Table 2). Nevertheless, mice receiving the cholesterol diet had significantly greater 
concentrations of both unesterified cholesterol (+1 35%) and cholesterol ester (+925%) in their 
livers compared to those fed the control diet (Figure 2). This, together, resulted in a hepatic 
cholesterol concentration that was 4-fold that of controls. Concurrently, the hepatic 
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triglyceride concentration was 1 .8- times increased in cholesterol-fed mice compared to mice 
fed the control diet. In mice fed plant sterols or plant stanols, cholesterol and triglyceride 
concentrations were significantly lower than in cholesterol-fed mice and did not differ from 
those in mice fed the control diet. T0901 3 1 7-treated mice showed a massive increase in 
hepatic triglyceride (5.2-fold) and total cholesterol concentration (0.6-fold) when compared to 
mice fed the control diet. 
Table 2: Plasma lipid concentrations of male C57BU6J mice fed semi-synthetic diet supplemented with 









3.8 ± 0.6 
0.94 ± 0.38 
3.5 ± 0.5 
D chmesterol ester 
control cholesterol sterols stanols 
cholesterol diet 
4.6 ± 0.3 
0.77 ± 0.26 
3.5 ± 0.3 
plant sterol diet plant stanol diet 
4.5 ± 0.6 
1 .08 ± 0.22 
3.7 ± 0.4 
4.4 ± 0.4 
0.89 ± 0.23 
3.6 ± 0.4 
Figure 2: Hepatic triglyceride (A) and cholesterol 
(B) concentrations in C57BU6 mice fed semi­
synthetic diet supplemented with cholesterol, 
plant sterols or plant stanols for 4 wk. Values are 
means ± SD, n =6. • different from control; 
b different from cholesterol, P<O.OS. 
Biliary cholesterol excretion is a major contributor to hepatic cholesterol turnover and 
an important determinant of fractional cholesterol absorption. Bile flow (Table 3) and biliary 
bile salt output (not shown) did not differ among the groups. Hepatobiliary sterol output rates 
did not differ significantly between groups fed cholesterol with or without plant sterols and 
stanols because of large variations between individual mice. 
Table 3 :  Hepatobiliary lipid output of male C57BU6J mice fed semi-synthetic diet supplemented with 
cholesterol, plant sterols or plant stanols for 4 wk
1 
bile flow, lllllinl/00 g body weight 
sterol output, nlllollllin/100 g body weight 
phospholipid output, nmo/Jmin/100 g body weight 
1 Values are means ± SD, n=6. 
control 
diet 
6. 1 ± 1 .0 
2.0 ± 0.9 
25.2 ± 9.8 
cholesterol 
diet 
6.0 ± I . I 
3.8 ± 2.3 
25.6± 1 3 . 1  
plant sterol plant stanol 
diet diet 
6.2 ± 1 .7 5.7 ± 0.9 
2.7 ± 1 .0 2.2 ± 1 . 1  
25.4 ± 9.5 24.4 ± 1 2.5 
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Hepatic alld illtestillal gelle expressioll 
To identify potential differences in LXR-mediated effects exerted by cholesterol and/or plant 
sterol and stanol feeding, gene expression patterns in liver tissue were determined (Table 4). 
Mice fed control diet supplied with the synthetic LXR agonist T090 1 3 17 were used as a 
positive control. Feeding the cholesterol diet significantly up-regulated the LXR target genes 
Abcg5 and Abcg8 (+ 194% and +143%, respectively), encoding the major regulator of 
hepatobiliary cholesterol excretion. In mice fed plant sterols or stanols, this up-regulation was 
significantly less pronounced (+87% for Abcg5 and +94% for Abcg8 with sterols and +63% 
and +6 1 %  for Abcg5 and Abcg8, with stanols, respectively). Expression of Abcg5 and Abcg8 
in the mice treated with T090 1 3 1 7  was increased by more than 300% compared to mice fed 
control diet. A similar induction by cholesterol feeding, in parallel with reduction by plant 
sterols or stanols, occured for Cyp7a1 ,  the gene encoding cholesterol-? -hydroxylase. 
Expression of Cyp7a1 is considered representative for bile salt synthesis. Concomitantly, the 
expression of the LXR target gene Srebp1c was increased by cholesterol feeding alone 
(+87%) and combined with plant sterols and stanols (+89% and +87%, respectively). All 
other genes analyzed did not differ among groups. 
Table 4: Hepatic mRNA expression levels in male C57BU6 mice fed semi-synthetic diet supplemented with 












control diet cholesterol diet plant sterol diet plant stanol diet 
1 .00 ± 0.3 1 2.94 ± 0.59 . 1 .87 ± 0.6 1 •b 1 .63 ± 0.45 •b 
1 .00 ± 0.29 2.43 ± 0.3 1 • 
1 .00 ± 0. 1 5  1 .38 ± 0. 1 5  
1 .00 ± 0.37 0.55 ± 0.22 
1 .00 ± 0. 1 4  1 .09 ± 0. 1 8  
1 .00 ± 0.38 1 .87 ± 0.41 a 
1 .00 ± 0 . 1 6  0.70 ± 0. 1 8  
1 .00 ± 0.37 0.99 ± 0.23 
1 .00 ± 0.33 3.30 ± 1 .59 a 
1 .00 ± 0.53 1 .09 ± 0.30 
1 .94 ± 0.46 •b 
1 .23 ± 0.28 
0.67 ± 0.24 
1 . 1 2 ± 0.25 
1 .89 ± 0.64 a 
0.79 ± 0. 1 7  
1 .02 ± 0.32 
1 .72 ± 0.45 a 
0.80 ± 0.29 
1 .6 1  ± 0.36 ab 
1 . 1 0  ± 0.36 
0.77 ± 0.47 
1 .03 ± 0.33 
1 .87 ± 0.9 1 a 
0.69 ± 0.27 
0.9 1 ± 0.38 
1 .95 ± 1 .06 
0.68 ± 0.20 
T090 1 3 1 7  3 
3.59 ± 1 .37 
3 .40 ± 1 .99 
1 .39 ± 0.29 
0.89 ± 0.34 
LI6 ± 0.29 
2.42 ± 1 . 1 1 
0.98 ± 0.32 
1 .33 ± 0.42 
2.36 ± 0.5 1 
1 .39 ± 0.23 
1 Values are means ± SD, n=6. a different from control; b different from cholesterol, P<0.05. 2 Gene expression 
was normalized to 1 8S rRNA. Expression of the control diet group was set to 1 .00. J The T090 1 3 1 7  -treated 
group was not included in the statistical analysis. 
Gene expression was measured in three segments along the lengths of the small 
intestine. The groups did not differ in the expression of Abcg5, Abcg8, Npcl 11 (Figure 3), 
Srb1, Acat2, or Hmgcr (data not shown), indicating that treatment did not influence 
intracellular cholesterol homeostasis at the level of gene expressions. However, large 
interindividual differences were noticed. The expression of Abca1 was significantly greater 
than in controls in the medial section of the small intestine of mice fed cholesterol or plant 
sterol diet (Figure 3). Feeding the T090 1 3 1 7  diet induced 2- to 9-fold increases in expression 
of Abcg5, Abcg8 and Abca1 along the whole axis of the small intestine when compared to the 
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proximal mid distal 
Figure 3: Intestinal gene expression in C57BU6 mice fed semi-synthetic diet supplemented with cholesterol, 
plant sterols or plant stanols for 4 wk. Expression was measured along three points of the small intestine (labeled 
proximal, mid, and distal) and corrected for that of I SS rRNA. T09 1 3 1 7  was used as a positive control for LXR 
activation (not included in the statistical analysis). Values are means ± SD, n =6. ' different from control, 
P<O.OS. 
Fractional cholesterol absorption in Abcg5'1- and wild-type mice 
The Abcg5/Abcg8 heterodimer prevents accumulation of plant sterols in enterocytes and is 
thought to contribute to regulation of cholesterol absorption. Mice lacking Abcg5 (Abcg5-1") 
should therefore, in principle, be prone to LXR activation upon feeding of plant sterol diet. 
We measured intestinal gene expression levels and fractional cholesterol absorption in wild­
type and Abcg5_,_ mice fed cholesterol only or cholesterol and plant sterol esters (Fig. 4). 
Unexpectedly, plant sterols did not differentially affect fractional cholesterol absorption in 
wild-type and Abcg5_,_ mice: plant sterol supplementation led to a significant reduction of 
fractional cholesterol absorption by 44% in wild-type mice and, in parallel, to a 49% 
reduction in Abcgs-'· mice. Expression of typical LXR target genes did not differ significantly 
between wild-type and Abcgs·'· mice (data not shown). 
e 
� ;1. 1lO • cholesterol c cholesterol and plant sterols .. 80 0 c .<:: .2 60 u e. "iii 0 40 c .. 0 .c 20 'ti .. 
� 0 
wild type Abcg5·1-
Figure 4: Fractional cholesterol absorption in AbcgS'· mice fed semi-synthetic diet supplemented with 
cholesterol, plant sterols or plant stanols for I wk. Fractional cholesterol absorption in Abcg5-t. mice was 
measured using the plasma dual-isotope ratio method as previously described (27). Filled bars: semi-synthetic 
diet containing cholesterol. White bars: same diet supplemented with plant sterols. Values are means ± SD, n=S-




Since the early 1 950s, plant sterols and stanols have been known to interfere with intestinal 
cholesterol absorption and to lower plasma cholesterol concentrations in humans ( 1 ;  2). 
Several concepts have been proposed to explain this effect (30). First, plant sterols and stanols 
may replace cholesterol from micelles in the intestinal lumen and therefore may lower the 
amount of cholesterol present in an absorbable form (5). Second, plant sterols and stanols may 
block uptake of cholesterol into the enterocyte or interfere with intracellular routing. This 
route may include the recently discovered ezetimibe-sensitive pathway involving Nieman­
Pick-C I -like-protein 1 (6) and possibly aminopeptidase N (CD I 3) (3 I ). Third, it has been 
suggested that interference with the esterification machinery inside the enterocyte and 
inhibition of chylomicron formation might be responsible for the observed plasma 
cholesterol-lowering effects of plant sterols, as proposed almost 50 years ago (32). 
Very recently it has been proposed that induction of intestinal genes involved in the 
control of cholesterol absorption may contribute. During the last few years it has been 
demonstrated that the enterocyte actively excretes sterols back to the intestinal lumen by the 
action of the Abcg5/ Abcg8 heterodimer. This process is regulated on the level of gene 
expression by the nuclear transcription factor LXR upon binding of oxysterols. As plant 
sterols are able to activate LXR either directly or after oxidation to oxyphytosterols in in vitro 
studies ( I  6- 1 8), it seemed plausible to speculate that the lowering of cholesterol absorption by 
plant sterols and stanols may also be due to LXR activation and subsequent increased 
expression of Abcg5/Abcg8 in the enterocyte. Stigmasterol, a plant sterol present in many 
commercially available plant sterol formulations, has been demonstrated to exert LXR 
activating actions in the adrenal gland of mice lacking both Abcg5 and Abcg8 (33). 
To test the hypothesis that the decrease in cholesterol absorption by plant sterols and 
stanols is related to induction of Abcg5/g8 expression mediated by LXR, we fed C57BU6 
mice a diet virtually free of sterols, enriched with cholesterol or enriched with cholesterol and 
either plant sterols or stanols for 4 weeks. Fecal neutral sterol excretion increased upon 
addition of plant sterols or stanols to the cholesterol diet, indicating the expected inhibitory 
effect on intestinal cholesterol absorption potentially enforced by an enhanced hepatobiliary 
clearance of cholesterol. The latter possibility, however, was excluded by measuring 
hepatobiliary lipid excretion rates in all groups of mice which did not reveal any increase of 
this parameter upon plant sterol or stanol feeding. 
In contrast to the situation described in humans, mice did not show reduced plasma 
cholesterol concentrations upon plant sterol and stanol supplementation but did show the 
expected decreased accumulation of cholesteryl esters in the liver. Hepatic cholesteryl ester 
concentrations have been demonstrated to reflect intestinal cholesterol uptake in mice (34 ). 
We therefore conclude that supplementation of the cholesterol containing diet with either 
plant sterols or stanols indeed reduced intestinal cholesterol absorption. 
To determine if this reduction was associated with changes in the expression of LXR 
target genes in the intestine or the liver, gene expression profiles of those tissues were 
analyzed. Along the axis of the small intestine, no significant changes in gene expression 
were observed, with the exception of Abcal which was up-regulated upon cholesterol feeding 
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in the medial section of the small intestine. Plant sterol and stanol supplementation did not 
show any additional effect. As anticipated, treatment of mice with the synthetic LXR agonist 
T090 1 3 1 7  did result in a significant induction of the expression levels of the LXR targets 
Abcg5, Abcg8, and Abcal (20). Npc l l l ,  involved in intestinal cholesterol absorption, was not 
influenced by plant sterol and stanol supplementation nor by T090 1 3 17 treatment. Our 
observations are in line with the very recent findings by Calpe-Berdiel et al. (35), which were 
published while this work was in progress. These authors fed different mouse strains with a 
Western-type diet with and without phytosterols and did not find differences in the intestinal 
expression of LXR target genes. It seems plausible to conclude that the observed effects of 
plant sterols and stanols on cholesterol absorption are not caused by LXR-mediated induction 
of intestinal gene expressions in mice but must be caused by upstream events. 
This conclusion is further supported by gene expression profiles of the liver: feeding 
cholesterol alone did result in an induction of the expression of Abcg5 and Abcg8. Assuming 
that LXR activation by plant sterol- and stanol-derived metabolites takes place, one would 
expect an additional increase of Abcg5/g8 expression upon plant sterol or stanol 
supplementation. However, the opposite was the case: addition of plant sterols or stanols 
partially prevented the effects usually associated with cholesterol feeding, i.e., it lowered the 
hepatic expression of Abcg5/g8 compared to mice fed cholesterol only. 
Our data contrast those of recently published in vitro studies which demonstrate LXR 
activation by plant sterols in cell lines ( 1 6- 1 8).  It is well known that cell lines frequently show 
differences in gene expression profiles compared with the tissues they are derived from. The 
commonly used CaCo2, HepG2 or HEK293 cell lines, for example, express only limited 
levels of Abcg5 and Abcg8 which makes them prone to accumulation of plant sterols in vitro. 
This limits the conclusions drawn from experiments in which cells were loaded with plant 
sterols and stanols (36). It is tempting to speculate that, in the in vivo situation, enterocytes do 
not react to plant sterols and stanols via LXR because they are largely protected from their 
accumulation by the action of Abcg5/g8. We therefore measured fractional cholesterol 
absorption in mice Jacking Abcg5 which, as a consequence, hyperabsorb plant sterols and 
accumulate them in plasma and various tissues, including the intestinal mucosa.( 15)  
Moreover, mice Jacking both Abcg5 and Abcg8 have been demonstrated to be prone to LXR 
activation by certain sterols, namely stigmasterol, in selected tissues (33). 
When Abcg5·'· mice and their wild-type littermates where fed cholesterol-rich diets, 
we could not observe any difference between the two groups with respect to fractional 
cholesterol absorption, in line with previous studies ( 1 5).  Moreover, the addition of plant 
sterols to the cholesterol diet reduced fractional cholesterol absorption to the same extent in 
Abcg5·'· mice and their wild-type littermates. This clearly demonstrates that the observed 
decline in cholesterol absorbed from the small intestine upon plant sterol supplementation is 
independent from the action of the Abcg5/Abcg8 heterodimer. Moreover, we could not detect 
differences in intestinal gene expression responses to plant sterols between Abcgs·'· and wild­
type mice which provides an additional piece of evidence that the cholesterol-lowering effects 
of plant sterols and stanols are independent from LXR. 
Based on our findings, it is tempting to speculate that a combination of dietary plant 
sterol and stanol supplementation with ezetimibe would have cumulative inhibitory effects on 
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intestinal cholesterol absorption in humans, because plant sterols and stanols would putatively 
lower the relative amount of cholesterol available for absorption, whereas inhibition of 
NPC l L l  by ezetimibe would decrease total sterol uptake. Very recent data (37) demonstrate 
that a combination of dietary plant sterols with ezetimibe has no additional effect on plasma 
LDL cholesterol concentrations in human hypercholesterolaemic patients when compared to 
the monotherapies. However, plasma Iathosterol concentrations were significantly higher 
upon treatment with plant sterols combined with ezetimibe when compared to single 
treatments, which may indicate a stronger reduced absorption of cholesterol compensated for 
by a more pronounced increase in (hepatic) cholesterol synthesis. 
Data presented in this study demonstrate that induction of Abcg5/Abcg8 transporter 
activity by LXR activation does not play a role in plant sterol- and stanol-induced reduction of 
intestinal cholesterol absorption in mice. 
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Abstract 
Objectives- Peroxisome proliferator-activated receptors (PPARs) control transcnpt10n of 
genes involved in lipid metabolism. Activation of PPARO may have anti-atherogenic effects 
through elevation of plasma HDL, theoretically promoting reverse cholesterol transport from 
peripheral tissues towards the liver for removal via bile and feces. Methods and results­
Effects of PPARO activation by GW6 l 0742 were evaluated in wild-type and Abcal -deficient 
(Abcal -1-) mice that lack HDL. Treatment with GW6 l 0742 resulted in a -50% increase of 
plasma HDL-cholesterol in wild-type mice, whereas plasma chole terol levels remained 
extremely low in Abcar'· mice. Yet, biliary cholesterol secretion rates were similar in 
untreated wild-type and Abcar'· mice and unaltered upon treatment. Unexpectedly, PPAR8 
activation led to enhanced fecal neutral sterol loss in both groups without any changes in 
intestinal Abcal ,  Abcg5, Abcg8 and HMG-CoA reductase expression. Moreover, GW6 10742 
treatment resulted in a 43% reduction of fractional cholesterol absorption in wild-type mice, 
coinciding with a significantly reduced expression of the cholesterol absorption protein 
Niemann-Pick C l Like l (Npcl 11) in the intestine. Conclusions- PPARO activation is 
associated with elevated plasma HDL and reduced intestinal cholesterol absorption efficiency 
that may be related to decreased intestinal Npcl 11 expression. Thus, PPARO is a promising 
target for drugs aimed to treat or prevent atherosclerosis. 
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Introduction 
Plasma levels of high-density lipoprotein (HDL) cholesterol are inversely related to 
development of atherosclerosis ( I ). This protective effect has been attributed to a role of HDL 
in reverse cholesterol transport (RCT), defined as the flux of excess cholesterol from 
peripheral cells to nascent HDL particles followed by transport to the liver. The liver is able to 
secrete cholesterol into bile, either as free cholesterol or after conversion into bile salts, for 
removal via the feces. Stimulation of HDL-mediated cholesterol efflux is considered an 
attractive approach to diminish the development of atherosclerosis. 
The ATP-binding cassette transporter A I (ABCA I )  is considered to be essential in RCT 
(2). ABCAI is ubiquitously expressed and probably involved in formation of pre-�-HDL 
particles and the efflux of cholesterol from peripheral tissues towards HDL (3). HDL is 
considered a major source for bile-destined cholesterol (4). However, we have recently 
demonstrated that, despite the absence of HDL, hepatobiliary cholesterol flux and fecal sterol 
excretion are not affected in Abcal -deficient (AbcaJ-'-) mice (5,6). The ABCG5/ABCG8 
heterodimer was recently shown to be of crucial importance for hepatobiliary cholesterol 
secretion and for transport of cholesterol from enterocytes back into the intestinal lumen, 
thereby promoting net cholesterol removal from the body (7,8). 
Several genes involved in the control of cholesterol metabolism are transcriptionally 
regulated by nuclear receptors. Peroxisome proliferator-activated receptors (PPARs) comprise 
a subgroup of the nuclear receptor superfamily, designated PPARil (NR l C l ), PPARo/� 
(NR I C2) and PPARy (NR I C3), which all serve functions in lipid homeostasis and energy 
metabolism (9). PPARo is ubiquitously expressed and activated by long-chain fatty acids and 
prostacyclins. Recent work suggests that activation of PPARo may induce RCT and hence 
have anti-atherogenic effects ( 1 0). Whether or not PPARo activation, like PPARa activation 
( I I ,  1 2),  is associated with altered bile formation and fecal sterol loss is not known. 
This study shows that PPARo activation in mice raised plasma HDL concentrations and 
accelerated fecal cholesterol removal from the body without changing hepatobiliary sterol 
excretion. Moreover, intestinal cholesterol absorption efficiency was reduced upon PPARo 
activation, which coincided with down-regulation of intestinal gene expression of the very 
recently identified cholesterol absorption protein Niemann-Pick C I Like I (Npcl 11) ( 1 3). 
Experimental procedures 
Animals 
Female Abcar'· mice with a DBN l background and age-matched DBNI wild-type mice 
were purchased from IFFA Credo (Saint-Germain-sur-1' Arbesle, France). Separate groups of 
wild-type DBN l mice were obtained from Harlan (Horst, The Netherlands). All experimental 




GW61 0742, previously referred to as GW0742 ( 14), (GlaxoSmithKline Pharmaceuticals, 
Stevenage, UK) (figure 1 )  is a high affinity ligand for PPARo. Specificity of GW61 0742, as 
evaluated by ligand binding studies, revealed EC50 values for GW61 0742 of 28 nM for 
murine PPARo versus 8900 nM and > 1 0000 nM for murine PPARa. and PPARy, respectively. 
For human PPARo, PPARa. and PPARy the EC50 values are 1 ,  1 200 and 4100 nM, 
respectively ( 14), L. Patel, personal communication). The specificity of GW1 5 1 6  has 
previously been described ( 1  0, 14 ). 
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Figure 1. Chemical structure of the PPARS-specific agonist GW601742. 
Experimental Methods 
Abcal..f. and DBA/I wild-type mice (n = 6 per group) were fed GW6 10742 mixed through 
chow at a level of 0.01 7% w/w for 8 days. With an average daily food intake of 3 gram, this 
provided an approximate intake of 20 mg/kg/day leading to an average plasma concentration 
of I JlM (L. Patel, personal communication). Control mice received standard chow without 
GW61 0742. From day 7 to 8, feces were collected from individual mice. Mice were then 
anaesthetized by intraperitoneal injection of ketamine ( 1  mllkg) and diazepam ( 1 0  mg/kg). 
Bile was collected for 30 minutes after cannulating the gallbladder and a blood sample was 
taken by cardiac puncture. Livers and small intestines were excised. Parts of both liver and 
intestine were snap-frozen in liquid nitrogen and stored at -80 °C for RNA isolation and 
biochemical analysis. Samples for microscopic evaluation were frozen in isopentane and 
stored at -80 °C or fixed in paraformaldehyde. 
Analytical Methods 
Livers were homogenized and hepatic and biliary lipids were extracted ( 15). Hepatic, biliary 
and plasma concentrations of cholesterol, triglycerides and phospholipids were determined as 
previously described (6). Fecal neutral sterols and fatty acids were analyzed by gas 
chromatography. Bile salts in feces and in bile were measured enzymatically. Pooled plasma 
samples were used for lipoprotein separation by fast protein liquid chromatography (FPLC). 
RNA Isolation and Measurement of mRNA Levels by Realtime PCR (Taqman-
RNA isolation, eDNA synthesis and real-time quantitative PCR were performed as described 
by Plosch et al. (6). Primer and probe sequences for Abcal, Abcg5, Abcg8, Acat2, Hmgr, 
Lxra, Mdr2 and Sr-bl (6) as well as for fl-actin ( I I ) have been published. Furthermore, the 
following primers/probes were used: For PparO, sense 5 ' -AGA TGG TGG CAG AGC TAT 
94 
PPARiJand cholesterol absorption 
GAC C-3 ' ;  antisense 5 ' -TCT CCT CCT GTG OCT OTT CC-3' ;  and probe 5 ' -CCC ACT 
TOG COT GGC GCC T-3' (accession number, NM_O l 3 14 1 ). For Pdk4, sense 5'-GCA TTT 
CTA CTC GOA TGC TCA TG-3' ;  antisense 5 ' -CCA ATG TOG CTT GOG TTT CC-3 ' ;  and 
probe 5'-CAG CAC ATC CTC ATA TIC AGT GAC TCA AAG AC-3' (accession number, 
NM_O I3743). For Npclll, sense 5'-GAG AGC CAA AGA TGC TAC TAT CTT CA-3' ;  
antisense 5'-CCC GOG AAG TTG GTC ATG-3' ;  and probe 5' -ACT CCA GCA AAC ACC 
GCA CTG CC-3' (accession number, A Y 437866). For 36b4, sense 5' -OCT TCA TTG TOG 
GAG CAG ACA-3' ;  antisense 5'-CAT GOT OTT CTT GCC CAT CAG-3' ;  and probe, 5'­
TCC AAG CAG ATG CAG CAG ATC CGC-3' (accession number, NM_007475). 
Isolation of Peritoneal Macrophages 
DBA/I wild-type mice were treated with the GW6 l 0742-containing diet for 8 days. 
Thioglycollate-elicited peritoneal macrophages of treated and untreated DBA/I wild-type 
mice were harvested as described by Herijgers et al. ( 1 6). Cells were washed and RNA 
isolation, eDNA synthesis and real-time PCR were performed as described. 
Plasma Dual Isotope Ratio Method 
Cholesterol absorption was measured using the plasma dual isotope ratio method ( 17).  DBA/I 
wild-type mice (n = 5 per group) received a diet with or without 0.0 17% w/w GW6 1 0742. 
After six days, mice received an intravenous injection of 1 . 1  �Ci eH]-cholesterol dissolved in 
intralipid and an oral dose of 1 .0 �Ci [ 14C]-cholesterol dissolved in medium-chain triglyceride 
oil. At 24, 48, and 72 hours after administration, blood samples were taken by retro-orbital 
puncture and feces was collected. At day 1 0, mice were anaesthetized and bile was collected 
for 30 minutes. [ 14C] and eH] activity in plasma, bile and feces was measured by liquid 
scintillation counting. Blood sampels obtained 72 hours after administration were used for the 
calculation of cholesterol absorption. 
In vitro activation of PPARs in Caco-2 cells 
Cell culture reagents were obtained from Eurobio (Les Ulis, France) and microporous PET 
membrane inserts (23. 1 mm, 3 J.l m  pore size) from Becton Dickinson (Le Pont de Claix, 
France). Caco-2 cells were routinely grown in plastic flasks (TPP, ATGC, Marne Ia Vallee, 
France) under a humidified atmosphere containing 1 0  % C02, at 37°C, in Dulbecco's 
modified essential medium containing 25 mM glucose and glutamax, �upplemented with 
penicillin-streptomycin ( 1 00 IU/ml and 1 00 g/ml, respectively), I % nonessential amino­
acids, and 20 % heat-inactivated Fetal Calf Serum (FCS). To establish the intestinal barrier 
model for the assay, Caco-2 cells (between passages 40-45) were plated at a density of 0.25 
106 cells per insert and grown in the complete medium. Confluence was routinely reached 8 
days after seeding. Cells were then cultured in asymmetric conditions, with medium 
containing FCS in the lower compartment and serum-free medium in the upper compartment. 
Media were changed every day. Three weeks after, cells were activated with ligands for 
PPARa (Wyl 4643 at 50 J.1M), PPARy (rosiglitazone at 1 00 nM) or PPARo (GW 1 5 1 6  at 1 00 
nM) for 24 hours in the upper compartment. After incubation, cell layers were briefly rinsed 
twice with ice-cold phosphate-buffered saline (PBS, 1 0  mM phosphate buffer, pH 7.5; 2.7 
mM KCl; 150 mM NaCl) and total cellular RNA was extracted using RNA-Plus (Q-BIOgene, 
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Illkirch, France). For quantitative PCR, total RNA were reverse transcribed using random 
hexameric primers and Superscript reverse transcriptase (Life Technologies, France). eDNA 
were quantified by real-time PCR on a MX 4000 (Stratagene) using specific primers for 
NPC l LI (sense 5'-GGG GCA TCA GTT ACA ATG CT-3' ;  antisense 5'-AAA CAC CGC 
ACT TCC CAT AG-3'). PCR amplification was performed in a volume of 25 fll containing 
I 00 nmol!L of each primer, 4 mmol/L MgCb, the Brilliant Quantitative PCR Core Reagent 
Kit mix as recommended by the manufacturer (Stratagene) and SYBR Green 0.33 X (Sigma­
Aldrich, Saint Quentin Fallavier, France). The conditions were 95°C for 1 0  minutes, followed 
by 40 cycles of 30 seconds at 95°C, 30 seconds at 55°C and 30 seconds at 72°C. NPC I L I  
mRNA levels were subsequently normalized to 28S mRNA (sense 5 '  -AAA CTC TGG TGG 
AGG TCC GT-3' ;  antisense 5 ' -CTT ACC AAA AGT GGC CCA CTA-3').  The activated 
condition was then normalized to the control condition set at 1 00 %. Each point was 
performed in triplicate. 
Immwwhistochemistry 
Histology of livers and small intestines was examined after hematoxilin/eosin staining on 
paraformaldehyde-fixed sections. Neutral lipids were stained by oil-red-O on frozen sections 
and peroxisome proliferation was determined by catalase staining. Intestinal cell proliferation 
was examined after Ki67 staining on paraformaldehyde-fixed sections, using a Ki-67 
polyclonal antibody (Novo Castra, Newcastle, UK) ( 1 :500). 
Statistics 
Statistical analyses were performed using SPSS Version 10.0 for Windows (SPSS Inc., 
Chicago, IL). Treated and untreated groups were compared by Student's t-test. A p-value < 
0.05 was considered statistically significant. 
Results 
Animal characteristics 
Table 1 shows that body weights of DBA/I wild-type and Abcar'· mice were similar and not 
influenced by treatment with GW6 1 0742. Liver weights of untreated wild-type and Abca r'· 
mice did not differ, but treatment with the PPARo agonist resulted in slightly increased liver 
weights in both trains. This was probably related to peroxisome proliferation, as revealed by 
enhanced catalase staining in liver sections of treated animals (data not shown). Treatment 
with GW6 1 0742 did not induce liver injury as indicated by unaffected plasma LDH and 
ALA T levels. 
PPAR8activation increases plasma HDL and induces Abca/ expression in macrophages, 
but has no effect on hepatobiliary cholesterol excretion -
In accordance with previous reports (5, 1 8), plasma cholesterol levels were -75% lower in 
Abcar'· mice than in wild-type mice (Table 1 ). Treatment with GW6 1 0742 increased total 
plasma cholesterol by -30% in wild-type mice, whereas cholesterol levels in Abcar'· 
remained extremely low. FPLC analysis (Figure 2) confirmed the complete Jack of HDL-
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cholesterol in Abcar'· mice and revealed a -50% increase in HDL-cholesterol levels in wild­
type mice upon PPARo activation. 
Table 1. Animal characteristics and plasma and hepatic lipid concentrations in untreated and GW6 10742-treated 
DBA/I wild-type and Abcar'· mice 
Genotype Wild-type Abcar'· Wild-type Abcar'· 
GW6 1 0742 + + 
Body weight (g) 20.9 ± 0.8 2 1 .4 ± 0.9 20.0 ± 1 .5 2 1 .4 ± 0.9 
Liver weight (% of bw) 4.2 ± 0.3 4.8 ± 0.5 5.7 ± 0.5b 5.9 ± 0.4 b 
ALAT (units/1) 94 ± 43 225 ± 1 8 1 '  76 ± 23 146 ± 1 59 
LDH (units/1) 653 ± 24 1  84 1 ± 335 603 ± 3 12  653 ± 404 
Plasma cholesterol (mM) 1 .9 ± 0.3 0.5 ± 0. 1 d 2.5 ± 0.3 b 0.5 ± 0.2'  
Plasma triglycerides (mM) 0.8 ± 0.2 1 .2 ± 0.6 0.7 ± 0.3 1 . 1  ± 0.4 
Liver cholesterol (nmol/mg liver) 3.9 ± 0.4 4.4 ± 0.8 3.7 ± 0.5 4.2 ± 0.3 
Liver phospholipids (nmol/mg liver) 20.6 ± 3.5 23.0 ± 6.8 23.4 ± 1 .7 22.3 ± 3.7 
Liver triglycerides (nmol/mg liver) 9.7 ± 3 . 1  9.3 ± 1 . 1  8.8 ± 2.6 1 3 . 1  + 3.6 h 
Values are expressed as mean ± SD (n=6 in all groups) ' Significant difference between wild-type and Abcal"'· 
mice with the same treatment. h Significant difference between GW6 1 0742 treated and untreated mice with the 
same genotype. 
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Figure 2. FPLC separation of pla�ma lipoproteins of untreated and GW6 10742-treated DBA/I wild-type and 
Abcar'· mice. DBA/I wild-type mice (open symbols) and Abcar'· mice (closed symbols) were treated with 
solvent (circles) or with GW6 1 0742 (squares) for 8 days (n = 6 per group). Plasma from all individual mice per 
group was pooled and subjected to gel filtration using Superose 6 columns. Cholesterol content in each fraction 
was measured. VLDL, very low den�ity lipoprotein; LDL, low density lipoprotein. 
Expression levels of both Abcal and Sr-bl in thioglycollate-elicited peritoneal 
macrophages of wild-type mice were approximately 3-fold upregulated upon PPARo 
activation (Figure 3), demonstrating that GW6 10742 did induce systemic effects. 
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Figure 3. Gene expression in the peritoneal 
macrophages of untreated (open bars) and 
GW61 0742-treated (closed bars) DBA/I 
wild-type mice, measured by real-time PCR. 
Data are presented as the mean of 3 assays 
performed in duplicate ± SD. Expression 
values are normalized to 36B4 and 
expression in untreated mice was set to 1 .00 
(n = 3 per group). * indicates significant 
differences (Student's t test, p < 0.05). 
Hepatic concentrations of cholesterol, phospholipids and triglycerides (Table I )  were 
similar in wild-type and Abcar'- mice and were not affected by PPAR3 activation in wild­
type mice, whereas hepatic triglycerides were slightly increased upon treatment in Abcar'· 
mice. 
Biliary secretion rates of bile salts, cholesterol and phospholipids were similar in untreated 
Abcar'- mice compared to wild-type mice (Table 2), in accordance with published data (5). 
Treatment with GW6 1 0742 did not significantly affect biliary secretion rates in wild-type or 
Abcal_,_ mice. This is in accordance with the absence of any effect on hepatic expression of 
several genes involved in cholesterol metabolism and transport (Figure 4, left hand panels). 
Only hepatic Abcb4 (Mdr2) expression was slightly but significantly induced upon treatment 
but this did not affect biliary phospholipid secretion. As a positive control, expression of the 
PPAR3 target gene Pdk4 ( 1 9), encoding pyruvate dehydrogenase kinase isoenzyme 4, was 
measured. Hepatic expression of this gene was -6-fold upregulated upon PPAR3 activation in 
both strains of mice. 




Bile flow (J.lllminlg liver) 
Bile salts (nmollmin!I OOg bw) 
Cholesterol (nmol/min/1 00 g bw) 
Phospholipids (nmollmin/I OOg bw) 
Cholesterol/phospholipid ratio 
Wild-type 
2.4 ± 0.6 
445 ± 203 
4.9 ± 1 .4 
40.9 ± 8.3 
0. 1 2  ± 0.02 
Values are expressed as mean ± SD (n=6 in all groups) 
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2 . 1  ± 0.7 
483± 1 69 
6.9 ± 3.2 
55.0 ± 1 5.0 
0. 1 2  ± 0.05 
Wild-type Abcar'· 
+ + 
2.2 ± 0.4 2.0 ± 0.5 
440 ± 1 65 428 ± 1 2 1  
7.5 ± 2.9 7.7 ± 2.2 
64. 1 ± 1 8.6 57.8 ± 1 8.6 
0. 1 3  ± 0.04 0. 1 3 + 0.01 
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Figure 4. Gene expression in the livers and intestines of untreated (open bars) and GW6 1 0742-treated (closed 
bars) DBNI wild-type and Abcar'· mice, measured by real-time PCR. Data are presented as the mean of 6 
assays performed in duplicate ± SD. Expression values are normalized to f3-actil1 and expression in untreated 
wild-type mice was set to 1 .00. "' and # indicate significant differences (Student's t test, p < 0.05 and p < 0.01 
respectively). 
Fecal excretion of neutral sterols is induced upon PPAR8activation 
Fecal excretion of acidic sterols (bile salts) was similar in all groups (Figure SA). However, 
fecal excretion of neutral sterols, 80% of which comprised of cholesterol, was 2 to 3-fold 
increased upon PPAR8 activation in wild-type and Abcar'· mice (Figure 5B). Since 
hepatobiliary efflux of cholesterol was not induced upon treatment, increased sterol excretion 
might be directly mediated by intestinal adaptations. Figure 4 (right hand panels) shows that 
intestinal expression levels of Abcal,  Abcg5 and Abcg8 were not affected upon treatment with 
GW61 0742. Expression of Acat2, responsible for esterification of cholesterol in enterocytes 
and crucial for cholesterol absorption, and of the gene encoding 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol 
synthesis, were also unaffected. 
To investigate whether increased intestinal cell proliferation may have contributed to 
increased fecal cholesterol excretion through accelerated cell shedding, a K.i67 staining was 
performed on intestinal sections. This, however, did not show any sign of accelerated 





?3 4 E 
-3 3  






Neutral sterols � B � 10 
0 8 E 
CJ control 
• GW610742 
-3 6  Cll Cll 
.9 4 
-a 2 u 
� 0 
Wild-type AbcaJ-I-
Figure 5. Fecal loss of acidic sterols (A) and neutral sterols (B) in untreated and GW6 1 0742-treated DBNI 
wild-type and Abcar'- mice. Feces of untreated (open bars) and treated (closed bars) wild-type and Abcal 
mice were collected during the last 24 hours of the experiment. • and # indicate significant differences 
(Student's 1 test, p < 0.005 and p < 0.00 1 respectively). 
= = � 100 .. 
= 80 ll " 
e 60 
� 40 "' .. 
0 20 ..c: "' 
� 0 '---....&..---
C control 
• GW61 0742 
Figure 6. Cholesterol absorption in untreated (open bars) and GW6 10742-treated (closed bars) DBNI wild-type 
mice. Cholesterol absorption in treated and untreated mice was measured using the plasma dual isotope method 
(11 = 5 per group). After six days of treatment, mice received an intravenous injection of eH]-cholesterol and an 
oral dose of [ 14C]-cholesterol. Plasma samples obtained 72 hours after administration were used for the 
calculation of fractional cholesterol absorption. Values represent means ± SO; * indicates significant differences 
(Student's 1 test, p < 0.005). 
PPARo activation decreases cholesterol absorption, accelerates fecal excretion of plasma­
derived cholesterol and reduces intestinal Npcl l1 expression 
Figure 6 shows that PPARo activation led to a 43% reduction of cholesterol absorption 
efficiency in DBNl wild-type mice, despite the unaffected expression levels of Abcg5 and 
Abcg8. Recently, Niemann-Pick C l  Like I protein has been identified as a critical component 
of the intestinal cholesterol absorption machinery ( 1 3).  Therefore, we measured mRNA levels 
of Npcll 1 along the length of the small intestine of untreated and treated mice. Expression of 
the gene was decreased by 35% in the jejunum upon PPARO activation and was also lower in 
ileal sections of treated animals (Figure 7). A similar decrease in intestinal Npclll expression 
(i.e., -40%) was observed in Abcar '- mice upon treatment with GW6 1 0742. 
Reduced cholesterol absorption is also apparent from Figure 8A, showing a markedly 
increased fecal recovery of orally administered (1C]-cholesterol in GW6 1 0742-treated mice. 
Figure 8B shows that fecal excretion of intravenously injected eH]-Iabeled cholesterol was 
higher upon treatment with GW6 1 0742, which is likely attributable in part to less efficient 
reabsorption of biliary eH]-cholesterol. However, the 2.5-fold increase in fecal eH]­
cholesterol loss is larger then expected on the basis of a 40% reduction in cholesterol 
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absorption efficiency. These data suggest that cholesterol may partly be excreted directly from 
plasma into the intestinal lumen (20). Conversion of labeled cholesterol into bile salts was not 
affected by PPAR& activation, as shown in figure 8D. Fecal excretion of [ 14C]-labeled bile 
salts (Figure 8C) was somewhat lower in the treated mice, probably due to the lower 
efficiency of cholesterol absorption in these animals. 
Total fat absorption was not affected by treatment with the PPAR& agonist, as indicated by 
similar fecal fat excretion rates in both groups (data not shown). 
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Figure 7. Expression of Npclll along the length of 
the small intestine of untreated (open bars) and 
GW6 1 0742-treated (closed bars) DBNI wild-type 
mice, measured by real-time PCR. Data are presented 
as the mean of 6 assays performed in duplicate ± SD . 
Expression values are normalized to fl-actin and 
expression in duodenum of untreated mice was set to 
1 .00. * indicate significant differences (Student's 1 
test, p < 0.05). 
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Figure 8. Fecal loss of intravenously and orally administered radiolabeled cholesterol in untreated and 
GW6 1 0742-treated DBNI wild-type mice. Panel A and B show fecal loss of [ 14C]-Iabeled and eu]-labeled 
neutral sterols respectively in treated (closed symbols) and in untreated (open symbols) mice. Panel C and D 
show fecal loss of [ 14C]-labeled and eu]-labeled bile salts, respectively. Values are presented as o/o of 
administered dose (11 = 5 per group). • and # indicate significant differences (Student's 1 test, p < 0.0 1 and p < 
0.05 respectively). 
Repression of Npclll expression is specific for PPARc5agonist in CaCo2 cells 
To assess the specificity of the observed effects on Npcl lJ expression, we have evaluated the 
consequences of PPARa, PPARy and PPAR& activation by specific agonists in polarized 
CaCo2 cells. Figure 9 shows that both the PPARa agonist Wyl 4643 and the PPARy agonist 
rosiglitazone had no effect on NPCJLJ expression, whereas the PPAR& agonist GW I 5 1 6  
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exhibited a clear (-33%) reduction in NPCJ Ll expression. This demonstrates that the reduced 
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Figure 9. Expression of Npcl/1 in 
polarized CaCo2 cells treated with 
PPARa, PPARy or PPARii agonists, as 
measured by real-time PCR. Data are 
presented as the mean of 3 assays 
performed ± SD. Expression values are 
normalized to 28S and expression in 
control cells was set to 1 .00. * indicate 
significant differences (One-tailed Mann­
Whitney U test, p < 0.05) 
This study shows that activation of PPARo results in increased plasma HDL levels in DBA/I 
wild-type mice. Although elevated HDL levels might theoretically deliver more cholesterol to 
the liver for excretion into bile, hepatobiliary excretion of cholesterol and bile salts was not 
affected upon PPARO activation in wild-type mice. In fact, excretion rates were highly similar 
in wild-type and Abcar'· mice, confirming that HDL is not an essential source for biliary 
cholesterol in mice (5,6). In spite of the unaltered biliary excretion rates, fecal loss of neutral 
sterols was doubled in both strains after treatment with GW6 1 0742, which could not be 
ascribed to either increased intestinal cholesterol synthesis or accelerated intestinal cell 
proliferation. PPARO activation reduced cholesterol absorption efficiency in wild-type mice 
without any change in intestinal Abcal, Abcg5 or Abcg8 expression, but did not affect total fat 
absorption. Reduction of cholesterol absorption without changes in Abcg5 and Abcg8 
expression has also been reported upon treatment of mice with the cholesterol absorption­
reducing drug ezetimibe (2 1 ) :  intestinal expression of the recently described potential target 
of ezetimibe, Npclll ( 13), appeared to be decreased upon PPARO activation. 
Analogous to the situation described in obese and hyperlipidemic rhesus monkeys ( 1 0), 
PPARo activation beneficially altered plasma lipid profiles in wild-type mice by increasing 
HDL-cholesterol concentrations. This increase in HDL-cholesterol levels was not observed in 
Abcar'· mice, supporting the essential role of ABCA I in HDL formation. The question by 
which mechanism PPARO activation elevates HDL-cholesterol concentrations remains to be 
answered. Induced expression of Abcal as well as Sr-bl in peritoneal macrophages isolated 
from GW61 0742-treated wild-type mice suggests that induction of these efflux mediators may 
contribute. However, bone-marrow transplantation studies (22) indicate that the contribution 
of macrophage-derived cholesterol to plasma HDL levels is limited in mice: plasma HDL­
cholesterol levels probably reflect ABCA ! -mediated efflux events in all peripheral organs and 
tissues. ABCAI -mediated cholesterol efflux appeared to be a major source of plasma HDL­
cholesterol in mice (23). Yet, we did not observe induction of hepatic Abcal expression. The 
reason for the discrepancy in PPARO-mediated effects on Abcal expression between 
macrophages and liver remains to be established. 
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HDL-cholesterol is considered a preferential source of biliary cholesterol (4). However, 
despite the marked differences in plasma HDL-cholesterol levels no differences in biliary 
cholesterol excretion were observed between untreated wild-type and Abcar'· mice or 
between treated and untreated wild-type mice. These observations are consistent with earlier 
work (5,6), indicating that delivery of HDL-cholesterol to the liver is not rate-controlling for 
biliary cholesterol secretion in mice. 
Surprisingly, fecal excretion of neutral sterols was 2 to 3-fold increased upon PPARO 
activation in both wild-type and Abcar'· mice, in spite of the fact that biliary cholesterol 
excretion was not induced. This could theoretically be due to a higher intestinal cholesterol 
synthesis. This parameter has not been measured directly, but intestinal expression of Hmgr 
was not affected upon PPARO activation which strongly suggests unaltered intestinal 
cholesterol synthesis. Most cholesterol is synthesized in the peripheral tissues in mice (24) 
and peripheral synthesis may have been enhanced upon PPARO activation to maintain total 
body cholesterol balance. It is also highly unlikely that accelerated intestinal cell turnover was 
the cause of enhanced fecal sterol loss: Ki67 staining on intestinal sections revealed no 
differences between GW6 10742-treated and untreated mice. 
Cholesterol absorption efficiency was clearly reduced upon PPARO activation in wild-type 
mice. Since the amounts of bile salts and phospholipids excreted into the intestinal lumen, 
important for efficient cholesterol absorption (25,26), as well as Acat2 expression were 
unaffected, these factors can be excluded as the cause of the reduced cholesterol absorption. 
Surprisingly, reduced cholesterol absorption was not associated with any change in intestinal 
expression of Abcg5 and Abcg8. Our data suggests that PPARO may reduce cholesterol 
absorption by interference with cellular uptake, i.e., by a mechanism that is related to the 
mode of action of the cholesterol absorption inhibitor ezetimibe (2 1 ). Very recently, Altmann 
et al. ( 1 3) proposed Niemann-Pick C 1  Like I protein to be critical for intestinal cholesterol 
absorption and to represent a target of ezetimibe. Our results show that PPARO activation 
clearly reduced intestinal expression of Npcl L1 , predominantly in the jejunal part of the small 
intestine where most of the cholesterol absorption takes place. Our in vitro results show that 
this reduced expression of Npclll is highly specific for PPARO activation. There was no 
effect of selective PPARa and PPARy agonists on NPCJLJ expression in Caco-2 cells, but a 
clear suppression by the PPARO agonist, indicating that the human NPCJLJ is also responsive 
to PPARO activation. 
No data are available yet on factors involved in Npcl L1 transcription regulation: whether 
PP ARO controls intestinal Npcl L1 expression by direct or indirect means remains to be 
established. Since the amount of Npc l l l  protein is clearly reduced in enterocytes of 
heterozygous Npclll+l- mice ( 1 3), it is likely that the -40% reduction in jejunal Npcl/1 
mRNA levels were associated with reduced amounts of the protein. Upon oral administration 
of 14C-cholesterol, absorption in chow-fed Npclll+l- mice into plasma and liver appeared to 
be reduced by -40% when compared to wild-type mice, although this difference failed to 
reach statistical significance (27). A significant reduction in fractional cholesterol absorption 
in heterozygote mice compared to wild-type controls was noted after feeding a diet containing 
0. 1 %  sodium cholate ( 1 3).  
It has been proposed that PPARO might induce anti-atherogenic actions ( 10). Our data 
support this notion, since PPARO activation resulted in elevated HDL-cholesterol levels. 
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However, potential anti-atherogenic effects would not be expected to be achieved by 
induction of the "classical" pathway of RCT since fecal cholesterol loss was enhanced 
without stimulation of hepatobiliary cholesterol excretion. Activation of PPARO may 
stimulate direct excretion of plasma-derived cholesterol via the intestine, a mechanism that 
has been described by Kruit et a!. (20), as suggested by the unexpectedly rapid fecal excretion 
of i.v. administered [3H]-Iabeled neutral sterols in GW61 0742-treated mice (Figure 8B). In 
addition, enhanced fecal neutral sterol loss as a consequence of impaired intestinal cholesterol 
absorption upon PPARO activation, which in effect increases RCT, can be considered a 
beneficial action. Indeed, studies have shown a 20% reduction of LDL levels in 
hypercholesterolaemic humans (28) and prevention of atherosclerosis development in Apoe·'· 
mice (29) upon inhibition of cholesterol absorption by ezetimibe. Our results suggest that 
reduction of cholesterol absorption upon treatment with GW6 10742 is, at least in part, 
mediated by reduced intestinal expression of Npcl 11,  a proposed target of ezetimibe. 
Interestingly, ezetimibe was also shown to increase plasma HDL-cholesterol in mice and in 
humans by a so far unidentified mechanism of action. Thus, PPARO is a promising target for 
development of novel drugs aimed at prevention of atherosclerosis. 
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Abstract 
The liver is considered the major "control center" for maintenance of whole body cholesterol 
homeostasis. This organ is the main site for de novo cholesterol synthesis, clears cholesterol­
containing chylomicron remnants and LDL particles from plasma and is the major contributor 
to HDL ("good cholesterol") formation. The liver has a central position in the classical 
definition of the reverse cholesterol transport pathway by taking up periphery-derived 
cholesterol from lipoprotein particles followed by conversion into bile acids or its direct 
secretion into bile for eventual removal via the feces. During the past couple of years, 
however, an additional important role for the intestine in maintenance of cholesterol 
homeostasis and regulation of plasma cholesterol levels has become apparent. First, molecular 
mechanisms of cholesterol absorption have been elucidated and novel pharmacological 
compounds have been identified that interfere with the process and positively impact plasma 
cholesterol levels. Secondly, it is now evident that the intestine itself contributes to fecal 
neutral sterol loss as a cholesterol-secreting organ. Finally, very recent work has 
unequivocally demonstrated that the intestine contributes significantly to plasma HDL 
cholesterol levels. Thus, the intestine is a potential target for novel anti-atherosclerotic 
treatment strategies that, in addition to interference with cholesterol absorption, modulate 
direct cholesterol excretion and plasma HDL cholesterol levels. 
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Introduction 
Maintenance of cholesterol homeostasis in the body requires accurate metabolic cross-talk 
between processes that govern de novo cholesterol synthesis and turnover to adequately cope 
with (large) fluctuations in dietary cholesterol intake. Dysbalance may lead to elevated plasma 
cholesterol levels and increased risk for cardiovascular diseases (CVD), the main cause of 
death in Western society. A multitude of epidemiological studies has shown the direct link 
between high plasma cholesterol, particularly of low density lipoprotein (LDL) cholesterol, 
and risk for CVD. Treatment of high plasma cholesterol has been focused for many years on 
interference with cholesterol synthesis by application of statins. Statins are competitive 
inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate­
controlling enzyme in the cholesterol biosynthesis pathway ( I ). Inhibition of cholesterol 
synthesis leads to reduced production of very low density lipoprotein (VLDL) particles by the 
liver and, particularly, up-regulation of LDL receptor activity. Both processes contribute to 
lowering of plasma LDL-cholesterol levels (2). Large clinical trials have established the 
beneficial effects of statin treatment (see (3) for review). However, a relative large group of 
hypercholesterolaemic patients does not adequately respond to statin therapy or remains at 
risk for CVD despite substantial reductions in LDL cholesterol (4; 5). Consequently, 
alternative strategies are currently actively pursued, particularly high density lipoprotein 
(HDL) raising approaches. In addition, strategies aiming at interference with intestinal 
cholesterol metabolism are gaining interest. A major development has been the introduction 
of ezetimibe, a potent inhibitor of intestinal cholesterol absorption that reduces plasma LDL­
cholesterol by approximately 20% in mildly hypercholesteroleamic patients (6). Likewise, 
phytosterol/stanol (esters)-enriched functional foods have successfully been introduced for 
lowering of plasma cholesterol levels through interference with cholesterol absorption (7). 
Recently obtained insights in intestinal cholesterol trafficking may open even more 
promising avenues for further developments. It appears that the intestine actively excretes 
cholesterol and, thereby, significantly contributes to fecal sterol excretion. In addition, it 
appears that the intestine is an important source of HDL-cholesterol, also known as "good" 
cholesterol. Thus, the intestine is an attractive target for new therapeutic strategies aimed to 
alter plasma cholesterol profiles and to reduce the risk for CVD. This review summarizes 
important new finding regarding the mechanism(s) of intestinal cholesterol absorption, with 
specific focus on newly identified transporter proteins, the novel concept of direct intestinal 
cholesterol secretion and the role of the intestine in HDL biogenesis. 
Cholesterol, some basic features 
Cholesterol is essential for mammalian life as a structural component of cellular membranes, 
influencing membrane organization and thereby membrane properties (8). Cholesterol is the 
precursor molecule of steroid hormones and, therefore, essential for metabolic control. In the 
liver, cholesterol can be converted into bile salts, which represents the major pathway for 
cholesterol metabolism in quantitive sense. Bile salts are amphipathic molecules that facilitate 
the absorption of dietary cholesterol, fats and fat-soluble vitamins in the small intestine. 
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Recently, it has become clear that bile salts are able to regulate gene expression through 
activation of the nuclear receptor, the Famesoid X Receptor (FXR) (9- l l ) . Cholesterol or, 
more correctly, oxidized cholesterol acts as ligand for the nuclear Liver X Receptor (LXR or 
NRH2 or NRH3) and directly contributes to regulation of expression of genes involved in 
cholesterol, lipid, and glucose metabolism. Accumulation of free cholesterol, rather than 
cholesteryl esters, has been shown to induce apoptosis in macrophages by activating the Fas 
pathway ( 1 2). Thus, cholesterol is a key component in cellular and whole-body physiology 
and cholesterol homeostasis is tightly regulated at a number of levels. 
Body cholesterol derives from two sources, i.e., de novo biosynthesis and diet. 
Cholesterol is synthesized from two-carbon acetyl-CoA moieties. The rate-controlling 
enzyme in the synthetic pathway is HMG-CoA reductase, a highly regulated enzyme that 
catalyses the conversion of HMG-CoA into mevalonate. Cholesterol itself regulates feed-back 
inhibition of HMG-CoA reductase activity, as accumulation of sterols in the endoplasmic 
reticulum (ER) membrane triggers HMG-CoA reductase to bind to Insig proteins, which leads 
to ubiquitination and degradation of HMG-CoA reductase ( 1 3 ;  1 4). In addition, cholesterol 
regulates the gene expression of HMG-CoA reductase indirectly by blocking the activation of 
the transcription factor sterol regulatory element-binding protein 2 (SREBP2). Under low­
cholesterol conditions, SREBP2 in the ER binds to the SREBP cleavage activating protein 
(SCAP), which escorts SREBP2 to the Golgi. In the Golgi, SREBP2 is cleaved to generate its 
transcriptionally active form, which activates transcription of HMG-CoA reductase. Upon 
accumulation of sterols in the ER-membrane, binding of cholesterol to the sterol-sensing 
domain of SCAP causes a conformation change, which induces binding of SCAP to the ER 
anchor protein Insig, preventing exit of SCAP-SREBP2 complexes to the Golgi thereby 
preventing activation of SREBP2 (( 1 5) for review). 
The contribution of the two sources to the total pool of cholesterol differs between 
species and prevailing diet composition, but the total cholesterol pool is similar in rodents and 
humans when expressed on the basis of body weight ( 1 6). Cholesterol synthesis in the liver is 
highly sensitive to the amount of (dietary) cholesterol that reaches the liver from the intestine 
via the chylomicron-remnant pathway ( 17). The Western-type human diet provides 
approximately 400 mg of cholesterol per day. On top of this, the liver secretes approximately 
I gram of cholesterol into bile per day ( 1 8). Intestinal cholesterol absorption efficiency in 
humans is highly variable, i.e., ranging from 1 5-85% in healthy subjects (see for review ( 1 9)). 
After uptake by enterocytes, cholesterol is packed with triglycerides into chylomicrons and 
secreted into the lymph. In the circulation, the triglycerides are rapidly hydrolyzed and free 
fatty acids are taken up by the peripheral tissues. Cholesterol-enriched chylomicron remnants 
are subsequently cleared by the liver. Since chylomicron remnants, which contain most of the 
cholesterol that is being absorbed from the intestine, are rapidly taken up by the liver, 
interference with the absorption process directly influences hepatic cholesterol synthesis. 
The healthy liver is perfectly equipped for handling large amounts of cholesterol. 
When relatively large amounts of cholesterol reach the liver, de novo synthesis and LDL 
uptake will rapidly be down-regulated. In addition, the liver can dispose excess cholesterol 
molecules in several ways. A rapid response involves esterification of cholesterol by Acyl 
CoA:cholesterol acyltransferase (ACAT) 2 for storage as cholesterylesters in cytoplasmic 
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lipid droplets. Cholesterylester can be hydrolyzed when necessary and this 
esterification/hydrolysis cycle provides cells with short-term buffering capacity for 
cholesterol. The liver, like the intestine, is able to produce and secrete VLDL particles, which 
consist of a neutral lipid core composed of cholesterylesters and triacylglycerols and a 
monolayer surface containing phospholipids, free cholesterol, and a variety of 
apolipoproteins. Finally, cholesterol can be converted into bile acids by the hepatocytes, 
followed by their secretion into the bile along with significant amounts of free cholesterol and 
phosphatidylcholine. In humans cholesterol lost via the feces consists of approximately 50% 
acidic (=bile acids) and 50% neutral sterols, emphasizing the point that conversion into bile 
acids represents a major pathway for cholesterol elimination. 
Peripheral cells, e.g., macrophages, muscle, and fat cells, are not able to form 
lipoproteins or to metabolize cholesterol extensively. Therefore, these cell types depend 
massively on efflux pathways for removal of their excess cholesterol. It is generally assumed 
that HDL is the primary acceptor for cholesterol efflux from cells: HDL cholesterol can 
subsequently be taken up by the liver for further processing. This pathway is generally 
referred to as the reverse cholesterol transport (RCT) pathway. The RCT pathway is 
particularly important for removal of excess cholesterol from macrophages, as accumulation 
of esterified cholesterol in these cells is considered a primary step in the development of 
atherosclerosis. Several epidemiological studies have shown that plasma HDL is an 
independent, negative risk factor for the development of CVD. The common hypothesis is 
that high HDL cholesterol levels decrease the risk for CVD by removing the excess of 
cholesterol from the macrophages and enhancing RCT. Recent work, however, indicated that 
this is an oversimplification and that current concepts of RCT require re-definition (see for 
review (20)). In addition, the anti-inflammatory and anti-oxidant features of molecules other 
than cholesterol associated with the HDL particle, like paraoxonase, platelet activating factor­
acetylhydrolase or lysophospholipids, are becoming increasingly apparent (2 1 -23). 
Towards understanding of intestinal cholesterol absorption 
In the past years, insight in regulation of cholesterol absorption has greatly increased by 
identification of transporter proteins involved. In addition, unraveling of molecular regulation 
of their expression is progressing. Yet, it should be realized that besides transporter proteins, 
the presence of bile acids in the intestinal lumen is an essential prerequisite for absorption to 
occur (24): micellar solibilization of (dietary/biliary) cholesterol is necessary for its 
absorption as exemplified by the fact that fractional cholesterol absorption is virtually zero in 
bile diverted rats and Cyp7al -deficient mice with strongly diminished bile acid pool size (24). 
Identification of novel proteins involved in cholesterol absorption 
Cholesterol absorption has long been considered a merely passive process, despite the fact 
that the process is clearly selective since dietary cholesterol is absorbed with relative high 
efficiency whereas structural similar phytosterols are not. Several candidate intestinal 
cholesterol transporters have been proposed during the past couple of years, e.g., SR-B 1 (25) 
and aminopeptidase N (26), but their role (if any) has remained elusive sofar. The recent 
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identification of the Niemann-Pick C l Like l (NPC 1 L l )  protein as a crucial molecule 
involved in cholesterol uptake by enterocytes (27) and of Abcg5 and Abcg8 proteins, as 
(intestinal) cholesterol efflux transporters (28-30), has provided definite proof that cholesterol 
absorption is a protein-mediated, selective and active process. 
The identification of NPC l L l  was strongly facilitated by the discovery of a powerful 
cholesterol absorption inhibitor named ezetimibe (3 1 ). Ezetimibe and analogs comprise a new 
class of sterol absorption inhibitors that reduce diet-induced hypercholesterolemia in mice, 
hamsters, rats, rabbits, dogs, monkeys and humans (6; 3 1 -35). Using a bioinformatics 
approach, Altmann et a/. identified the NPC l LI protein as putative cholesterol transporter in 
intestinal cells (27). NPC I L l  is expressed in the intestine at the brush border membrane and 
Npcl 1- deficient mice show a 69% reduction in fractional cholesterol absorption. Importantly, 
treatment with ezetimibe did not further reduce fractional cholesterol absorption efficiency in 
these mice, indicating that NPC I L l  at least is involved in a pathway targeted by ezetimibe 
(27). In support of this, recent studies have shown that ezetimibe glucuronide, the active 
molecule, indeed binds to cells expressing NPC 1 L l  (36). Using intestinal brush border 
membrane (BBM) fractions, the authors showed that ezetimibe binds specifically to a single 
site in the brush border membrane and that this binding is lost in BBM fractions of NpcJ/J ­
deficient mice (36). The exact cellular localization of NPC I L I is, however, still under debate. 
Iyer et a/. showed that NPC I L l  is glycosylated and enriched in the BBM of rat enterocytes 
(37). Davies et a!., who were the first to identify NPC I L l  as a homolog of the Niemann Pick 
type C (NPC) protein (38), showed in Hep02 cells that NPC I Ll localized to a subcellular 
vesicular compartment and not in the plasma membrane. Using immortalized fibroblasts from 
wild-type and Npcl 11 knock-out mice these authors also showed that lack of NPC ! L l  activity 
causes dysregulation of caveolin transport and localization, suggesting that the observed sterol 
transport defect may be an indirect result of an inability of Npcl /1 -deficient cells to properly 
target and/or regulate cholesterol transport in the cell. 
Another possible mechanism of action of ezetimibe was proposed by Smart and 
colleagues (39). These authors described the presence of a stable complex of annexin (ANX) 
2 and caveolin (CA V) I located in enterocytes of zebrafish and mouse. Disruption of this 
complex by morpholino antisense oligonucleotides in zebrafish prevented normal uptake of 
cholesterol. Ezetimibe treatment of zebrafish, C57Bl/6 mice fed a Western type diet and LDL 
receptor knock-out mice disrupted the ANX2-CA V I  complex, suggesting that ANX2 and 
CA V I  are components of an intestinal sterol transport complex and targets for ezetimibe. 
Interestingly, C57BL/6 mice fed a standard diet did not show disruption of the ANX2-CA V I  
complex upon ezetimibe treatment (39), but did show decreased cholesterol absorption. 
Moreover, recent research using CA VI-deficient mice revealed that inhibition of cholesterol 
absorption by ezetimibe did not require the presence of CA V I  ( 40). In addition, rabbits 
appear not to form the ANX2-CA V I  complexes, yet, their cholesterol absorption efficiency is 
still inhibited by ezetimibe (4 1) .  Collectively, these studies make a mode of action in which 
ezetimibe acts by deregulating the ANX2-CA V I  complex less likely. 
Other proteins critical in control of sterol absorption are the ATP-binding cassette 
(ABC) transporter proteins 05 and 08. ABC05 and ABC08 act as functional heterodimers 
(42) and are localized at the canalicular membrane of hepatocytes and at the brush border 
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membrane of enterocytes. Mutations in the human genes encoding ABCG5 or ABCG8 have 
been shown to cause the inherited disease sitosterolemia (28-30), which is characterized by an 
accumulation of plant sterols (e.g., sitosterol, campesterol) in blood and tissues due to their 
enhanced intestinal absorption and decreased biliary removal. Thus, ABCG5/ABCG8 limit 
plant sterol absorption by effective efflux back into the intestinal lumen. Since 
ABCG5/ABCG8 also accommodates cholesterol, as evidenced from the fact that Abcg5/g8-
deficient mice show a strongly reduced biliary cholesterol secretion (43), this system also 
provides a means to control cholesterol absorption efficiency. Yet, Abcg5 and/or AbcgB 
deficiency in mice clearly enhances phytosterol absorption (43-45), but reported effects on 
cholesterol absorption efficiency are minimal (43; 44). On the other hand, overexpression of 
ABCG5 and ABCGS in mice as well as pharmacological induction of their expression did lead 
to a strongly decreased fractional cholesterol absorption (44; 46; 47), indicating a role for 
ABCG5 and ABCG8 in control of cholesterol absorption under certain conditions. 
Other transporter proteins, like the Scavenger Receptor BI (SR-BI) and ABCAI have 
been suggested to play a role in control of cholesterol absorption. In the small intestine, SR­
BI is localized both at the apical and at the basolateral membrane of enterocytes, with 
different expression levels along the length of the small intestine (48). Mice deficient in SR­
B I ,  however, show only a small increase in fractional cholesterol absorption efficiency and a 
small decrease in fecal neutral sterol output (49). On the other hand, intestine-specific 
overexpression of SR-BI in mice did lead to increased cholesterol and triglyceride absorption 
in short-term absorption experiments (50), indicating that SR-BI might have a role in 
cholesterol absorption. 
In spite of earlier reports (5 1 )  suggesting an apical localization, it is evident that 
ABCAI is localized at the basolateral membranes of chicken enterocytes (52) and of human 
CaCo-2 cells (53). Studies assessing intestinal cholesterol absorption in mice lacking Abca l 
has yielded conflicting results (54; 55), suggesting that the overall effect of Abca l on 
absorption is at most minor. However, as will be described later, this protein does have an 
important function in intestinal cholesterol metabolism. 
After uptake, cholesterol is esterified by the enzyme ACAT 2 in the endoplasmic 
reticulum (ER) of enterocytes. Acat2-deficiency in mice did not affect cholesterol absorption 
efficiency on a low-cholesterol containing chow diet (56). However, Acat2-deficient mice did 
show a clear reduction in cholesterol absorption upon feeding a high-fat/high-cholesterol diet 
and, as a consequence, were resistant to diet-induced hypercholesterolemia (56). Other 
proteins crucial for cholesterol absorption are those involved in chylomicron formation, like 
apolipoprotein B (apoB) and microsomal triglyceride transfer protein (MTP), and proteins 
involved in intracellular chylomicron trafficking such as SARA2. Mutations in the MTP gene 
result in abetalipoproteinemia, an inherited human disease characterized by extremely low 
plasma cholesterol and triglyceride levels and an absence of apoB-containing particles. 
Patients suffer from fat and cholesterol malabsorption and neurological diseases due to 
malabsorption of lipid-soluble vitamins. Mutations in SARA2 cause chylomicron retention 
disease or Anderson disease (57): both are characterized by an inability to secrete 
chylomicrons causing severe fat malabsorption and accumulation of chylomicron-like 
particles in enterocytes. SARA2 belongs to the Sari -ADP-ribosylation factor family of small 
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GTPases and is involved in intracellular trafficking of chylomicrons through the secretory 
pathway (57). 
Plasma Lymph 
Figure 1. Schematic overview of the major routes of cholesterol in enterocytes. Dietary and biliary cholesterol 
are taken up via the action of NPC I L I .  In the ER. cholesterol is esterified and incorporated into chylomicrons. 
which are subsequently secreted into lymph. Non esterified sterols can be re-secreted into the intestinal lumen 
via the action of ABCOS/08 or secreted towards ApoA I via the action of ABCA I .  
ABCAI ,  ABC05, ABC08, ATP-binding cassette transporter A I ,  05, 08; ACAT2, acyl-coenzyme 
A:cholesterol acyl transferase 2; ApoAI, ApoB48, apolipoprotein AI, B48; C, cholesterol; CE, cholesterylester; 
ER, endoplasmatisch reticulum; MTP, microsomal triglyceride transfer protein; NPC I L I ,  Niemann Pick C I like 
I protein; SARA2, Sari -ADP-ribosylation OTPase 2; TO, triglycerides. 
Regulation of cholesterol absorption 
As indicated above, cholesterol can be taken up from the intestinal lumen by NPC l L I  and 
effluxed back into the lumen via ABCG5 and ABCG8. When both processes are active and 
present in the same cells, a classical futile cycle arises, enabling very sensitive regulation. 
Interference with this system has great potential for reducing plasma cholesterol. 
An established application hereof is provided by ezetimibe that interferes with 
NPCl L l  activity (27; 36). Lowering of NPC l L l  expression provides another potential means 
to reduce cholesterol absorption. Mechanisms involved in transcriptional control of NPC l L l  
are beginning to be unraveled. The nuclear receptor peroxisome proliferator-activated 
receptor (PP AR) o/� (NR 1 C2) has been shown to decrease cholesterol absorption, 
presumably via decreasing NPCJ Ll expression (58). Activation of PPARO/� by the synthetic 
agonist GW61 0742 resulted in a 43% reduction of cholesterol absorption in mice, which 
coincided with unchanged intestinal expression of Abcg5 and Abcg8 but a decreased intestinal 
expression of Npcl ll . Treatment of the human colon-derived CaCo-2 cells with PPARo/�, but 
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not with PPARy or PPARa, decreased NPCJLJ expression as well (58). Whether PPAR�/� 
regulates NPCl L I  directly, via transcriptional repression, or indirectly is still under 
investigation. 
Major regulatory pathways in cholesterol metabolism are controlled by the nuclear 
receptor Liver X receptor (LXR). Two LXR isotypes have been identified in mammals, i.e., 
LXRa (NRl H3), which is mainly expressed in the liver, kidney, intestine, spleen and 
adrenals, and LXR� (NRI H2), which is expressed ubiquitously. Natural ligands for both 
LXRs are oxysterols. After activation, LXR heterodimerizes with retinoid X receptor (RXR) 
(59; 60). Activated RXRILXR heterodimers bind to specific LXR response elements (LXREs) 
in the promoter regions of their target genes and activate gene transcription. LXR target genes 
include many genes involved in cellular cholesterol efflux like ABCAJ,  ABCG 1, ABCG5, and 
ABCG8 (5 1 ;  6 1 ; 62), genes involved in bile acid synthesis (cholesterol-7a-hydroxylase 
(Cyp7a)) in rodent models and genes involved in lipogenesis like sterol regulatory element­
binding protein (SREBP) J C, fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). 
Global LXR activation by synthetic agonists therefore has a plethora of effects including 
elevated HDL levels, hypertriglyceridemia, hepatic steatosis, increased biliary cholesterol 
excretion, reduced intestinal cholesterol absorption efficiency and increased neutral sterol loss 
via the feces (63; 64). The decreased intestinal cholesterol absorption is primary due to 
increased cholesterol efflux of cholesterol towards the intestinal lumen due to increased 
Abcg5 and Abcg8 expression, as fractional cholesterol absorption is reduced upon LXR 
activation in wild-type mice but remains unaltered in Abcg5/g8-deficient mice (47) and in 
Abcg5-deficient mice (44) under these conditions. Other mechanisms, such as reduced 
intestinal Npcl 11 expression after LXR activation could contribute to reduced cholesterol 
absorption, as recently shown in Apo£2-knock-in mice (65). 
Dietary phytosterols and phytostanols and their esters have been introduced in 
functional foods to suppress intestinal cholesterol absorption and hence to reduce the risk for 
CVD (7). Phytosterols and stanols were thought to decrease cholesterol absorption by 
competing with cholesterol for incorporation into mixed micelles in the intestinal lumen (66). 
However, several recent studies suggested additional mechanisms involving alterations of 
intestinal gene expression. Igel and colleagues (67) showed for the first time that phytosterols 
and stanols are actually taken up by the enterocyte and subsequently re-secreted into the gut 
lumen, most probably through the action of Abcg5/Abcg8 transporters. This finding indicated 
that phytosterols and stanols, in addition to modes of action within the intestinal lumen, could 
exert metabolic actions from inside the enterocyte. Moreover, dietary phytostanol 
consumption (2.5 g) once a day reduces LDL cholesterol as effective as consumption of 2.5 g 
phytostanols ingested in three daily portions (68), suggesting that luminal concentrations may 
not be key in controlling metabolic actions. The identification of a phytosterol-derived agonist 
for the nuclear receptor LXR (69) led to the proposal that phytosterols and stanols could 
decrease cholesterol absorption via activation of intestinal LXR. In vitro studies in CaCo-2 
cells indicated that phytostanols indeed are able to induce the expression of ABCAJ,  an 
established LXR target gene (70). Recent in vivo studies, however, showed that dietary 
phytosterols and phytostanols decrease cholesterol absorption without activating LXR in 
rodent models. Field et al. (71 )  showed that addition of 2% phytostanols to a chow diet did 
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not affect intestinal expression of ABC sterol transporters and Npclll in male Golden Syrian 
hamsters. Likewise, Calpe-Berdien et al. (72) showed very recently that decreased cholesterol 
absorption upon addition of 2% phytosterol to a Western type diet was not associated with 
transcriptional changes in Abcal,  Abcg5, Abcg8 or Npclll in C57BU6J, ApoK1• and LDLr"'· 
mice. Plosch and colleagues showed similar results using 0.5% phytosterol or phytostanol in a 
semi-synthetic diet containing 0.2% cholesterol in C57BU6J mice. Additionally, these 
authors showed that the plant sterol/stanol-induced reduction of cholesterol absorption in 
mice is not influenced by Abcg5-deficiency (Journal of Nutrition, in press) indicating that 
intra-luminal events are most relevant for the inhibitory effect of these dietary compounds. 





Figure 2. Schematic overview of the regulation of cholesterol transport in enterocytes. Plant sterols, ezetimibe 
PPARS!IJ agonists and LXR agonists all reduce cholesterol absorption through different mechanisms. Plant 
sterols interfere with micellisation of cholesterol; ezetimibe binds to NPC I LI and thereby interferes with the 
cholesterol uptake; agonists for PPARS!IJ reduces expression of NPC I L I  and thereby the amount of NPC I L 1  
protein; agonists for LXR increases the expression of  ABCGS and ABCG8 and thereby enhance the efflux of 
cholesterol towards the intestinal lumen. 
LXR, Liver X Receptor; PPARB!IJ, peroxisome proliferators-activated receptor B!lJ. 
Novel role of the intestine in reverse cholesterol transport 
It is clear that the intestine fulfills a major role in cholesterol homeostasis as cholesterol 
absorbing organ. However, recent research revealed that the intestine also acts as an excretory 
organ in the reverse cholesterol transport (RCT) pathway (64; 73). This pathway is classically 
defined as the HDL-mediated flux of cholesterol from peripheral cells to the liver, followed 
by its secretion into bile and disposal via the feces. RCT is extremely important in prevention 
of CVD as it removes excess cholesterol from macrophages present in the arterial vessel wall. 
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The amount of cholesterol secreted into bile is substantial and, as only part will be absorbed 
by the intestine, it contributes significantly to cholesterol loss via the feces. However, a novel 
pathway that contributes to fecal cholesterol loss has recently been established. 
Already in the nineteen-sixties, it was suggested that non-dietary cholesterol present in 
the intestinal lumen consists of a fraction secreted by the liver into the bile and a second 
fraction directly secreted by the intestine. Measuring dietary cholesterol, cholesterol 
absorption and cholesterol loss via the feces in patients with complete obstruction of common 
bile duct due to carcinoma of the head of the pancreas unequivocally established the presence 
of intestinally secreted cholesterol in the feces (74). By intestinal perfusion studies in humans, 
Simmonds et al. (75) tried to quantify this route. Using a triple lumen tube system, perfusion 
studies were carried out using micellar solutions with radio-labeled cholesterol. Decrease in 
specific activity was interpreted as secretion of endogenous cholesterol from the intestine and 
the contribution of endogenously secreted cholesterol from the intestine was estimated to be 
about 44% of total fecal output, but direct proof for the existence of this pathway could not be 
provided (75). 
After these early experiments, the focus of research shifted more towards the liver. 
Biliary cholesterol and bile acid secretion were believed to represent the major pathways for 
removal of excess cholesterol. However, recent calculations of cholesterol fluxes in different 
mouse models again emphasized the relevance of intestinal cholesterol secretion. A striking 
example is provided by the Cyp7aJ-deficient mouse (76). Cyp7al is important for the 
conversion of cholesterol into bile acids and catalyzes the formation of 7 -hydroxycholesterol 
(77). As Cyp7al is rate-controlling in this pathway, it is regulated in a complex manner 
involving multiple nuclear receptors. Cyp7aJ-deficiency in mice leads to a strongly decreased 
fecal bile acid loss and decreased bile acid pool size. Surprisingly, fecal neutral sterol output 
is increased two-fold in Cyp7al ;. mice, although biliary cholesterol concentration remained 
unaffected (76). As dietary intake and cholesterol absorption were known, it can be calculated 
from these data that direct intestinal cholesterol secretion contributed at least 30% to the 
increased fecal neutral sterol output. 
Plosch and colleagues showed that the pathway of intestinal cholesterol secretion can 
be induced in mice by treatment with the synthetic LXR agonist T090 1 3 1 7  (64). In C57BU6 
mice, efflux of cholesterol from the intestinal epithelium into the lumen, calculated from the 
difference between dietary and biliary input minus fecal output, contributed up to 36% of the 
total fecal cholesterol loss. Pharmacological LXR activation in these mice tripled the 
intestinal cholesterol secretion, showing that this represents a valid, inducible pathway for 
removal of cholesterol in mice. 
To further characterize this route, Kruit et al. (73) studied the effects of LXR 
activation by the synthetic agonist GW3965 in wild-type and Mdr2-deficient mice. Mdr2-Pgp 
(or Abcb4 according to the new nomenclature) mediates the ATP-dependent translocation of 
phospholipids at the canalicular membrane of hepatocytes. Consequently, Mdr2-deficiency 
leads to an inability to secrete phospholipids into the bile. Due to the tight coupling of 
phospholipid and cholesterol secretion, these mice also show a strongly impaired biliary 
cholesterol secretion (78; 79). Despite the impaired biliary cholesterol secretion, chow-fed 
MdrZ1- mice showed a similar fecal neutral sterols loss as wild-type mice, suggesting that the 
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intestine indeed contributes to the fecal neutral sterol loss. LXR activation increased fecal 
neutral sterol output to a similar extent in Mdr2·!- and wild-type mice, although biliary 
cholesterol secretion remained impaired in Mdr2"1. mice, whereas it increased in wild-type 
mice. These data show that the increased fecal cholesterol loss upon LXR activation is 
independent of biliary cholesterol secretion. Although fractional cholesterol absorption 
decreased to a greater extent in Mdr2"1. mice compared to wild-type mice upon LXR 
activation, it could be calculated that at least 57% of fecal cholesterol originated from 
intestinal secretion in Mdr2"1. mice (73). 
The most intriguing question, i.e., the origin of intestinal-derived cholesterol, has 
remained unanswered so far. Part of the cholesterol could, in theory, originate from enhanced 
sloughing of intestinal cells or reflect a consequence of increased intestinal de novo 
cholesterol synthesis. Indeed, the Cyp7ar1· mice showed an increased intestinal cholesterol 
synthesis (76). Upon LXR activation, however, intestinal HMGCoA reductase gene 
expression remained unchanged (64; 73), indicative for unchanged cholesterol synthesis, 
while fecal sterol loss increased 3-fold. Staining for the proliferation marker Ki-67 revealed 
no signs of increased intestinal cell proliferation upon LXR activation, making the possibility 
of enhanced cell shedding less likely (73). Using intravenously injected radiolabeled 
cholesterol as marker, Kruit and colleagues additionally showed that fecal loss of plasma­
derived cholesterol was 1 .7-fold increased upon LXR activation in Mdr2·1 mice, suggesting 
that the intestine, independently of biliary cholesterol, plays an important role in cholesterol 
transport from plasma to the feces (73). 
Further research should be done to identify the putative proteins involved in this 
pathway. The sterol efflux proteins ABCG5/ABCG8 seem to be good candidates, as increased 
fecal neutral sterol output upon LXR activation requires the presence of Abcg5 and Abcg8 
(47) and transgenic mice overexpressing human ABCG5 and ABCGB (hG5G8Tg) showed a 
severely increased fecal neutral sterol loss (46). However, deficiency of Abcg5 and/or Abcg8 
leads to only a mild (43; 47) or no (44) decrease in fecal neutral sterol loss and the increased 
fecal neutral sterol excretion loss in the hG5G8Tg mice was inhibited in hG5G8Tg mice 
lacking Mdr2 (Mdr2"1"hG5G8Tg mice), suggesting that biliary cholesterol secretion is 
responsible for the increased fecal sterol loss in hG5G8Tg mice (80). However, the hG5G8Tg 
mice showed a high expression of human ABCG5 and ABCGB in the liver but their expression 
in the intestine was far less pronounced (46). Thus, it remains the question whether intestinal 
ABCG5 and ABCG8 are important for intestinal cholesterol efflux under normal conditions. 
Virtually nothing is known about transporter systems involved in uptake of plasma 
cholesterol by enterocytes prior to its excretion into the intestinal lumen. LXR activation was 
found to upregulate a number of cholesterol transporters, of which only SR-BI is known to be 
involved in cholesterol uptake, at least in the liver. Chow-fed SR-Br1· mice show only a small 
decrease in fecal neutral sterol loss, suggesting a relatively small contribution of intestinal 
SR-B I in control of fecal cholesterol excretion. However, basolaterally localized SR-B I in 
the enterocyte could theoretically play a role in cholesterol uptake into the enterocyte 
particularly when, due to activation of ABCG5 and ABCG8, free cholesterol in the 
enterocytes decreases and uptake of the sterol from the plasma compartment may become 
energetically favorable. 
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Intestinal contribution to HDL biogenesis 
The intestine, along with the liver, has been known for many years to synthesize and secrete 
apolipoprotein A-I (ApoA-I), the principal apolipoprotein of HDL. Already in 1 977, 
Glickman and Green described the synthesis of ApoA-1 by the intestine of rats (8 1 ). One year 
later, Wu and Windmueller estimated that intestinally synthesized ApoA-1 contributes up to 
56% of total plasma ApoA-I in rats (82). A potential role for the intestine in HDL particle 
assembly was initially suggested from experiments in hepatectomized dogs (83) and studies 
describing the presence of HDL in mesenteric lymph (84-87). More recently, in vitro studies 
using the human colon carcinoma cell line CaCo-2 showed basolateral efflux of cholesterol in 
high density ApoB-free, ApoA-I containing lipoproteins (88; 89). 
In addition to ApoA-1, ATP-binding cassette (ABC) transporter 1 (ABCAl )  is of 
crucial importance for HDL formation. In 1 999, three different groups independently reported 
mutations of the ABCAl gene as cause of Tangier disease (90-92). Tangier disease is 
characterized by an almost complete absence of plasma HDL, abnormal accumulation of 
cholesteryl esters in reticuloendothelial cells of many tissues and early incidence of 
atherosclerosis. No abnormalities in the ApoA-1 protein (93) or in protein synthesis were 
found. These findings, and the subsequent generation of Abcar'· mice which also lack plasma 
HDL (55), underscores that ABCAl is crucial for HDL formation. 
ABCA I performs the rate-controlling step in HDL formation by mediating the efflux 
of cholesterol and phospholipids to nascent ApoA-1. ABCAl is widely expressed throughout 
the body (94), however, not all tissues are important for the regulation of plasma HDL. Bone 
marrow transplantation studies in which bone marrow of wild-type and Abcar'· mice was 
transplanted into Abcar1· or wild-type mice, respectively, revealed that macrophage 
expression of Abcal contributed only minimally to plasma HDL (95). Macrophage ABCA l 
is, however, important for the development of atherosclerosis because deficiency of Abcal in 
bone marrow-derived cells increased the susceptibility for atherosclerosis in sensitive strains 
of mice (96; 97). Conversely, overexpression of ABCAJ in bone marrow-derived cells 
inhibited the progression of atherosclerotic lesions in such mice (98). 
As the liver and intestine both synthesize ApoA-I and both express significant levels 
of ABCA I ,  these organs are prone to contribute to plasma HDL levels. Indeed, mice 
overexpressing human ABCAJ in the l iver and in macrophages showed increased plasma 
HDL levels. Since macrophage ABCAl contributes only minimally to pla�ma HDL (95), this 
indicates that plasma HDL is controlled by hepatic ABCAI .  A similar conclusion can be 
drawn from studies employing adenoviral Abcal transfer to mouse liver in vivo (99; 100). 
Basso et a/. showed that treatment of C57BU6 mice with adenovirus containing rABCAJ­
GFP resulted in  a 2-fold increase in plasma HDL levels (99). Wellington et al. treated mice 
with increasing concentration of ABCAJ-containing adenoviruses, resulting in dose-dependent 
increase in hepatic ABCAl protein expression. HDL cholesterol was increased in mice 
injected with low doses of adABCAJ,  but, surprisingly, higher doses did not further raise 
plasma HDL levels ( 1 00). Liver-specific Abcal knockdown by 50 % in mice using siRNA 
resulted in a 40% decrease of plasma HDL cholesterol levels, indicating that hepatic Abcal 
expression correlates with plasma HDL levels in mice ( 10 1 ). 
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The creation of liver-specific Abcal knock-out (AbcarV·L) mice definitively showed 
that the liver is the major contributor to plasma HDL as liver-specific deficiency of Abcal 
resulted in a decrease of plasma HDL cholesterol levels by 80%. Further analysis revealed 
that in vivo catabolism of HDL ApoA-1 isolated from wild-type mice was 2-fold higher in 
Abcal-U-L mice, due to a 2-fold higher rate of catabolism of ApoA-1 by the kidneys ( 102). 
These data unequivocally demonstrate that hepatic Abca1 is responsible for the maintenance 
of the circulating plasma HDL by direct lipidation of lipid-poor ApoA- 1 containing particles. 
These data also show that, although the liver is the major organ responsible for HDL levels, 
additional extra-hepatic sites exists that contribute to HDL biogenesis. 
To address the contribution of intestinal ABCAl to plasma HDL, intestine-specific 
Abcal knockout (Abcal il·r) were created using the Cre/Lox system with the Cre transgene 
under the control of the villin promoter ( 1 03). Intestinal Abcal deficiency resulted in a 30% 
decrease in plasma HDL cholesterol levels, establishing that intestinal Abcal is critically 
involved in HDL biogenesis. Combined deletion of both hepatic and intestinal Abcal resulted 
in a 90% decrease of plasma HDL, which is similar to the level found in the whole-body 
Abcar'· mice, proving that the liver and the intestine are really the two major sites for HDL 
biogenesis. Absence of intestinal Abcal resulted in decreased transport of dietary cholesterol 
into plasma HDL, however, total intestinal cholesterol absorption was not affected. 
Surprisingly, lymphatic HDL content was hardly affected in Abcaril-i mice. In contrast, HDL 
was virtually absent in lymph of AbcarV·L mice, indicating that lymph HDL originates from 
the plasma compartment rather than directly from the intestine ( 103). This finding has solved 
a long-lasting debate on the origin of lymphatic HDL (8 1 ;  84-86; 104; I 05). It would be 
interesting to see whether lack of intestinal Abcal influences the development of 
atherosclerosis. 
Modulation of plasma HDL by intestine- specific LXR activation 
As discussed above, LXR is a major regulator of cholesterol metabolism and LXR agonists 
are considered promising candidates for novel treatment strategies against atherosclerosis. 
Indeed, treatment of ApoE1" and LDLr·l· mice, both sensitive to atherosclerosis development, 
with synthetic LXR agonists inhibited development of atherosclerosis ( 1 06; 107). However, 
general LXR activation also leads to increased lipogenesis, hypertriglyceridemia and hepatic 
steatosis in rodents (63) and is therefore not a suitable approach for use in humans. Specific 
LXR activation in the intestine could be beneficial in this respect, as it theoretically would 
lead to decreased cholesterol absorption, increased intestinal cholesterol excretion and 
increased plasma HDL levels. Preliminary data from our laboratory, using an intestine­
specific LXR agonist in Wistar rats, showed that intestine-specific LXR activation indeed has 
the desired effect in this model without adverse effects on triglyceride metabolism. 
1 20 
Role of intestine in cholesterol metabolism 
Concluding remarks 
During the past 5 years, a number of developments have greatly contributed to appreciation of 
the important role of the intestine in maintenance of cholesterol homeostasis (Figure 3). 
I .  Identification of transporter proteins involved i n  uptake and secretion of cholesterol by 
enterocytes 
2 .  Establishment of the direct cholesterol excretion pathway of  the intestine 
3 .  Definition of the role of  the intestine in HDL biogenesis 
A wealth of data indicate that the intestine should be considered as a promising target for 
development of anti-atherosclerotic drugs that, in addition to interference with cholesterol 
absorption, may directly modulate cholesterol excretion and plasma HDL cholesterol levels. 
Diet 
Intestine Peripheral tissue 
Figure 3. Schematic overview of the involvement of the intestine in cholesterol homeostasis. The intestine is 
critically involved in the control of plasma cholesterol due to its role in ( I )  intestinal cholesterol absorption, (2) 
direct cholesterol excretion into the intestinal lumen and (3) HDL biogenesis. 
CM, chylomicron; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density 
lipoprotein 
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The reverse cholesterol transport (RCT) pathway is generally defined as the HDL-mediated 
flux of excess cholesterol from peripheral cells to the liver, followed by its secretion into bile 
and disposal via the feces. In this classical view, the liver has an exclusive role in RCT both 
as HDL producing organ and as cholesterol excreting organ. The work described in this 
thesis, however, shows that this concept requires modification_ In this thesis, the importance 
of the intestine in RCT was addressed using multiple mouse models and pharmacological 
ligands for (organ-specific) nuclear receptor activation. Data shows that the intestine has a 
major impact on RCT and should be considered as a potential target for development of anti­
atherosclerotic therapies that, in addition to interference with cholesterol absorption (chapter 
2, 4, 5, and 6), may directly modulate cholesterol excretion (chapter 2 and 4) and plasma HDL 
cholesterol levels (chapter 3 and 4). 
Influencing intestinal cholesterol absorption 
In the last 5 years, insight in regulation of cholesterol absorption by the intestine has greatly 
increased by identification of transporter proteins involved and unraveling (in part) of 
transcriptional control of their expression. Identification of the Niemann Pick C I like I 
(NPClLI )  protein as crucial molecule involved in cholesterol uptake by enterocytes ( 1 )  
together with the identification of ABCG5 and ABCG8 as (intestinal) cholesterol efflux 
transporters (2-4) has provided evidence that cholesterol absorption is a protein-mediated, 
selective and active process. Nuclear receptors such as the Liver X receptor (LXR) and the 
peroxisome proliferator-activated receptor (PPAR) o/� (NR1C2) have been shown to regulate 
cholesterol absorption by influencing the expression of Npcl ll , Abcg5 and AbcgB in mice. 
General LXR activation is known to reduce cholesterol absorption by inducing 
expression of Abcg5 and Abcg8 in mice (5). In experiments described in chapter 2 we treated 
wild-type FVB mice and Mdr2-deficient mice with the synthetic LXR agonist GW3965 in 
order to establish the intestinal cholesterol excretion pathway (see below). For this purpose 
we quantified relevant cholesterol fluxes among which fractional cholesterol absorption, and 
we could confirm previous studies showing decreased fractional cholesterol absorption 
associated with increased intestinal expression of Abcg5 and Abcg8. In addition to this, we 
found decreased intestinal Npcl 11 expression in the Mdr2-deficient mice upon LXR 
activation, but not in the wild-type mice, coinciding with a greater decrease in fractional 
cholesterol absorption compared to the wild-type mice. Recently, LXR activation was also 
shown to decrease Npc/ll expression in cholesterol fed ApoE2-KI mice (6). Both these 
studies show that LXR activation leads to down-regulation of intestinal Npcl ll expression 
under certain circumstances, which may represent a physiological response to reduce 
cholesterol absorption efficiency during dietary overload. 
In chapter 4 the effects of intestine-specific LXR activation were investigated in rats. 
In this study, we showed that treatment of Wistar rats with the synthetic LXR agonist 
GW3965 resulted in an intestine-specific response: no LXR activation in liver or bone 
marrow cells was noticed. The compounds bioavailability after oral administration was 74% 
(M.C. Jaye, personal communication), suggesting differences in co-factor recruitment by 
GW3965-activated LXR in the liver versus the intestine. This study demonstrated, for the 
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first time, that increased expression of intestinal Abcg5 and Abcg8 upon LXR activation leads 
to decreased fractional cholesterol absorption in rats resulting in increased fecal sterol loss 
independent from biliary cholesterol secretion. 
Besides LXR, activation of PPARO/� has been shown to impact on reverse cholesterol 
transport in primates (7). In chapter 5 we investigated the effects of PPARO/� activation on 
RCT in mice. In this study, we showed that, beside the HDL-raising effect of PPARO/� 
activation, PPARo/� activation also led to a decreased fractional cholesterol absorption. 
Surprisingly, no effect on intestinal Abcg5 or Abcg8 expression was noticed, however, Npclll 
expression was decreased. Treatment of the human colon-derived CaCo-2 cells with 
PPARo/�, but not with PPARy or PPARa, decreased NPCJLJ expression as well. Whether 
PPARO/� regulates NPC I L l  directly, via transcriptional repression, or indirectly is still under 
investigation. 
Plant sterols and stanols have been known to decrease cholesterol absorption and, 
thereby, decrease plasma LDL cholesterol levels for many years. For this reason, functional 
foods containing plant sterols/stanols or their esters are currently actively marketed. Yet, the 
mechanism by which plant sterols and stanols act has remained largely unclear. The discovery 
of plant sterol derivatives as ligands for LXR (8) suggested that plant sterols and stanols could 
act as LXR ligands and decrease cholesterol absorption by increasing ABCG5/G8 expression. 
In chapter 6, this possibility was explored by feeding mice cholesterol-enriched diets with or 
without plant sterols or stanols and analyzing intestinal gene expression of LXR target genes. 
Although plant sterols and plant stanols massively increased neutral fecal sterol excretion and 
reduced hepatic cholesterylester content, reflecting decreased cholesterol absorption, no 
changes in intestinal expression of Abcg5/g8 or Npclll were found. Feeding Abcgs·'· mice the 
plant sterol-enriched diet reduced the fractional cholesterol absorption to the same extent as in 
wild-type mice, showing that plant sterol-induced reduction of cholesterol absorption in mice 
is not mediated by interference with expression of the Abcg5/g8 heterodimer. 
The intestinal cholesterol excretion pathway 
Fecal cholesterol is generally thought to consist of (unabsorbed) dietary cholesterol and 
(unabsorbed) biliary cholesterol. However, already in the nineteen-sixties it was suggested 
that part of the cholesterol lost in the feces was directly secreted by the intestine (9). Plosch 
and colleagues showed, by carefully calculating cholesterol fluxes in mice, that the intestinal 
cholesterol excretion pathway could be induced upon treatment with an LXR agonist ( 1 0). In 
chapter 2 we analyzed this pathway using wild-type and Mdr2-deficient mice to segregate 
biliary cholesterol secretion and intestinal cholesterol excretion. To induce the intestinal 
cholesterol excretion pathway, mice were treated with the LXR agonist GW3965. This study 
clearly demonstrated that the increased fecal cholesterol loss upon LXR activation is 
independent of biliary cholesterol secretion in mice. Using intravenously injected radiolabeled 
cholesterol as marker, it was additionally shown that fecal loss of plasma-derived cholesterol 
was increased upon LXR activation in Mdr2·'· mice, clearly demonstrating that the intestine, 
independently of biliary cholesterol, plays an important role in cholesterol transport from 
plasma to the feces. In chapter 4 we show that not only general LXR activation, but also 
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intestine-specific LXR activation could increase fecal neutral sterol loss by inducing the 
intestinal cholesterol excretion pathway. 
Although the study described in chapter 2 unequivocally established the existence of 
an intestinal cholesterol excretory pathway, the transporter system involved in uptake and 
secretion of plasma cholesterol by the enterocytes is still unknown. Assessment of individual 
steps of the intestinal cholesterol excretion pathway is complex, as segregating biliary from 
intestinal secretion is technically difficult. However, use of dedicated intestinal perfusion 
systems in specific, genetically-modified mouse models holds great promise in this respect. 
Modulation of plasma HDL levels by the intestine 
The intestine, along with the liver, has been known for many years to synthesize and secrete 
ApoA-I, the principle apolipoprotein of HDL. As chylomicrons also contain ApoA-I, 
contribution of intestinal ApoA-I synthesis to HDL biogenesis has remained unclear. The key 
protein in HDL biogenesis is the ATP binding cassette A I  (ABCAl ), as ABCAI-deficient 
mice and humans (Tangier patients) show an almost complete lack of plasma HDL ( 1 1 - 14). 
Timmins and colleagues showed, using liver-specific Abcal ·deficient mice, that hepatic 
Abcal is responsible for maintenance of the majority (- 80%) of circulating plasma HDL, 
presumably by direct lipidation of ApoA-1 ( 15). The fact that HDL is still present in liver­
specific Abcal knock-out mice demonstrates that, although the liver is the major organ 
responsible for HDL levels, additional extra-hepatic sites must exist that contribute to HDL 
biogenesis. 
Using intestine-specific Abcal deficient mice, it was demonstrated that the intestine is 
also a major contributor to the steady-state plasma HDL pool (chapter 3). Deficiency of 
Abcal in the intestine leads to a 30 % reduction in plasma HDL levels. As dietary cholesterol 
is thought to be packed into chylomicrons and secreted into lymph, lymph collection 
experiments were performed in these mice. Surprisingly, no decrease in (dietary) cholesterol 
secretion into lymph or lymphatic HDL cholesterol was noticed in the intestine-specific 
Abcal -deficient mice, although short-term cholesterol absorption experiments showed diet­
derived cholesterol to be decreased in plasma HDL. Subsequently, lymphatic HDL was found 
to be severely decreased in liver-specific Abcal-deficient mice with very low plasma HDL. 
These data suggest that HDL derived from intestinal Abcal  is secreted directly into the 
circulation and that HDL in lymph is predominantly derived from the plasma compartment. 
The physiological effects of intestine-specific enhanced expression of ABCAl on 
reverse cholesterol transport were evaluated in chapter 4. As ABCAl is regulated by LXR, 
we treated Wistar rats with the synthetic LXR agonist GW3569 and showed that this 
compound resulted in an intestine-specific LXR response. Lipoprotein profile analysis of 
plasma showed that the increased intestinal Abcal expression resulted in a small, but relevant 
increase in plasma levels of small HDL particles. These results indicate that intestine-specific 
activation of LXR leads to a potentially anti-atherosclerotic response without adverse effects 




The main strategy to treat high plasma cholesterol has been focused for many years on 
interference with hepatic cholesterol synthesis by statins. Large clinical trials have established 
the beneficial effects of statin treatment (see ( 1 7) for review). However, a relative large group 
of hypercholesterolaemic patients does not adequately respond to statin therapy or remains at 
risk for CVD despite substantial reductions in LDL cholesterol ( 1 8; 1 9). Consequently, 
alternative strategies, such as those targeting reverse cholesterol transport and/or cholesterol 
absorption are urgently needed. HDL-raising strategies hold great promise in this respect, 
because of the presumably increased rate of macrophage cholesterol efflux, and additionally 
because of the anti-inflammatory and anti-oxidant features of HDL, which are becoming 
increasingly apparent. 
Raising HDL levels is a beneficial (side-) effect of many of the currently applied 
LDL-cholesterol lowering treatments. The "ancient" bile acid resins (cholesterylamine, 
colestipol) raise plasma HDL levels by -5- 10  % (20), probably due to alleviation of FXR­
mediated suppression of ApoA-1 gene transcription (2 1 ). The currently used statins are also 
known to elevate plasma HDL levels by 5- 1 0%, probably in part due to reduction in 
cholesteryl ester transfer protein (CETP) activity (22). Fibrates, which are commonly used to 
treat hypertriglyceridemia, are also known to raise HDL cholesterol by 1 0-20%, depending on 
plasma triglyceride levels. Fibrates induce expression of ApoA-1 and ApoA-11 via PPARa. 
activation, which will raise plams HDL when the capacity of (hepatic) ABCAl is sufficient 
(23). In addition, fibrate-induced lowering of plasma TG levels will contribute because less 
CETP-mediated exchange of HDL-cholesterol to ApoB-containing lipoproteins will occur. 
Strategies specifically directly aiming at raising HDL are currently actively pursued. One 
strategy, which has shown to be promising in the reduction in atheroma burden in humans 
(24), consists of the infusion of ApoA-1 Milano/phospholipid complexes. The mutation in 
ApoA-1 underlying ApoA-IM,Iano is associated with very low plasma HDL cholesterol levels 
without increased risk for atherosclerosis. This protective action of ApoA-IM,Iano has been 
attributed to a faster catabolism of ApoA-I Milano compared to normal ApoA-I (25). Another 
approach, which is currently being evaluated in humans, involves the application of CETP 
inhibitors. CETP promotes the transfer cholesterol from HDL to ApoB-containing 
lipoproteins in exchange for triglycerides. Studies done with CETP inhibitors in humans 
showed markedly increased plasma HDL cholesterol (26-28), however, data showing the 
relationship between CETP inhibition, HDL levels and atherosclerosis or CVD are still 
lacking. Inhibition of CETP does not only increase HDL cholesterol levels, it also induces a 
shift to larger HDL and LDL particles (26) of which the clinical implications are not yet 
known. 
Strategies focused on interference with intestinal cholesterol metabolism have recently 
gained interest. A major development has been the introduction of ezetimibe, a potent 
inhibitor of intestinal cholesterol absorption that reduces plasma LDL-cholesterol by 
approximately 20% in mildly hypercholesteroleamic patients (29). Ezetimibe acts through 
binding the Niemann Pick C 1 like 1 (NPClL l )  protein (30), which is known to facilitate 
sterol uptake in the enterocyte ( 1 ). 
1 33 
Chapter S 
All these drugs are promising as mono-therapy or perhaps as dual therapy with statins. 
However, work described in this thesis indicates that other approaches may successfully target 
reverse cholesterol transport, HDL levels and cholesterol absorption, i .e . ,  intestine-specific 
LXR activation or PPARO/� activation. The compounds used are still in an experimental 
phase, but have the potential to develop into the "new kids on the block". Tissue-specific 
LXR activators or perhaps even better, gene specific-LXR activators, especially those 
increasing the expression of ABC transporters, would be particularly promising and are 
eagerly awaited for. PPARO/� agonists have shown to have great potential as anti­
atherosclerotic drugs. In addition, recent research showed the involvement of PPARO/� in 
regulation of glucose metabolism and improvement of insulin sensitivity after treatment with 
a PP ARO/� agonist in a mouse model for type II diabetes. This suggests that targeting 
PPARo/� might be a promising new therapeutic approach to treat patients with metabolic 
syndrome or type II diabetes, affecting both the glucose and the lipid disturbances associated 
with these conditions. 
Reference List 
I .  Altmann SW, Davis HR. Jr., Zhu U, Yao X, Hoos LM, Tetzloff G, lyer SP, Maguire M, Golovko A, 
Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick CJ Like I protein is critical for intestinal 
cholesterol absorption. Science 2004;303: 1 20 1 - 1 204. 
2. Berge KE, Tian H, Graf GA. Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. 
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters . 
Science 2000;290: 1 77 1- 1 775. 
3. Lee MH, Lu K, Hazard S, Yu H. Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N,  Pegoraro R, 
Srivastava AK, Salen G, Dean M, Patel SB. Identification of a gene, ABCG5, important in the regulation 
of dietary cholesterol absorption. Nat Genet 200 1 ;27:79-83. 
4. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H. Ose L, Stalenhoef AF, Mietinnen T, 
Bjorkhem I, Bruckert E, Pandya A, Brewer HB. Jr.. Salen G, Dean M, Srivastava A, Patel SB. Two genes 
that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving 
sterolin- 1 and sterolin- 2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 200 I ;69:278-
290. 
5. Yu L, York J, von Bergmann K, Liitjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion 
by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Bioi Chern 
2003;278: 1 5565-1 5570. 
6. Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, Staels B, Lestavel S. Niemann-Pick C l  
like I gene expression i s  down-regulated b y  LXR activators i n  the intestine. Biochem Biophys Res 
Commun 2006;340: 1 259- 1 263. 
7. Oliver WR, Jr., Shenk JL, Snaith MR. Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, 
Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective 
peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl 
Acad Sci U S  A 200 1 ;98:5306-53 1 1 .  
8. Kaneko E, Matsuda M ,  Yamada Y ,  Tachibana Y ,  Shimomura I, Makishima M .  Induction of intestinal 
ABC transporters by a phytosterol-derived liver X receptor agonist. J Bioi Chern 2003;278:36091 -36098. 
9. Cheng SH, Stanley M. Secretion of cholesterol by intestinal mucosa in patients with complete common 
bile duct obstruction. P S E B M 1 959;223-225. 
1 34 
General discussion 
1 0. Pli.isch T, Kok T, Bloks VW, Smit MJ, Havinga R, Chimini G, Groen AK, Kuipers F. Increased 
hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of 
ABCA I .  J Bioi Chern 2002;277:33870-33877. 
I I . McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer U, de Wet J, 
Broccardo C, Chimini G, Francone OL. High density lipoprotein deficiency and foam cell accumulation 
in mice with targeted disruption of ATP-binding cassette transporter- ! .  Proc Natl Acad Sci U S A 
2000;97:4245-4250. 
1 2. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler 
C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, 
Schmitz G. The gene encoding ATP-binding cassette transporter I is mutated in Tangier di�ease. Nat 
Genet 1 999;22:347-35 1 .  
1 3 .  Brooks-Wilson A, Marcil M ,  Clee SM, Zhang LH, Roomp K, van Dam M ,  Yu L, Brewer C, Collins JA, 
Molhuizen HO, Loubser 0, Ouelette BF, Fichter K, Ashboume-Excoffon KJ, Sensen CW, Scherer S, 
Molt S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B,  Pimstone S, Kastelein JJ, Genest J ,  Jr., 
Hayden MR. Mutations in ABC I in Tangier disease and familial high-density l ipoprotein deficiency. Nat 
Genet 1 999;22:336-345. 
1 4. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, 
Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette 
transporter I .  Nat Genet 1 999;22:352-355. 
1 5 .  Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, 
Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca l causes 
profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-1. J Clin Invest 2005; I I  5 : 1 333-
1 342. 
1 6. Grefhorst A, Elzinga BM, Voshol PJ, Pli.isch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, 
Romijn JA, Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver 
X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Bioi 
Chern 2002;277:34 1 82-34 1 90. 
17 .  Ong HT. The stalin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 
2005;98:599-6 1 4. 
I 8. Illingworth DR, Crouse JR, III, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, 
Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB. A comparison of simvastatin and 
atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med 
Res Opin 200 1 ; 1 7:43-50. 
1 9. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. 
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin 
across doses (STELLAR* Trial). Am J Cardiol 2003;92: 1 52- 1 60. 
20. Claude! T, Staels B, Kuipers F. The Famesoid X receptor: a molecular link between bile acid and lipid 
and glucose metabolism. Arterioscler Thromb Vase Bioi 2005;25:2020-2030. 
2 1 .  Claude! T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart J-C, Dallongeville J, Hum DW, 
Kuipers F, Staels B. Bile acid-activated nuclear receptor FXR suppresses apilopoprotein A-I transcription 
via a negative FXR response element. J Clin Invest 2002; 1 09:96 1 -97 1 .  
22. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester 
transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin 
in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004;34:2 1 -28. 
23. Staels B, Dallongeville J ,  Auwerx J ,  Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of 
fibrates on lipid and lipoprotein metabolism. Circulation 1 998;98:2088-2093. 
24. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon 
WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano 




25. Chiesa G, Sirtori CR. Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol 2003 ; 1 4 : 1 59-
1 63. 
26. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. 
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl 1 Med 
2004;350: 1 505- 1 5 1 5 . 
27. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand 
TM. Wester RT, Williams JA, Perlman ME. Bamberger MJ. Raising high-density lipoprotein in humans 
through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. 
Arterioscler Thromb Vase Bioi 2004;24:490-497. 
28. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J. Zwinderman AH, Posma JL, van Tol A, 
Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT -705, in 
humans: a randomized phase II dose-response study. Circulation 2002 ; 1 05:2 1 59-2 1 65.  
29.  Sudhop T,  Lutjohann D,  Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. 
Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; I 06: 1 943- 1 948. 
30. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Jr., Dean 
DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, 
Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The 
target of ezetimibe is Niemann-Pick C l -Like I (NPC I L I ). Proc Natl Acad Sci U S  A 2005; 102:81 32-






List of publications 




Cholesterol fulfills an essential role in mammalian physiology. It is an important structural 
component in the cell membrane of all cells in the body. In addition, cholesterol provides the 
backbone for synthesis of biologically important compounds, like steroid hormones and bile 
salts. Yet, high plasma cholesterol levels, particularly high LDL-cholesterol levels, are 
associated with increased risk for cardiovascular diseases (CVD). CVD represents the main 
cause of death in Western societies. High plasma HDL-cholesterol levels, on the other hand, 
are negatively correlated with atherosclerosis and CVD. HDL is considered to be athero­
protective partly due to its function in the reverse cholesterol transport (RCT) pathway. RCT 
is generally defined as the HDL-mediated flux of excess cholesterol from peripheral cells to 
the liver, followed by its secretion into bile and disposal via the feces. In this classical view, 
the liver has an exclusive role in RCT both as HDL producing organ and as cholesterol 
excreting organ. The work described in this thesis, however, shows that the intestine is also of 
crucial importance for RCT. 
In chapter 2 the direct contribution of the intestine to fecal cholesterol excretion was 
examined. The fecal neutral sterol fraction is generally thought to consist of (unabsorbed) 
dietary and biliary cholesterol and its bacterial metabolites, together with cholesterol derived 
from sloughed intestinal cells. However, already in the nineteen-sixties it was suggested that 
part of the cholesterol lost in the feces was directly secreted by the intestine. We analyzed the 
contribution of this pathway using wild-type and Mdr2-deficient mice to segregate biliary 
cholesterol secretion and intestinal cholesterol excretion. To induce the intestinal cholesterol 
excretion pathway, mice were treated with the Liver X receptor (LXR) agonist GW3965. 
Activation of the nuclear receptor LXR is known to enhance RCT by increasing the 
expression of several genes involved in this pathway. This study clearly demonstrated that the 
increased fecal cholesterol loss upon LXR activation is independent of biliary cholesterol 
secretion in mice. Using intravenously injected radiolabeled cholesterol as marker, it was 
additionally shown that fecal loss of plasma-derived cholesterol was increased upon LXR 
activation in Mdr2"1. mice, clearly demonstrating that the intestine, independently of biliary 
cholesterol, plays an important role in cholesterol transport from plasma to the feces. The 
intestine is, therefore, by definition an important player in the RCT pathway. 
An important protein in the RCT pathway is the ABC-transporter A l  (ABCAl).  
ABCAl is known to mediate the transport of cholesterol and phospholipids from cells 
towards nascent HDL particles and therefore crucial for the efflux of excess cholesterol from 
peripheral cells. Hepatic ABCA 1 is critically involved in HDL biogenesis. In chapter 3 we 
addressed the role of ABCA I in the intestine. For this purpose, mice which specifically lack 
A heal in the intestine were generated. Using these intestine-specific AbcaJ-deficient mice, we 
could demonstrate that the intestine contributes significantly to the steady-state plasma HDL 
pool. As dietary cholesterol is thought to be packed into chylomicrons and secreted into 
lymph, lymph collection experiments were performed in these mice. Surprisingly, no decrease 
in (dietary) cholesterol secretion into lymph or lymphatic HDL cholesterol was noticed in the 
intestine-specific AbcaJ-deficient mice, although short -term cholesterol absorption 
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experiments showed the appearance of diet-derived cholesterol to be decreased in plasma 
HDL. Subsequently, lymphatic HDL was found to be severely decreased in liver-specific 
Abcal -deficient mice with very low plasma HDL. These data suggest that HDL derived from 
intestinal ABCAl  is secreted directly into the circulation and that HDL in lymph is 
predominantly derived from the plasma compartment. 
The RCT pathway can be enhanced via activation of the nuclear receptor LXR and, 
therefore, LXR agonist potentially have anti-atherosclerotic actions. However, LXR 
activation also induces expression of genes involved in lipogenesis in the liver leading to 
hepatic steatosis and production of large, triglyceride-enriched atherosclerotic VLDL 
particles. This adverse effect clearly limits the applicability of general LXR activation for 
therapy. In chapter 4 we examined the physiological effects of intestine-specific LXR 
activation. Intestine-specific LXR activation in rats led to increased fecal cholesterol loss, 
partly due to decreased fractional cholesterol absorption and partly due to increased intestinal 
cholesterol secretion. In addition, intestine-specific LXR activation resulted in a small 
increase in plasma levels of HDL cholesterol. These results indicate that intestine-specific 
activation of LXR leads to a potentially anti-atherosclerotic response without adverse effects 
on triglyceride metabolism that occur during general LXR activation. 
Dietary plant sterols and plant stanols have been known as efficient modulators of 
plasma LDL cholesterol levels in humans due to their ability to reduce intestinal cholesterol 
absorption. For this reason, functional foods containing plant sterols/stanols or their esters are 
currently actively marketed. Yet, the mechanism by which plant sterols and stanols act has 
remained largely unclear. The discovery of plant sterol derivatives as ligands for LXR 
suggested that plant sterols and stanols could act as LXR ligands and decrease cholesterol 
absorption by increasing ABCG5/G8 expression. In chapter 5, this possibility was explored 
by feeding mice cholesterol-enriched diets with or without plant sterols or stanols and 
analyzing intestinal gene expression of LXR target genes. Although plant sterols and plant 
stanols massively increased neutral fecal sterol excretion and reduced hepatic cholesterylester 
content, reflecting decreased cholesterol absorption, no changes in intestinal expression of 
Abcg5/g8 or Npcl l1 were found. Feeding Abcgs·l· mice the plant sterol-enriched diet reduced 
the fractional cholesterol absorption to the same extent as in wild-type mice, showing that 
plant sterol-induced reduction of cholesterol absorption in mice is not mediated by 
interference with expression of the Abcg5/g8 heterodimer. 
Beside the nuclear receptor LXR, the peroxisome proliferator-activated receptor 
(PPAR) O/� has been suggested to be involved in the control of RCT. In chapter 6 we 
analyzed the effect of PPARO/� activation on RCT. Treatment of mice with the PPARo/� 
agonist led to increased plasma HDL-cholesterol, surprisingly without induction of hepatic or 
intestinal Abcal .  Additionally, PPARO/� activation also led to decreased fractional 
cholesterol absorption. Surprisingly, no effect on intestinal Abcg5 or Abcg8 expression was 
noticed, however, expression of Npcl l1 which mediates (dietary) cholesterol uptake from the 
intestinal lumen by enterocytes was decreased. These data suggest that PPARO/� is a 
promising target for development of novel drugs aimed at prevention of atherosclerosis. 
Finally, the currents state of knowledge regarding the emerging roles of the intestine 
in control of cholesterol metabolism is reviewed in chapter 7, which put the topics addressed 
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in this thesis in a physiological and clinical perspective. Overall, we can conclude from the 
studies described in this thesis that the intestine plays an important role in reverse cholesterol 
transport and, therefore, should be considered as a potential target for development of anti­
atherosclerotic drugs that, in addition to interference with cholesterol absorption, may directly 
modulate cholesterol excretion and plasma HDL cholesterol levels. 
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Als component van celmembranen is cholesterol is een belangrijke bouwsteen in dierlijk 
Ieven. Daamaast functioneert het als precursor molecuul voor steroide hormonen en 
galzouten. Naast de synthese van cholesterol door cellen, is ons voedsel een belangrijke bran 
van cholesterol. Een goede balans van cholesterol opname, aanmaak en uitscheiding in het 
lichaam is erg belangrijk, aangezien hoge plasma cholesterol concentraties, specifiek hoog in 
de zogenaamde Low-Density-Lipoprotein (LDL) fractie, worden geassocieerd met een 
verhoogd risico voor hart en vaatziekten. Daamaast wordt hoge cholesterol concentraties in de 
High-Density-Lipoprotein (HDL) fractie juist geassocieerd met een lager risico voor hart en 
vaatzieken. HDL-cholesterol wordt hierdoor vaak "goed" cholesterol genoemd en LDL­
cholesterol "slecht" cholesterol. 
De belangrijkste veroorzaker van hart en vaatziekten is atherosclerose, ook wei 
aderverkalking genoemd. Een belangrijke eerste stap in de ontwikkeling van atherosclerose is 
de ophoping van (LDL) cholesterol (in macrofagen) in bloedvaten. Deze ophoping wordt 
gevolgd door een ontstekingreactie en de ader kan dan dichtslibben. Als het dichtslibben van 
de ader in het hart gebeurd kan dit tot een hartaanval leiden. De overmaat aan cholesterol in 
perifeer weefsel (zoals macrofagen) kan worden verwijderd via reverse cholesterol transport 
(RCT). HDL-cholesterol speelt hier een belangrijke rol aangezien het cholesterol uit perifere 
cellen opneemt. RCT wordt gedefinieerd als de HDL bemiddelde flux van cholesterol van 
perifere cellen (zoals macrofagen) naar de lever, gevolgd door de secretie in de gal en 
verwijdering via de ontlasting. De lever wordt gezien als verreweg het belangrijkste orgaan in 
deze route, doordat de lever HDL produceert en cholesterol uitscheidt naar de gal. De studies 
beschreven in dit proefschrift Iaten echter zien dat de darm ook een grate rol speelt in deze 
route. 
In hoofdstuk 2 is de bijdrage van de darm aan cholesterol uitscheiding in de ontlasting 
bestudeerd. Aangenomen wordt dat fecale cholesterol afkomstig is uit het dieet, uit gal en van 
dade darm cellen, maar a! in 1 960 is gesuggereerd dat een dee! van de fecale cholesterol ook 
wordt uitgescheiden door de darm. Deze route hebben we geanalyseerd door te kijken naar de 
fecale cholesterol uitscheiding in Mdr2 deficiente (Mdr2"1") muizen. Mdr2 is een 
transportereiwit dat het transport van fosfolipiden van de lever naar de gal bewerkstelligt. 
Doordat de secretie van fosfolipiden en cholesterol gekoppeld zijn, hebben deze muizen 
behalve fosfolipiden ook geen cholesterol in de gal. Door het gebruik van deze Mdr2"1• 
muizen en controle muizen, kan er een onderscheid gemaakt worden van cholesterol 
afkomstig uit gal en cholesterol afkomstig uit de darm. Om de fecale cholesterol secretie te 
stimuleren, zijn de muizen behandeld met de LXR agonist GW3965. Activatie van de 
nucleaire receptor LXR induceert de reverse cholesterol transport route, door de expressie van 
genen betrokken bij deze route te verhogen. De resultaten van deze studie Iaten duidelijk zien 
dat de verhoogde fecale cholesterol uitscheiding na LXR activatie onafhankelijk is van gal 
cholesterol. Door gebruik te maken van intraveneus geinjecteerd gelabelde cholesterol, 
konden wij Iaten zien dat fecaal verlies van cholesterol uit het bloed verhoogd was in LXR 
behandelde Mdr2+ muizen, wat duidelijk laat zien dat de darm, onafhankelijk van cholesterol 
143 
Emerging roles of the intestine in reverse cholesterol transport 
uit de gal, een belangrijke rol heeft in het cholesterol transport van bloed naar feces. De darrn 
is hierdoor bij definitie een belangrijk orgaan in de reverse cholesterol transport route. 
Een belangrijk eiwit betrokken RCT is het ABC transporteiwit A I  (ABCAI ). ABCAI 
is betrokken bij het transport van cholesterol en fosfolipiden van cellen naar HDL en is 
daarom cruciaal voor de efflux van overtollig cholesterol van perifere cellen (zoals 
macrofagen). In de lever is ABCAI betrokken bij de vorrning van HDL. In hoofdstuk 3 is 
gekeken naar de rol van ABCAI in de darm. Om dit te onderzoeken zijn muizen ontwikkeld 
die ABCA l specifiek in de dunne darm missen. Deficientie van Abca l in de darrn verlaagt de 
bloed HDL cholesterol concentraties met 30%. Dit bewijst dat de darm significant bijdraagt 
aan de bloed HDL cholesterol concentraties. Cholesterol uit het dieet wordt opgenomen door 
de darm en vervolgens in chylomicronen uitgescheiden in het lymfatische systeem. 
Deficientie van Abcal in de darm leidde tot onze verbazing niet tot een verlaging in 
cholesterol secretie naar lymfe of lymfatisch HDL cholesterol, hoewel de verschijning van 
dieet cholesterol in de HDL fractie in bloed wei verlaagd was. Dit suggereert dat HDL 
afkomstig van de darm niet in het lymfe systeem wordt vervoerd, maar direct naar het bloed 
wordt vervoerd. Om dit te onderzoeken hebben we lymfe collectie experimenten uitgevoerd in 
muizen die Abcal specifiek in de lever missen. In deze muizen is de forrnatie van HDL door 
de lever verhinderd, maar wordt nog wei HDL door de darm gesynthetiseerd. Aangezien 
hepatische ABCAI erg belangrijk is voor HDL synthese, hebben deze muizen sterk verlaagde 
plasma concentraties. Lever-specifieke Abcal deficientie leidde ook tot een verlaagde HDL 
concentratie in  de lymfe. Deze data Iaten zien dat de HDL afkomstig van de darm direct in de 
bloed circulatie wordt uitgescheiden en dat de HDL in de lymfe voomamelijk uit het plasma 
compartiment komt. 
Het transport van cholesterol van de periferie naar de ontlasting kan worden kan 
worden verhoogd door de activering van de nucleaire receptor LXR. Stoffen (agonisten) die 
LXR activeren worden daarom beschouwd als potentiele drugs tegen atherosclerosis. Een 
groot nadeel is dat LXR activering in de lever leidt tot een vette lever. In hoofdstuk 4 hebben 
we gekeken naar de fysiologische effecten van darm-specifieke activering van LXR. Darm­
specifieke LXR activering in ratten leidt tot verhoogde fecale cholesterol uitscheiding, deels 
door een verlaagde cholesterol opname en een verhoogde cholesterol secretie door de darm. 
Ook resulteerde darm-specifieke LXR activatie tot een verhoging in HDL-cholesterol in het 
bloed. Deze resultaten geven aan dat darm-specifieke activatie van LXR leidt tot een anti­
atherosclerotische response zonder de bijwerkingen op het vet metabolisme in de lever. 
Verlaging van de cholesterol absorptie resulteert in een verlaging van de "slechte" 
LDL-cholesterol concentraties in het bloed. Een natuurlijke manier om de cholesterol 
absorptie te remmen is door het eten van plant sterolen. Hiervan wordt gebruik gemaakt in 
"functionele" voedingsmiddelen die cholesterol verlagen door toevoeging van plant sterolen. 
Hoe plant sterolen de cholesterol absorptie remmen is echter nog groot en deels onbekend. De 
ontdekking van derivaten van plant sterolen als liganden voor LXR suggereert dat plant 
sterolen werken als LXR agonisten en de cholesterol absorptie remmen door verhoogde 
expressie van de sterol transportereiwitten ABCG5/G8. ABCG5/G8 bewerkstelligen de sterol 
transport vanuit de darmcel naar het darm lumen. Verhoogde expressie van ABCG5/G8 
resulteert in verhoogde secretie van cholesterol naar de darm lumen waardoor de cholesterol 
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absorptie verlaagt. In hoofdstuk 5 hebben we deze mogelijkheid onderzocht door muizen 
plant sterolen te voeren en de expressie te meten van genen die worden geactiveerd door 
LXR. Hoewel de plant sterolen de fecale cholesterol excretie bevorderen en de accumulatie 
van cholesterol esters in de lever verhinderen, bleef de expressie van Abcg5/g8 of Npcl lJ (een 
transporter eiwit betrokken bij de sterol opname uit het darm lumen door de darmcel) 
onveranderd. Plant sterolen in het dieet verlaagde de fractionele cholesterol absorptie in 
Abcg5 deficiente muizen vergelijkbaar in controle muizen. Uit deze experimenten kunnen we 
concluderen dat sterolen transporters Abcg5/g8 niet betrokken zijn bij de door plant sterolen 
veroorzaakte verlaging in cholesterol absorptie. Dit suggereert dat plant sterolen en stanolen 
de cholesterol absorptie remmen door interferentie van cholesterol incorporatie in micellen en 
niet door interferentie in gen expressie. 
Behalve de nucleaire receptor LXR wordt van de nucleaire receptor PPAR8/� 
verwacht betrokken te zijn bij de regulatie van RCT. In hoofdstuk 6 hebben we het effect van 
PPAR8/� op de RCT route geanalyseerd. Behandeling van muizen met een PPAR&� agonist 
resulteerde in een verhoogd plasma HDL-cholesterol, zonder inductie van Abca l in de lever 
of darm. PPAR8/� agonist behandeling resulteerde ook in een verlaagde cholesterol absorptie. 
Dit zonder verandering van de expressie van Abcg5/g8, maar door verlaging van de expressie 
van Npcl lJ. Uit deze studies blijkt dat PPAR8/� activatie resulteert in een anti-atherosclerose 
response en is hierdoor een aantrekkelijk target voor de ontwikkeling van nieuwe medicijnen 
ter preventie van atherosclerose. 
Ten slotte wordt de huidige staat van kennis over de te voorschijn komende rol van de 
darm in de regulatie van het cholesterol metabolisme besproken in hoofdstuk 7. De 
onderwerpen besproken in dit proefschrift worden in een fysiologisch en klinisch perspectief 
geplaatst. Over het geheel kan worden geconcludeerd uit de studies beschreven in dit 
proefschrift dat de darm een belangrijke rol speelt in de regulatie van cholesterol transport en 
zou hierdoor moeten worden beschouwd als een potentieel target voor de ontwikkeling van 
anti-atherosclerotische medicijnen die behalve de cholesterol absorptie remmen ook de 
cholesterol uitscheiding bevorderen en bloed HDL cholesterol concentraties verhogen 
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